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Abstract 
 
Campylobacter jejuni, which is a commensal bacteria of birds and some mammals, is the 
most common Campylobacter species associated with campylobacteriosis. It can colonise 
the intestinal tract of many birds, including poultry, at very high numbers without eliciting a 
pathological immune response or causing symptoms in the animals. Contamination of poultry 
with C. jejuni during processing and subsequent poor food handling is the major cause of 
infection in humans. 
 
Effective strategies to control Campylobacter contamination and to prevent 
campylobacteriosis are still lacking, as current knowledge about the pathogenic mechanisms, 
virulence and pathogen-host interaction mechanisms of Campylobacter in poultry is relatively 
poor. Since contaminated poultry is the major source of campylobacteriosis in industrialised 
countries, identification of virulence and colonisation factors will without doubt lead to new 
strategies for minimising colonisation of C. jejuni in poultry intestines. A starting point for 
identifying potential virulence factors is to identify proteins that are secreted from 
Campylobacter and therefore can interact with host molecules/cells.  
 
In 2000, the complete genome sequence of C. jejuni subsp. jejuni NCTC 11168 was 
completed, which contains 1,654 coding DNA sequences (CDS). In 2007, the genome 
sequence was re-annotated and re-analysed. The number of predicted CDS was reduced to 
1643 and 18.2% of CDS having their product functions updated. A range of bioinformatics 
techniques have been employed in this study to identify secreted and surface-exposed 
proteins, which may have the ability to interact with chicken immune cells. Results indicate 
that 6.96% of C. jejuni proteins have been predicted to contain a signal peptide, and 8.63% 
are predicted to be non-classically secreted using the web servers SignalP4.0 and 
Secretome2.0. Among them, a subset of 70 putative non-classically secreted proteins have 
been selected for further analysis, as they were predicted to be located on the cell surface or 
  XIX
extracellularly using Gneg-PLoc and Gneg-mPLoc. They have been analysed further for the 
presence of transmembrane helices, transmembrane beta-barrels, putative proteases, 
enzymes, and virulence. Finally 28 hypothetical putative non-classically secreted virulent 
proteins were identified as candidates for further analysis. 
 
One of the proteins from the list, Cj0391c, was selected to be expressed as a recombinant 
protein in an E. coli BL21(DE3) pRSET-A expression system. This purified recombinant 
protein was shown to induce a reduction in viability of chicken macrophage HD11 cells, and 
induced apoptosis, suggestive of possible roles of this protein in immune system evasion or 
suppression of immune responses in poultry.  
 
Furthermore, this protein was computationally modelled and molecular dynamics simulations 
performed at different conditions. The protein Cj0391c was predicted to be alpha-helical. It 
was modelled based on the structure of an alpha-helical pore-forming toxin, dermcidin. The 
constructed Cj0391c hexameric structural model was then inserted and simulated in a 
phosphatidylethanolamine-phosphatidylglycerol bilayer. Under simulated conditions, the 
model maintained structural integrity at low temperature (300 K) without the presence of zinc, 
but not at higher temperatures, 310 K and 314 K. The helical bundle was maintained with the 
presence of zinc from low temperature 300 K to higher temperature 314 K. Simulations also 
suggest a wider pore in the presence of zinc, suggestive of higher channel conductance. 
Thus, similar to human dermcidin, zinc may play a role in enabling formation of a stable 
hexameric channel with a pore of sufficient size to cause pathological membrane 
permeability, leading to cell death.  
 
Results from this study will help to improve our understanding of pathogenic mechanisms, 
more specifically, the virulence factors involved in C. jejuni pathogenicity. The molecular 
modelling and simulation revealed one possible mechanism of a protein toxic to chicken 
macrophage cells. These potential extracellular virulence factors can be used as virulence 
  XX
candidates for anti-Campylobacter strategies. By modelling identified proteins, antigenic 
determinants and/or functional regions/mechanisms may be found, which can then be used 
to design vaccines aimed at immunising poultry against Campylobacter colonisation. 
 
 
  
Chapter 1 
 1
 
 
 
 
 
 
 
 
 
 
CHAPTER 1. LITERATURE 
REVIEW 
Chapter 1 
 2
1.1 Introduction 
 
Campylobacter species are motile, Gram-negative, microaerophilic, spiral-shaped rods 
belonging to the family Campylobacteraceae (Montville & Matthews, 2008). These organisms 
have been accepted as one of the most common causes of campylobacteriosis worldwide 
(Nachamkin & Blaser, 2000). C. jejuni and C. coli colonise the intestinal tract of poultry at 
very high numbers without eliciting any pathological immune response (Hendrixson & DiRita, 
2004; Newell & Fearnley, 2003). Under experimental conditions, the dose of viable C. jejuni 
required to colonise chicks and chickens can be as low as 40 colony forming units (CFU) 
(Cawthraw et al, 1996). After passage through the poultry system, the colonisation potential 
of C. jejuni can exhibit an enhancement of at least 1,000-fold in most strains and up to 
10,000-fold in some strains experimentally (Cawthraw et al, 1996), which means that entire 
flocks can be rapidly infected by horizontal transfer.  
 
C. jejuni and C. coli are the most common Campylobacter species associated with 
campylobacteriosis (Montville & Matthews, 2008). In addition, C. jejuni is linked with Guillain-
Barré syndrome (GBS) which is an autoimmune syndrome that can result in respiratory and 
severe neurological dysfunction and death (Haddad et al, 2010). Campylobacteriosis is 
responsible for about 30% to 40% of severe GBS cases (Nachamkin & Blaser, 2000).  
 
C. jejuni is now recognised as the most common agent of enteritis in the world, with almost 
400 million cases reported each year (Walker, 2005). Campylobacteriosis is the most 
frequently reported zoonosis in industrialised countries, with incidence varying from 
21.9/100,000 in the United States to 396/100,000 in New Zealand (de Zoete et al, 2007; 
Haddad et al, 2010). In Europe, the annual number of campylobacteriosis cases exceeds the 
number of salmonellosis cases, with 62.98 campylobacteriosis cases per 100,000 population 
(Fosse et al, 2008).  
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Travel-associated campylobacteriosis is also an important issue. There are approximately 80 
million travellers per annum from industrialised countries to campylobacteriosis endemic 
regions (Tribble et al, 2008b). A study performed among Swedish travellers revealed that the 
risk for a traveller to acquire campylobacter-associated diarrhoea in India is 1,253 per 
100,000 persons (Ekdahl & Andersson, 2004). 
 
Campylobacteriosis has a major health impact in industrialised countries (Haddad et al, 
2010). In Fosse et al.’s study, the incidence and severity of foodborne human zoonoses 
cases in Europe have been calculated as risk scores (Fosse et al, 2008). Campylobacter 
species have the highest non-control ratio, due to the non-detection of hazards during meat 
inspection and potential secondary contamination (Fosse et al, 2008). 
 
Reducing the level of Campylobacter in poultry will limit the number of campylobacteriosis 
cases. Several strategies to help achieve this aim have been studied. Firstly, high hygiene 
levels during poultry breeding and prevention of chicken carcass contamination has been 
considered the most efficient method (Katarzyna et al, 2009). Nevertheless, it is difficult to 
introduce this strategy globally due to the relatively high cost related to the implementation of 
various interventions (Katarzyna et al, 2009). The method of upgrading biosecurity at the 
farm level and hygiene practices in processing poultry may also vary between countries 
(Katarzyna et al, 2009). Alternatively, genus/species-specific bacteriophage treatment of 
chickens before butchering or directly onto the chicken carcasses is also under consideration 
(Atterbury et al, 2003; El-Shibiny et al, 2005). However, there are many drawbacks to this 
method, such as the acquisition of resistance to bacteriophage control, and also 
campylobacter and bacteriophage genetic microbial diversity via recombination events (Scott 
et al, 2007). The most efficient strategy for decreasing campylobacteriosis is still 
immunoprophylactic methods. However, despite more than 10 years of research, as yet no 
effective anti-campylobacter vaccine has been developed. 
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1.2 Campylobacter 
 
1.2.1 Characteristics 
 
Campylobacter were first isolated from sheep and cattle with infectious abortion in the 1900s 
(Smith & Taylor, 1919). They were originally classified as Vibrio fetus until reclassified as 
Campylobacter in 1963 (Sebald & Veron, 1963). So far 25 species and 8 sub-species have 
been described (Man, 2011). C. jejuni and C. coli are the most common species involved in 
human acute bacterial diarrhoea worldwide (Nachamkin and Blaser, 2000). C. jejuni is most 
commonly detected specifically in poultry, while C. coli and C. lari are also detected regularly 
in birds (Pielsticker et al, 2012). Particularly, C. coli shows a prevalence of almost 50% in 
turkeys (Humphrey et al, 2007).  
 
Campylobacters are characterised as non-spore-forming, oxidase-positive, Gram-negative 
rods that are slender, spirally curved with tapering ends at the early stage of growth. The 
shapes become round as the culture ages. The cell size ranges from 1.5-6.0 µm in length 
and 0.2-0.5 µm in width and they have a polar flagellum at one or both ends (Ketley, 1997b; 
Young et al, 2007). Campylobacters cannot ferment or oxidase sugars, and are normally 
microaerophilic. They can change biosynthetic processes in response to lower oxygen levels 
in the environment (Gaynor et al, 2004). In the laboratory, C. jejuni is identified as a catalase 
positive, urease negative bacterium that can reduce nitrate. It is susceptible to nalidixic acid 
but resistant to cephalothin.  
 
Campylobacter can be divided into two groups, non-thermophiles (<37ºC) and thermophiles 
(37-42ºC), based on their temperature preference (Griffiths & Park, 1990). C. jejuni belongs 
to the latter group, since it has an optimal growth temperature at 42ºC, with the ability to 
grow slowly at 37ºC. Unlike any other intestinal bacteria such as Salmonella, Campylobacter 
grows only under microaerophilic conditions in an atmosphere with 10% CO2, 5% O2 and 
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85% N2 (Skirrow, 1977). It is commonly found in the intestine of warm-blooded animals and 
birds (Wallis, 1994). 
 
1.2.2 Pathogenesis 
 
There are clearly different mechanisms of virulence in humans, where disease is caused, 
and poultry, where the bacterium is a commensal. In humans, despite of the high incidence 
of campylobacteriosis, the bacterial factors involved in C. jejuni intestinal colonisation and 
pathogenesis are comparatively poorly understood compared to the other enteric pathogens 
(Oldfield & Wooldridge, 2009). In the review of Dasti et al. (2010), the list of bacterial factors 
involved in the human pathogenesis is shown (Table 1.1). Motility is known to be essential 
for C. jejuni pathogenesis mechanisms in humans (Oldfield & Wooldridge, 2009). In addition, 
cellular invasion and toxin production are also important C. jejuni pathogenesis mechanisms 
in humans (Oldfield & Wooldridge, 2009). Many investigations of the C. jejuni adhesive 
properties to different host epithelial-cell lines have been studied in vitro (Wooldridge & 
Ketley, 1997). Several C. jejuni adhesins have been revealed including lipooligosaccharide, 
flagellin, P95, Peb1 (CBF1) and Peb4 (CBF2) (Fry et al, 2000b; Grant et al, 1993; Kelle et al, 
1998; McSweegan & Walker, 1986; Pei et al, 1991). The pathogenesis of C. jejuni is further 
discussed in the Section 1.7.  
 
1.2.3 Reservoirs for C. jejuni 
 
C. jejuni is a commensal bacteria of birds and some mammals, such as pigs, dogs, cattle 
and sheep (Chansiripornchai & Sasipreeyajan, 2009). Natural reservoirs for C. jejuni are wild 
birds, whose intestines offer a suitable biological niche for their survival and dissemination. 
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Table 1.1: Representative bacterial factors involved in the human pathogenesis of campylobacteriosis (reproduced from Dasti et al, 2010). 
 Bacterial factor Remark Reference 
Responses to stress GroESL Heat shock response (Thies et al, 1999) 
 DnaJ Heat shock response (Konkel et al, 1998) 
 Lon protease  Heat shock response (Thies et al, 1999) 
 RacR-RacS Regulator of temperature-dependent signalling (Bras et al, 1999) 
 γ-glutamyltranspeptidase Utilization of glutamine and glutathione (Hofreuter et al, 2008) 
Motility and chemotaxis Flagellum O-linked glycosylation (Guerry, 1992) 
 Flagellum FlgR-FlgS Regulator for flagellum protein biosynthesis (Hendrixson, 2006) 
 Flagellum fliA (sigma28) Transcription of flagellar genes (Carrillo et al, 2004) 
 Flagellum rpoN (sigma54) Transcription of flagellar genes (Hendrixson & DiRita, 2003) 
 FlgP, FlgQ Flagellar motility (Sommerlad & Hendrixson, 2007) 
 CheY Response regulator needed for flagellar rotation (Yao et al, 1997) 
Binding and adhesion Flagellum Non-motile mutants show less adherence (Yao et al, 1994) 
 LOS Mimicry with GM1 and GD1a gangliosides - GBS (Young et al, 2007) 
 GadF Fibronectin-binging outer membrane protein (Konkel et al, 1997) 
 PEB1 Periplasmic binding protein (Pei & Blaser, 1993) 
 JlpA Surface-exposed lipoprotein (Jin et al, 2001) 
Invasion Flagellum Aflagellated mutants are less invasive (Wassenaar & Blaser, 1999) 
 LOS Lipooligosaccharide (Louwen et al, 2008) 
 Cia Campylobacter-invasive antigens, especially CiaB 
= Secreted through the flagella export apparatus 
(Konkel et al, 2004; Rivera-Amill et al, 2001) 
 CadF Activation of Rac1 and Cdc42 (Krause-Gruszczynska et al, 2007a; Krause-
Gruszczynska et al, 2007b) 
 CPS Capsular polysaccharide (Karlyshev & Wren, 2001) 
Toxins CdtA,B,C Cytolethal distending toxin CdtB causes (Pickett & Whitehouse, 1999) 
   • cell cycle arrest and apoptosis (Hickey et al, 1999) 
   • IL-8 secretion  
Crossing polarized epithelia Unknown Disruption of tight junctions (MacCallum et al, 2005b) 
  Translocation of intestinal commensal bacteria (Kalischuk et al, 2009) 
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C. jejuni normally colonise chickens shortly after birth and are the most important source for 
human infection (Dasti et al., 2009). C. jejuni can colonise the intestinal tract of many birds 
including poultry at very high number (up to 109 colony-forming units per gram in caecal 
contents) without eliciting any pathological immune response or causing symptoms 
(Hendrixson & DiRita, 2004; Newell & Fearnley, 2003). C. jejuni is the strain most prevalent 
in poultry (65-95% vs. C. coli 5-35%) (de Zoete et al, 2007), while C. coli predominates in 
swine (Kist & Bereswill, 2001). As chickens are considered as the natural host of C. jejuni, 
data on the source arribution in some of the European countries have been collected (Table 
1.2). C. jejuni can also colonise turkeys and ducks less frequently. Beside poultry, other 
sources for C. jejuni have been described, such as sheep, pigs, cats, dogs, water, raw milk, 
while rodents and insects are also considered as possible vectors (Bates et al, 2004; Guerin 
et al, 2007; Hald et al, 2004; Hastings et al, 2011; Sahin et al, 2002).  
 
Several surveys have indicated a seasonal variation in the prevalence of poultry flock 
colonisation, which demonstrates a higher rate of infection in summer than in winter 
(Berndtson et al, 1996; Hald, 1999; Jacobs-Reitsma et al, 1994). The reason for this 
seasonal variation is unknown, but this may reflect levels of environmental contamination. 
Some poultry farms have more ventilation during the summers, which may increase the 
contact of the chickens with the outside environment (Nachamkin, 2008).  
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Table 1.2: Source Attribution of C. jejuni and C. coli in Europe using Multi-Locus Sequence Typing (reproduced from EFSA, 2010).  
Attribution 
Model 
Source Animal 
Dataset 
Clinical 
Dataset 
Species 
% Attribution 
to Chicken 
% Attribution to 
Other Sources 
Comments Reference 
Asymmetric 
Island 
1145 isolates 
from 10 previous 
studies 
1255 from NW 
England; Jan 
2000 till Dec 
2002 
C. jejuni 56.5 
35.0 (cattle) 4.3 
(sheep) 
2.3 (wild animals) 
1.1 (environment) 
 (Wilson et al, 2008) 
Population 
structure 
5247 from 
Scotland July 
2005 to Sep 2006 
(9.6% C. coli) 
999 from 
Scotland and 
3419 from 
PubMLST 
C. jejuni 58 
38 (ruminants) 
4 (wild bird & 
environment) 
 (Sheppard et al, 2009) 
Asymmetric 
Island 
As above As above C. jejuni 78 
38 (ruminants) 
4 (wild bird & 
environment) 
 (Sheppard et al, 2009) 
Population 
structure 
As above As above C. coli 40 
40 (sheep) 14 (cattle) 
6 (pigs) 1 (turkey) 
 (Sheppard et al, 2009) 
Asymmetric 
Island 
As above As above C. coli 56 
40 (sheep) 14 (cattle) 
<1 (pig) <1 (turkey) 
 (Sheppard et al, 2009) 
Population 
structure 
680 
contemporaneous 
isolates from 
Scotland 
225 from rural 
children in 
Grampian 
2000-06 
C. jejuni 
and C. 
coli 
19 
42 (cattle) 24 (wild 
birds) 12 (sheep) 3 
(pigs) 
Rural 
children < 5 
years 
(Strachan et al, 2009) 
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Table 1.2: Source Attribution of C. jejuni and C. coli in Europe using Multi-Locus Sequence Typing (reproduced from EFSA, 2010) (cont.).  
Attribution 
Model 
Source Animal 
Dataset 
Clinical 
Dataset 
Species 
% Attribution 
to Chicken 
% Attribution to 
Other Sources 
Comments Reference 
Population 
structure 
680 
contemporaneous 
isolates from 
Scotland 
85 from rural 
children in 
Grampian 
2000-06 
C. jejuni 
and C. 
coli 
43 
35 (cattle) 6 (wild 
birds) 15 (sheep)  
1 (pig) 
Rural 
children < 5 
years 
(Strachan et al, 2009) 
Modified 
Hald 
793 isolates 
481 from 
Manawatu, 
New Zealand 
C. jejuni 80 
10 (cattle) 9 (sheep)  
4 (environment) 
 (Mullner et al, 2009) 
Dutch 
Model 
521 isolates As above C. jejuni 52 
17 (cattle) 10 (sheep) 
5 (wild bird) 11 (water)
 
(French and the Molecular 
Epidemiology and 
Veterinary Public Health 
Group, 2008) 
Modified 
Hald Model 
521 isolates As above C. jejuni 67 
23 (cattle) 8 (sheep) 1 
(wild bird) <1 (water) 
 
(French and the Molecular 
Epidemiology and 
Veterinary Public Health 
Group, 2008) 
Island 
Model 
521 isolates As above C. jejuni 75 
17 (cattle) 4 (sheep) 2 
(wild bird) <1 (water) 
 
(French and the Molecular 
Epidemiology and 
Veterinary Public Health 
Group, 2008) 
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1.3 Epidemiology  
 
In the developing world, It is estimated that 40-60% of children under 5 years old will develop 
at least one symptomatic Campylobacter infection (Coker et al, 2002). A passive clinical 
surveillance study in Karachi, Pakistan shows that annual incidence of C. jejuni infection is 
29 per 1,000 person-years, with peak incidence in 2 year-old children (Soofi et al, 2011). 
Additionally, the attention on association between Campylobacter and HIV infection may be 
increased as morbidity and mortality have been discovered among HIV positive patients 
(Molina et al, 1995; Sorvillo et al, 1991; Tee & Mijch, 1998). Long-term carriage of 
Campylobacter can occur among HIV infected patients, which sometimes associated with 
recurrent attacks of enteritis and bacteremia (Guerry et al, 2012). With the growing HIV 
pandemic, it is suggested that the burden of campylobacteriosis in developing world may be 
listed in the top 10 in 2020 (Guerry et al, 2012).  
 
In developed countries, estimates of the level of campylobacteriosis in the general population 
vary between geography and over time (Guerry et al, 2012). The incidences in the USA are 
around 15/100,000 with a slight decline over the past decade, and rates in Europe are 50-
90/100,000 with an increasing trend (Janssen et al, 2008). Some Eastern European 
countries and New Zealand have comparatively high incidence rates, which are about 300-
400/100,000 per annum (Guerry et al, 2012). It is believed that the true incidence rates are 
10-100 times higher than those reported historically as a lot of campylobacteriosis cases 
have been miss an/or not reported (Guerry et al, 2012). The results of population-based 
estimates of campylobacteriosis studies in a number of western countries are listed in the 
Table 1.3. These results support that the incidence rates in developed countries ranges from 
3 to 15 cases per 1,000 person-years.  
 
Finally, travellers-associated campylobacteriosis cases are high with 5-15% of diarrheal  
Chapter 1 
 11
Table 1.3: Global estimates of Campylobacter incidence in developed countries (reproduced from Guerry et al, 2012). 
Reference Kubota et al. (2008) Tam et al. (2012) De Wit et al. (2001) Hall et al. (2008) Scallan et al. (2011) 
Country Japan UK Netherlands Australia US 
Year of study 2006-2007 2008-2009 1998-1999 2000-2004 2006 
Study design Two 2-week cross-
sectional, population-
based telephone 
surveys combined with 
catchment area 
surveillance 
Prospective, 
community cohort 
study and prospective 
study of general 
practice presentation 
in national surveillance 
system 
Prospective 
population-based 
study with nested 
case-control study in 
general population 
Empirical model based 
on published and 
unpublished data from 
multiple active 
/passive surveillance 
source  
Empirical model based 
on published and 
unpublished data from 
multiple active/passive 
surveillance sources 
Numbers 4,247 Household 
interviews, 8,462 
laboratory confirmed 
cases ascertained in 
active surveillance 
6,836 Cohort 
participants, 800,000 
catchment area for 
national surveillance 
4,860 Patients 
enrolled in cohort 
Not applicable Not applicable 
Incidence estimate 
(95% CI), per 1,000 
person-years  
15.1 (7.4-28.6) 10.9 (7.4-15.9) 4.8 (1.7-10.4) 11.8(7.6-26.7) 2.8 (not given) 
Foodborne illness rank 1 of 3 overall 4 of 12 overall; 1 of 5 
bacterial 
1 of 5 bacterial 1of 3 overall  4 of 31 overall; 3 of 21 
bacterial 
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cases globally (Riddle et al, 2006; Shah et al, 2009), with more frequency in some SE Asia 
areas (Guerry et al, 2012). Data from a Canadian community from June 2005 to May 2009 
revealed that of the 446 cases of travel-related disease due to enteropathogens reported, 
campylobacteriosis was the most frequently identified (n = 123,28%) (Ravel et al, 2011). 
Similarly, surveillance data collected by GeoSentinel Travel Network showed that for 17,353 
ill returned travellers, the incidence of Campylobacter infection was identified in 8.5 per 100 
diarrheal cases, which was the leading bacterial etiology (Freedman et al, 2006).  
 
1.3.1 Transmission 
 
Several environmental reservoirs can lead to human infections by C. jejuni. C. jejuni 
colonises the gastrointestinal tract of its natural host chicken in high numbers, and is rapidly 
spread throughout the entire flock via the faecal-oral route (Young et al, 2007). The main 
route of C. jejuni human infection is through undercooked poultry, processed retail poultry 
meats, or improperly handling other food types that are cross-contaminated during food 
preparation and handling (Altekruse et al, 1999). In some European countries, 70% of the 
chickens were colonised with Campylobacter at the time of slaughter (Bywater, 2004). As 
much as 70% of raw poultry meat products sold in the USA in 1999/2000 were found to carry 
Campylobacter (Zhao et al, 2001). When the chicken is slaughtered, the bacteria within the 
digestive tract comes into the contact with the meat, and it can survive processing 
procedures. When the meat is not correctly cooked or prepared, the bacteria is then ingested 
and may cause campylobacteriosis. Consumption of contaminated poultry, beef and 
unpasteurised milk are responsible for approximately 90% of human infection cases (Figure 
1.1). Sheep, contaminated water and pet animals are responsible for the remaining 10% of 
cases (Wilson et al., 2008). Large scale outbreaks of campylobacteriosis are rare, and are 
usually linked to the consumption of polluted water or raw milk (Oldfield & Wooldridge, 2009). 
In the USA, campylobacteriosis cases are estimated to be about 2.4 million per year 
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                      Figure 1.1: Most important routes for human infection by Campylobacter jejuni (reproduced from Young et al, 2007). 
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(Friedman, 2000), with up to 70% of sporadic infections related to Campylobacter-
contaminated poultry (Harris et al, 1986). Finally, although direct infection from human to 
human might occur, it is of no large epidemiological relevance (Nachamkin & Blaser, 2000). 
 
1.3.2 Trends 
 
In the western countries, the people most at risk of infection are young children, 
immunocompromised patients and young adults (Friedman, 2000). In developing nations, 
children and immunocompromised patients are the populations who are most at risk and the 
mortality rates are much greater compared to the developed countries for many economic 
associated reasons (O'Ryan et al, 2005). Children at weaning age are of particular concern 
in developing countries as they are not receiving maternal antibodies against Campylobacter 
and they are immunologically immature (Coker et al, 2002; Nachamkin et al, 1994). 
Furthermore, children in developing nations have more access to farm animals, untreated 
drinking water and milk (O'Ryan et al, 2005). In developing countries, such as Thailand, 
Mexico and Peru, the incidence rates for children under 5 years old were as high as 40,000-
60,000 per 100,000 population (Calva et al, 1988; Oberhelman et al, 1999; Taylor et al, 
1988). In contrast, the estimated incidence rate for the same age group in industrialised 
countries was less then 300/100,000 during the same period (Skirrow, 1987).  
 
Males present with campylobacteriosis 1.2-1.5 times more often than females, which is most 
apparent in young adults (Friedman, 2000; Kapperud & Aasen, 1992; Skirrow, 1987). The 
reason for this observation is unclear, but it might be that males are more at risk of C. jejuni 
infection due to their different food handling and consumption practices than females (Ekdahl 
& Andersson, 2004; Samuel et al, 2004).  
 
A seasonal trend has also been discovered as there are more campylobacteriosis cases in 
summer compared to the winter season (Louis et al, 2005; Meldrum et al, 2005; Miller et al, 
2004; Nylen et al, 2002). There are several possible reasons for this trend: (1) more 
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barbecues occur in summer, giving rise to a higher chance for people to ingest undercooked 
poultry or contaminated food; (2) high temperatures encourage the growth of C. jejuni in 
environmental waters; (3) children have more chance to come into contact with farm animals 
during the school holidays; (4) flies can act as vectors by carrying the bacteria from 
uncooked meat or animals faeces and contaminating food sources (Ekdahl et al, 2005; Kemp 
et al, 2005; Louis et al, 2005; Stanley et al, 1998).  
 
1.3.3 Economic Impact 
 
Foodborne zoonoses, such as campylobacteriosis, have a major health impact in 
industrialized countries (Haddad et al, 2010). Lethality and hospitalization rates were 
combined to assess severity, using a term (λ) to increase the weighting of lethality. The score 
for the clinical severity of campylobacteriosis using this method was 11.2, compared with 
32.3 for Salmonella enteric infection (Fosse et al, 2008). Campylobacter spp. are responsible 
for approximately 17% of food-borne infection associated hospitalisation in Europe (Mead et 
al., 1999). 
 
In Australia, the economic burden of foodborne disease is AUD$2.6 billion per year 
(www.foodstandards.gov.au). This website also reported Campylobacter being responsible 
for 51.3% of the total number of foodborne illness in Australia, which means that the cost of 
campylobacteriosis in Australia is about AUD$1.3 billion/year. The cost includes cost of 
salary due to illness, medication, product recall, hospitalisation and others. In New Zealand, 
a study showed that the cost of Campylobacter associated disease was NZD$4.48 billion in 
the year of 1995 (Withington & Chambers, 1997). In the USA, the cost of Campylobacteriosis 
is about $1.3-6.2 billion per annum, and $1.5-8 billion per annum if the associated 
complications were included(Buzby et al, 1997). In addition, C. jejuni is an important factor in 
the development of GBS, which remains a public health burden (Fujimura, 2013). 
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1.4 Clinical Aspects of C. jejuni Infection 
 
Infection in humans occurs via oral ingestion of C. jejuni contaminated food or water, 
bacterial colonisation of the colonic mucosal layer, adherence to the underlying epithelial 
cells, secretion of virulence proteins and internalisation of C. jejuni by epithelial cells 
(Raphael et al, 2005; Young et al, 2007). Campylobacter infection is commonly characterised 
as an acute gastroenteritis with inflammation, abdominal pain, fever and diarrhoea (Black et 
al, 1988). The infection dose can be as low as 500-800 CFU (Robinson, 1981). The 
incubation period prior to the onset of symptoms arising from campylobacteriosis is usually 
between 1 to 7 days (Ketley, 1997b). Although campylobacteriosis generally lasts one week, 
symptoms can last up to 2 weeks (Young et al, 2007). Generally, it is self-limiting with the 
presence of a couple of days of prodromal symptoms i.e. fever, vomiting, headaches and 
abdominal pain. For more severe cases, these symptoms are followed with 3-7 days of 
diarrhoea with/without blood. In general, the illness can range from mild to severe with 
dehydration that might require hospitalization (Dasti, et al., 2009). Differences in virulence 
potential in C. jejuni strains and differences between patient immune statuses may contribute 
to the wide range of clinical symptoms (Poly et al, 2007). There are two disease 
manifestations involved with campylobacteriosis, which are associated with socio-economic 
status (Blaser et al, 1980). In industrialised countries, it manifests as bloody diarrhoea with 
mucus. In the developing countries, watery diarrhoea predominates, and infection is more 
frequent in children. The milder cases are predominant in young children from developing 
countries, while the severe symptoms predominate in patients from industrialised countries.  
 
Patients with full protective immunity, partial immunity or with/without previous 
Campylobacter infection may elicit different immune response and clinical outcomes (i.e. 
asymptomatic infection, watery diarrhoea, inflammatory diarrhoea with/without blood) (Ketley, 
1997a). Infections occur at all ages, although peaks are described for children younger than 
4-years-old and for patients aged between 15 and 39 years old (Dasti, et al., 2009).  
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1.4.1 Complications of C. jejuni Infection 
 
Campylobacteriosis has been recognised as an important risk factor for the development of 
inflammatory bowel disease and extra-intestinal manifestations such as polyarthralgia (i.e., 
reactive arthritis) or GBS (Haddad et al, 2010). The incidence of GBS in humans is < 0.1% of 
all Campylobacter infections (Allos, 2001). The immune system involvement in the 
progression of GBS involves the accumulation of T-cells and immunoglobulin-mediated, 
macrophage-orchestrated attacks on the peripheral nerves. The disease is self-limiting, with 
muscle strength usually reaching a nadir within 2 to 3 weeks, followed by partial or complete 
recovery over a period of weeks to months. This attack damages the axons or nerve fibres 
and leads to the inability to conduct electrical impulses stimulating the senses and movement 
of the extremities (Goodman & Sladky, 2005). Even with treatment, GBS can still cause 
respiratory distress.  
 
Other complications, such as Miller-Fisher syndrome (MFS) and acute post-infectious 
polyneuritis are also usually associated with serological evidence of recent previous infection 
with Campylobacter species (Mishu & Blaser, 1993). MFS is a variant of GBS and is known 
to be involved in peripheral nerve demyelination. Symptoms include areflexia, ataxia and 
paralysis of one or more of the eye muscles. Some evidence of post-Campylobacter infection 
risk of select chronic disease is listed in Table 1.4.  
 
1.4.2 Treatment and Preventions 
 
Infections caused by C. jejuni or C. coli are characterised by fever, abdominal cramping, and 
diarrhoea (with or without blood). Infection is normally self-limiting and lasts several days to > 
1 week (Nachamkin and Blaser, 2000, Montville and Matthews, 2008). Normal treatment  
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Table 1.4: Summary evidence of post-Campylobacter infection risk of select chronic health consequences (reproduced from Guerry et al., 
2012).  
Sequelae Post-infective 
attributable risk* 
Comment Reference 
Guillain Barré 
syndrome 
1 per 1,000 14-32% of GBS cases can be attributed to C. jejuni (Nachamkin & Blaser, 2000) 
Reactive 
arthritis 
1-5% 5% of C. jejuni ReA may be chronic or relapsing (Pope et al, 2007) 
Inflammatory 
bowel 
3-4 per 1,000 Recent evidence suggests that C. jejuni can breach the intestinal 
barrier and may prime the intestine for chronic inflammatory 
responses in susceptible individuals (Kalischuk and Buret, 2010) 
(Gradel et al, 2009; Jess et al, 2011; 
Rodriguez et al, 2006) 
Irritable bowel 
syndrome 
1-10% IBS developed in 36% of patients associated with a large waterborne 
outbreak of mixed Campylobacter and STEC in Walkerton, Canada. 
Symptoms persist in approximately 40-50% at 5-7 years 
(Dunlop et al, 2003; Marshall et al, 
2006; Rodriguez & Ruigomez, 1999; 
Thornley et al, 2001) 
*Post-infective attributable risk considers the absolute difference of the rate of sequelae after C. jejuni compared to the rate of the sequelae in an 
unexposed population.  
STEC=Shiga Toxin-producing Escherichia coli 
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involves rehydration to replace the electrolytes and fluid loss as a result of diarrhoea and/or 
vomiting (Faruque et al, 1993; Mackenzie & Barnes, 1988; Skirrow, 2000). In severe cases 
or when the patient is immunocompromised or pregnant, macrolides (e.g. erythromycin) are 
usually prescribed (Mamelli et al, 2003).  
 
Campylobacteriosis confirmation can take up to 4 days, as time is needed to isolate and 
culture the bacteria from patient stool samples (Allos, 2001). Sometimes fluoroquinolones 
are given, as they are the antimicrobial drugs of choice in the treatment of other enteric 
pathogens, e.g., Salmonella or Shigela species are also susceptible to them. Thus, the 
patient could be treated without the need for laboratory testing results (Allos, 2001). 
Tetracylines have been suggested to replace erythromycin in the case that Campylobacter 
develops erythromycin resistance (Funke et al, 1994; Moore et al, 2005). The newer 
macrolides, azithromycin and clarithromycin, are effective with campylobacteriosis treatment, 
but they are more expensive and without added therapeutic advantage (Allos, 2001).  
 
There are several ways of thinking to prevent campylobacteriosis. Firstly, the improvement of 
strategies to help reduce cross-contamination during food processing and slaughter. 
Secondly, treatment of the meat before retail sale in order to reduce the number of live 
Campylobacter on the carcass. Third, public education of food handling and cooking, and 
awareness of potential cross contamination in the kitchen (Humphrey et al, 2001). However, 
development of a vaccine to protect chicks from colonisation would be the most efficient way 
to prevent the disease (discussed in the Section 1.11).  
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1.5 Genetic Features of C. jejuni 
 
The complete genome sequence of C. jejuni NCTC11168 was completed in 2000, which 
reveals that C. jejuni has the densest bacterial genome sequenced to date, with 94.3% of the 
genome encoding proteins (Parkhill et al. 2000). The entire genome contains 1,641,481 base 
pairs (bp) with a low G+C content (30.6%), and 1,654 predicted CDS (Parkhill et al, 2000). 
The genome is unusual as there are virtually no insertion sequences, no phage-associated 
sequences, few repeat sequences, and with the presence of hypervariable sequences 
(Parkhill et al, 2000). 
 
In 2007, the genome sequence from C. jejuni NCTC 11168 was re-annotated and re-
analysed by more advanced genomic screening techniques (Gundogdu et al, 2007). The 
number of predicted CDS was reduced to 1643, and 18.2% of CDS had their product 
functions updated (Gundogdu et al, 2007). Importantly, major updates in this analysis 
involved the genes for biosynthesis of important surface structures, which include 
lipooligosaccharide, capsule and both O- and N-linked glycosylation (Gundogdu et al, 2007). 
It was shown that 55.4% of C. jejuni genes are similar to Helicobacter pylori, 28.0% are 
similar to Escherichia coli (E. coli) and 27.0% are similar to Bacillus subtilis.  
 
The intragenomic mechanisms and genetic exchanges between strains results in C. jejuni 
displays extensive genetic variation. C. jejuni is naturally competent, enabling it to import 
macromolecular DNA from the environment and incorporate it into its genome (Wiesner et al, 
2003). Natural transformation enables horizontal gene transfer to occur, generating genetic 
diversity among C. jejuni strains (Dingle et al, 2001). The horizontal transfer of C. jejuni 
plasmid and chromosomal DNA happens in vitro and during chicken colonisation without any 
selective pressure, which may contribute to its genome plasticity and antibiotic resistance 
(Avrain et al, 2004; de Boer et al, 2002; Wilson et al, 2003). However, the frequency of 
natural transformation is affected by carbon dioxide and the bacterial cell density, which 
reveals that horizontal exchange may be environmentally regulated in vivo (Wilson et al., 
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2003). Several genes that have been identified are required for natural transformation, which 
include some components of the type II secretion system (T2SS) (Wiesner et al, 2003) 
(discussed in Section 1.9.3). In addition, genes with implicated elements of a plasmid-
encoded type IV secretion system (T4SS) (discussed in Section 1.9.4), genes for N-linked 
glycosylation, genes for lipooligosaccharide (LOS) biosynthesis and a putative DNA-
processing enzyme encoding gene, were also found to be necessary for wild-type levels of 
natural transformation (Bacon et al, 2000; Fry et al, 2000a; Larsen et al, 2004; Takata et al, 
2005). However, no specific mechanism has been identified to explain how extracellular DNA 
is recognized and accepted by C. jejuni (Young et al, 2007).  
 
Genome sequencing of C. jejuni reveals the presence of hypervariable sequences that 
consist of homopolymeric tracts, and also the high frequency of variation within these 
sequences (Parkhill et al, 2000). Most of the hypervariable sequences are in the regions 
where encoded proteins are involved in the biosynthesis or modification of surface –
accessible carbohydrate structure, which consists of the capsule, LOS and flagellum (Parkhill 
et al, 2000). Mechanisms such as phase variation, gene duplication and deletion, frameshifts 
and point mutations, are the main factors responsible for the variation in these structures 
(Gilbert et al, 2002; Guerry et al, 2002; Karlyshev et al, 2005b; Karlyshev et al, 2002; Linton 
et al, 2000; Parkhill et al, 2000).  
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1.6 Immune Responses 
 
1.6.1 Human Immune Response 
 
Adherence of the bacteria to underlying epithelial cells brings about the production of 
interleukin (IL)-8, a chemokine that is able to recruit professional phagocytes such as 
macrophages, dendritic cells, monocytes and neutrophils, which then encounter and rapidly 
interact with C. jejuni (Hu et al, 2006a; Young et al, 2007). Such an interaction will trigger a 
massive innate pro-inflammatory response through the activation of nuclear transcription 
factor kappaB (NF-κB), the cytokines IL-1ß, IL-6, IL-10, IL-12 and TNF-α, and also induction 
of TH-1-specific adaptive cell-mediated immunity (Hu et al, 2006a; Young et al, 2007) (Figure 
1.2). The cytolethal-distending toxin (CDT) and the surface-exposed heat-shock protein 
adhesion factor Jlp, are responsible for the IL-8 production from the human epithelial cells 
(Hickey et al, 2000; Jin et al, 2003). Anti-Campylobacter specific immunoglobulins IgA, IgG, 
and IgM have been identified from patients’ serum samples (Kaldor et al, 1983). C. jejuni 
infection of two polarised intestinal epithelial lines, Caco-2 and T84, exhibits the activation of 
mitogen-activated protein kinase family proteins extracellular signal-regulated kinases and 
p38 (MacCallum et al, 2005a; Watson & Galan, 2005). For the T84 cell line, extracellular 
signal-regulated kinases activation is essential for the stimulation of IL-8 (Watson & Galan, 
2005). For an intestinal cell line as INT 407, CDT contributes to IL-8 secretion. Therefore, C. 
jejuni can breach the physical barrier of intestinal epithelium, and these cells can in turn 
signal for the recruitment of inflammatory cells to the site of infection (Figure 1.2).  
 
Human innate immune responses against pathogen microbes are mainly mediated by the 
activation of Toll-like receptors (TLRs) (Kopp & Medzhitov, 2003). The main TLRs involved in 
bacterial infections are TLR2/1/6 (detects lipoproteins), TLR4/myeloid differentiation protein-2 
(detects lipopolysaccharide/LPS), TLR5 (detects flagellin) and TLR9 (detects DNA)  
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Figure 1.2: Molecular and cellular feature of the humans and chickens innate immune 
response to Campylobacter jejuni (reproduced from Young et al, 2007). 
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(de Zoete et al, 2010). After TLR activation, a signal cascade involving the adapter protein 
MyD88 (all TLRs except TLR3) or TRIF (TLR3 and TLR4 only) results in the activation and 
translocation of nuclear transcription factors that in turn induce the transcription of cytokines 
and other immune genes (Akira, 2006). TLR signalling also involves a TLR4-mediated, 
MyD88-independent pathway associated with the induction of late phase NF-κB and 
interferon (IFN)-inducible genes, such as IFN-ß, which is involved in natural killer (NK) cell 
activation and maturation of dendritic cells (Yamamoto et al, 2003). Campylobacter flagellin 
is not recognised by the human TLR-5 due to a complex series of mutations in the flagellin 
TLR-5 recognition site and compensatory amino acid changes in flagellin (Andersen-Nissen 
et al, 2005). C. jejuni is not recognised by human TLR-9 as well, because of the AT-rich 
nature of the C. jejuni genome (Dalpke et al, 2006). However, the intracellular pathogen-
recognition receptor NOD1 plays a crucial role in immune stimulation by C. jejuni (Zilbauer et 
al, 2007).  
 
The role of monocytes and macrophages in C. jejuni infection various between different cell 
lines or primary cells (Young et al, 2007).  Evidence shows that the monocyte cell line THP-1 
stimulated with C. jejuni induces NF-κB and the pro-inflammatory cytokine IL-1β production 
(Siegesmund et al, 2004; Wassenaar et al, 1997). However, a signification proportion of C. 
jejuni infected monocytic cells also undergo apoptosis (Hickey et al, 2005; Wassenaar et al, 
1997). There are a few studies showing that clinical isolates of C. jejuni survived for several 
days in murine peritoneal macrophages and the macrophage cell line J774A.1 (Day et al, 
2000; Hickey et al, 2005; Nachamkin & Yang, 1989). Interestingly, one group (Kiehlbauch et  
al, 1985) found that C. jejuni is killed immediately by macrophages derived from human 
monocytes. The possible reasons for the different observation might be the use of different 
C. jejuni strains and/or the different macrophage-like cell lines.  
 
An adaptive human immune response has been observed during C. jejuni infection, although 
the bacteria has multiple levels of variation in its surface structure, which would help it to 
evade antibody responses (Young et al, 2007). Antibodies from human sera have been 
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identified during C. jejuni infection, which include antibodies to flagella, major outer 
membrane protein (MOMP), outer membrane protein (OMP), LOS and CDT (Abuoun et al, 
2005; Guerry et al, 2000; Panigrahi et al, 1992). CDT has been recognised as a major 
antigen for antibody production, and neutralizing antibodies that are directed against CDT 
are observed during human infection (Abuoun et al, 2005). CDT will be further discussed in 
Section 1.8.7.  
 
Children with campylobacteriosis under 6 months old show low levels of specific IgA, IgG 
and IgM, which may due to the presence of maternal antibodies (Kaldor et al, 1983). About 
80%-90% patients who were infected with culturable C. jejuni produced C. jejuni specific 
serum immunoglobulins (Lee & Newell, 2006). Elevated levels of IgA were only detectable 
from the onset of symptoms until the clearance of C. jejuni (Lee & Newell, 2006). However, 
elevated IgG persisted after the clearance (Lee & Newell, 2006).  
 
1.6.2 Chicken Immune Response 
 
As with all vertebrates, the immune system of all avian species including chickens is 
comprised of two arms, an innate (non-specific) immunity and adaptive (specific) immunity 
(Erf, 1997; Sharma, 1991). Humoral immunity is characterized by B lymphocyte secreted 
antibodies under the control of the bursa of Fabricius, while the cellular immune system is 
under the control of the thymus (Sharma, 1991). Other important chicken cellular immune 
response cells include macrophages, dendritic cells, NK cells and effector cells of antibody 
dependent cellular cytotoxicity (Sharma, 1991).  
 
The chicken intestinal innate immune system comprises several tissues, cells (i.e. epithelial 
cells, monocytes/macrophages, dendritic cells, NK cells and neutrophils), and germline-
encoded molecules (i.e. chemokines, cytokines, antimicrobial peptides and nitric oxide) that 
can limit commensal and pathogenic bacteria (Brisbin et al., 2008). The primary site of C. 
jejuni infection colonisation in chickens occurs in the deep crypts of ceacum, in the mucous 
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layer located close to the epithelial cells (Lee & Newell, 2006). C. jejuni infection colonisation 
produces both systemic and secretory IgA antibody responses to a range of antigens 
including flagellin (Cawthraw et al, 1994; Widders et al, 1996). C. jejuni has been shown to 
be able to adhere to, invade in and stimulate inflammatory responses from chicken 
macrophages and epithelial cells in vitro (Smith et al., 2005; Byrne et al., 2007; Larson et al., 
2008; Van Deun et al., 2008). An elevated production of IL-1β, IL-6 and inducible nitric oxide 
synthase was identified from both cell types, which indicates that C. jejuni can stimulate 
chicken innate immune responses (Young et al, 2007) (Figure 1.2).  
 
A crucial step in the host innate immune response to bacterial entrance in the gastrointestinal 
(GI) tract is the activation of TLRs. TLRs are expressed on a variety of GI mucosa cells, 
including macrophages and epithelial cells (He et al., 2006; Linde et al., 2008) and are 
recognised by specific bacterial ligands. Once TLRs are activated, they promote the 
expression of effector molecules such as antimicrobial peptides, nitric oxide (NO), and 
inflammatory cytokines (Hermans et al, 2012). Several TLRs have been identified to play a 
role in C. jejuni recognition, such as the chicken cell-surface-expressed chTLR2, chicken 
TLR4/myeloid differentiation protein-2 complex, and TLR21. TLR2, TLR4 and TLR21 
recognise lipopeptides, LOS and unmethylated single-stranded microbial 2′-deoxyribo DNA 
motifs, respectively (Hermans et al, 2012). Activation of chTCR2, chTLR4 and chTLR21 
results in a chicken innate immune response involving myeloid differentiation primary 
response gene 88 (MyD88)-dependent activation of NF-κB and subsequent production of 
inflammatory cytokines and chemokines (Brownlie et al, 2009; de Zoete et al, 2010; Keestra 
et al, 2010). Furthermore, chTLR4 and chTLR21 ligands can induce the production of 
inducible nitric oxide synthase-mediated NO from chicken monocytes (He et al, 2006).  
 
In the first two weeks of a chicken’s life, when the innate intestinal immune system is still 
under development, maternal antibodies are still present, which protects the newborn chicks 
against C. jejuni colonisation (Cawthraw et al, 1994; Sahin et al, 2001). Exposure to C. jejuni 
at this stage can stimulate a slow progressive humoral immune response, the recruitment of 
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heterophils and lymphocytes, and proinflammatory cytokines IL-1β, IL-8 and K203 
(Cawthraw et al, 1994; Ge et al, 2006; Sahin et al, 2003). Some immunoblotting results 
revealed that the maternal antibodies reacted strongly with outer membrane surface 
components (flagellin, LOS, and MOMPs) of C. jejuni (Cawthraw et al, 1994; Sahin et al, 
2001; Shoaf-Sweeney et al, 2008). A study showed that chicken maternal antibodies 
conferred partial protection against C. jejuni and delayed colonisation in young chicks (Sahin 
et al, 2003). After the first 2 weeks of age, as the maternal antibodies decline, 
Campylobacter can be detected in 2-3 weeks old chicks (S. Cawthraw et al., 1994). Other 
factors such as changes in the microbiota and management practices may also have an 
impact (Wigley, 2013). It is revealed that by 3 weeks of age the chicks produce their own 
antibodies in response to C. jejuni, primarily to flagellin (Cawthraw et al, 1994; Jeurissen et 
al, 1998). C. jejuni produces CDT in chicks, as in humans, but neutralizing antibodies against 
CDT are not found in chicks, which is opposite to humans (Abuoun et al, 2005).  
 
The capsule expressed by many pathogens normally induces a strong antigenic response, 
but the chicken humoral response to polysaccharides is weak (Jeurissen et al, 1998). It may 
be associated with incomplete response by chicken to T-cell independent type 2 (TI-2) 
antigens (e.g. polysaccharides) (Jeurissen et al, 1998). TI-2 antigens active chicken B cells 
independently of T cells, which may associated with their ability to crosslink cell-surface 
immunoglobins, thereby contributes to C. jejuni colonisation in chicken (Young et al, 2007). 
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1.7 Campylobacter Virulence Mechanisms 
 
Virulence is the sum of mechanisms that permits an organism to adhere to and colonise host 
tissue, the occurrence of cytopathogenic effects, and the host characteristics involved 
(Haddad et al, 2010). It is the measure of the degree of pathogenicity of an organism. The 
mechanism of pathogenesis of C. jejuni comprises of four main stages: adhesion to intestinal 
cells, colonization of the digestive tract, invasion of targeted cells, and toxin production 
(Haddad et al, 2010). 
 
In response to the high number of cases of human campylobacteriosis, various virulence 
study models are available depending on the virulence stage being analysed. Despite the 
high cost and limited availability, animal models are frequently used to study digestive 
disease, in particular to analyse the colonization stage. Eukaryotic cell cultures have been 
developed because of fewer restrictions on their use and the lower cost of these cultures 
studies compared with animal models, and this ex vivo approach makes it possible to mimic 
the bacterial cell–host interactions observed in natural disease cases. Models are 
complemented by molecular biology tools, especially mutagenesis and DNA microarray 
methods to identify putative virulence genes or proteins and permit their characterisation. No 
current model seems to be ideal for studying the complete range of C. jejuni virulence. 
However, the models available deal with different aspects of the complex pathogenic 
mechanisms particular to this bacterium (Haddad et al.).  
 
1.7.1 Adherence Mechanisms 
 
Adhesins belong to an important class of bacterial proteins, which play an important role in 
the processing of bacterial adherence to the host cells (Garg & Gupta, 2008). This class of 
proteins include fimbria and pili, which are found in a variety of bacteria including E. coli, 
Virbio cholera, Neisseria species et al. (Garg & Gupta, 2008). Adhesins have been 
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considered as important vaccine candidates as they are often surface exposed (Garg & 
Gupta, 2008).  
 
Several proteins that are related to C. jejuni adherence to eukaryotic cells have been 
identified. C. jejuni CadF is a protein similar to the E. coli OmpA and it functions by forming 
membrane channels (Mamelli et al, 2006). It binds specifically to fibronectin, which is located 
basolaterally on epithelial cells in situ (Konkel et al, 1997; Monteville & Konkel, 2002; 
Monteville et al, 2003). The CadF fibronectin-binding domain contains a novel fibronectin-
binding motif, which consists of amino acids 134-137 (FRLS) (Konkel et al, 2005). CadF is 
required for C. jejuni binding and invasion in vitro, and cadF mutants show reduced 
colonisation ability compared to the wild type (Monteville et al, 2003; Ziprin et al, 1999). In 
addition, CadF appears to have multiple functions, as it is also required for signalling to the 
host cell leading to the activation of the small GTPases Rac and CDC42, and subsequence 
uptake of bacteria into the host cell (Krause-Gruszczynska et al, 2007a).  
 
JlpA is another characterized adhesin, which is a surface-exposed lipoprotein that is crucial 
for Hep-2 cell binding (Jin et al, 2001). It binds to heat shock protein (Hsp) 90α, and activates 
the NF-κB and p38 mitogen-activated protein kinase (Jin et al, 2003). NF-κB and mitogen-
activated protein kinase both contribute to proinflammatory responses (Jin et al, 2003). It has 
been suggested that some of the inflammation during C. jejuni pathogenesis may be related 
to JlpA-dependent adherence (Young et al, 2007).  
 
Another lipoprotein, autotransporter CapA, is also implicated as an adhesin (Ashgar et al, 
2007). C. jejuni mutants with capA gene deficiency have decreased adherence to Caco-2 
cells in vitro (Ashgar et al, 2007). The mutants also display decreased colonization and 
persistence in a chicken model (Ashgar et al, 2007). The capA mutants were severely 
impaired in their ability to colonise chickens, and was rapidly cleared from infected birds, in 
contrast to the wide-type strain, which persisted in high numbers during the 6-week 
experimental time (Ashgar et al, 2007).  
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Interestingly, some putative C. jejuni adhesins are located in the periplasm. For instance, the 
Peb1 adhesin (also known as CBF1), is a periplasmic-binding protein, and shares similarity 
with the periplasmic-binding proteins of amino acid ATP-binding cassette (ABC) transporters 
(Leon-Kempis Mdel et al, 2006; Pei & Blaser, 1993). Antibodies induced against the Peb1 
protein block the adherence of C. jejuni to intestinal cells (Kervella et al, 1993; Pei et al, 
1998). Peb1 binds tightly to both aspartate and glutamate and mutants lacking peb1 cannot 
grow if amino acids aspartate and glutamate are the major carbon source (Leon-Kempis 
Mdel et al, 2006). Although Peb1 has not been localized to the inner or outer membrane, it 
has been detected in the culture supernatant (Leon-Kempis Mdel et al, 2006). In addition, 
Peb1 contains a predicted peptidase II signal recognition site, which indicates that it is 
possible that some Peb1 is surface accessible (Leon-Kempis Mdel et al, 2006; Pei & Blaser, 
1993). Peb1-deficient mutants have decreased colonisation ability in mice, which could be 
attributed to the loss of either the adhesion or the amino acid transportation, or both (Leon-
Kempis Mdel et al, 2006; Pei et al, 1998).  
 
Protein Peb4 was first classified as a cell-binding factor, which is homologous to a petidyl-
prolyl cis/trans isomerise of E. coli. The petidyl-prolyl cis/trans isomerise has multiple roles in 
E. coli, for example, being involved in outer membrane protein biogenesis, in pilus assembly, 
and for in vivo persistence (Justice et al, 2006; Oldfield & Wooldridge, 2009). Later it was 
found that Peb4 is required for optimal cell adhesion and biofilm formation (Asakura et al, 
2007).  
 
Another periplasmic proteins, Cj1496c, is a glycoprotein that has sequence similarity to a 
magnesium transporter. Cj1496c is also required for wild type levels of adherence(Kakuda & 
DiRita, 2006). The mechanisms of periplasmic proteins affecting host-cell adherence is still 
unclear.  
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1.7.2 Colonisation 
 
C. jejuni can colonise chickens at very high numbers (up to 1010 CFU per gram of infected 
intestine) (Young et al, 2007). Deep crypts of the caecum is the primary site of colonisation 
(Young et al, 2007). C. jejuni is commonly found in the mucus layer close to epithelial cells 
(Young et al, 2007). Chicken caeca are large closed pouches, found off the colon (Young et 
al, 2007). They are located just past the ileal junction (Young et al, 2007). Experiments 
where chicken intestinal mucus was added to human epithelial cells show that less C. jejuni 
invasion is observed, which indicates that the chicken intestinal mucus might play a 
important role in the asymptomatic nature of chicken colonisation (Nachamkin et al, 1993).   
 
Colonisation factors are a class of proteins that enable bacteria to colonise the host. 
Campylobacter posses a single polar flagella which has been shown to be critical for 
intestinal colonization and invasion (Yao et al, 1994). Flagellin has been shown to be the 
immunodominant antigen during human and animal colonisation, and it is also required for 
colonization in vivo (Guerry et al, 2000). Flagellar biosynthesis is regulated in a hierarchical 
fashion with genes expressed in the order in which they are required for the assembly of the 
flagellum. The production of flagella, however, requires a significant expenditure of energy. 
Therefore, the regulation of these genes is of critical importance to the organism. However, 
unlike other bacterial species, only three sigma factors have been identified in C. jejuni (σ70, 
σ54 and σ28) (Parkhill et al, 2000). These observations suggest that a number 
of Campylobacter genes are coordinately regulated.  
 
Among members of the family Enterobacteriaceae, the genes flhC and flhD are the initial 
regulators of the flagellar regulatory cascade (Macnab, 2003). Within this scheme, a 
feedback mechanism ensures the correct order of flagellar gene expression. In C. jejuni that 
lacks the flhC and flhD regulators, the genes in the flagella regulon expressed intermediate 
and late in the flagella regulatory cascade are controlled by the sigma factors σ54 and σ28, 
respectively. Gene flhA and fliA are also involved with C. jejuni colonisation. Based on 
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studies on the flhA gene and the gene fliA in C. jejuni strain NCTC 11168, it has been 
observed that a number of genes with unknown functions, but not appearing to be directly 
involved in flagella function, were also co-regulated along with those genes associated with 
flagella function (Carrillo et al, 2004; Parkhill et al, 2000). The flhA gene is expressed early in 
the cascade and is involved in the export of flagella proteins, while the gene fliA encodes σ28. 
Additionally, mutants in the gene that encodes the flagellin FlgR also display defects in 
chicken colonisation (Hendrixson, 2006).  
 
Other regulators that are not related to flagellar motility are also associated with efficient 
chicken colonisation, and include CbrR (Stintzi, 2003). CbrR regulates deoxycholate 
resistance, and contains two response-regulator domains and a GGDEF domain (Stintzi, 
2003).  
 
Another wide-type chicken colonisation system required by C. jejuni is RacRS, which is a 
two-component system (Purdy et al, 1999). Mutants lacking RacRS expression have a 
growth defect at 42ºC (Purdy et al, 1999). The RacRS system is involved in a temperature-
dependent manner, which can act as both as an activator and repressor (Purdy et al, 1999).  
 
C. jejuni mutants in DccRS, a two-component system, also have defective in chicken 
colonisation compared with the wild type (Purdy et al, 1999). No known predicted functions 
have been identified within DccRS-regulated genes (Purdy et al, 1999). However, one of 
genes seems to be essential for bacteria growth, while two genes mutants lead to 
colonisation defects in chicken (Purdy et al, 1999).  
 
Several other genes not involved in motility or gene regulation were also found to be 
essential for chicken colonisation. These genes include genes that encode the protein N-
linked glycosylation related enzymes (Hendrixson & DiRita, 2004; Kakuda & DiRita, 2006; 
Karlyshev et al, 2004), and various adherence and invasion factors, such as cadF and ciaB 
(Ziprin et al, 2001; Ziprin et al, 1999). In addition, Campylobacter invasive antigen/Cia 
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proteins, which are normally involved in host invasion, have been shown to play an important 
role in the colonisation process since Cia negative strains colonised chickens at 
approximately 1000-fold lower levels than wild-type strains (Biswas et al, 2007).  
 
Finally, other factors such as antimicrobial resistance mechanisms, and metabolism 
mechanisms that are related to low iron, low oxygen and high serine or other amino acids 
environment, may also have an impact on chicken colonisation (Lin et al, 2003; Luo et al, 
2003; Palyada et al, 2004; Smith et al, 2005; Velayudhan et al, 2004; Woodall et al, 2005).  
 
1.7.3 Invasion 
 
To establish an infection, C. jejuni must cross the mechanical and immunological barriers of 
the GI tract (Young et al, 2007). The mucus layer of the GI epithelium is the first of line of 
defence, but C. jejuni penetrates this barrier by several mechanisms, which include its 
motility and corkscrew morphology, and its relatively short LOS O-sidechain (Young et al, 
2007). The short O-sidechain of the LOS is proposed to reduce nonspecific binding to mucin 
glycoproteins (McSweegan & Walker, 1986). After C. jejuni passes the mucus layer, it 
interacts with the underlying epithelial cells using various mechanisms.  
 
Campylobacter invades the human intestinal epithelial cell layer (van Spreeuwel et al, 1985), 
but complete understanding of the exact mechanism that controls the invasion is 
complicated, as it varies between strains (Young et al, 2007). It is shown that microtubule 
polymerisation is required by all strains for maximal invasion (Hu & Kopecko, 1999; 
Monteville et al, 2003). Some strains also require microfilament polymerisation (Biswas et al, 
2003; Oelschlaeger et al, 1993). Microtubule polymerisation mechanism for invasion makes 
Campylobacter different from other invasive organisms that use a microfilament-dependent 
mechanism of entry. Human epithelial cell membrane pseudopods that extend towards and 
envelop C. jejuni, have been visualised by scanning electron microscopy (Biswas et al, 
2003). Immunofluorescence experiments have also shown that these pseudopods contain 
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microtubules (Hu & Kopecko, 1999). Once internalised within cells, C. jejuni-containing 
vacuoles seem to move along microtubules to the perinuclear region of the cell by 
interactions with dynein (Hu & Kopecko, 1999).  
 
The invasion factors normally disrupt the host cell membranes and stimulate endocytosis, 
which facilitates the entry of bacteria into the host body across protective epithelial tissue 
layers (Garg & Gupta, 2008). Biopsies of humans diagnosed with C. jejuni exhibit the 
presence of intercellular bacteria revealing that host cell invasion may be important in C. 
jejuni infection and subsequent tissue damage (van Spreeuwel et al, 1985). Some isolates of 
C. jejuni are highly invasive in cell-based models, such as in the human enterocyte-derived 
Caoco-2 cell line. However, many isolates show low levels of invasion in vitro (Biswas et al, 
2003). The method of C. jejuni entry into host cells needs to be better investigated and may 
be strain-dependent (Oldfield & Wooldridge, 2009). The highly invasive strain C. jejuni 81-
176 displays microtubule-dependent invasion, and is also likely to rely on microtubule motors 
for uptake and intracellular motility (Hu & Kopecko, 1999). This strain contains a virulence 
plasmid pVir that encodes a T4SS (discussed in Section 1.9). Most other strains of C. jejuni 
that do not carry this plasmid appear to invade human epithelial cells via a microfilament-
dependent (Konkel & Cieplak, 1992) or microfilament/microtubule-dependent mechanisms 
(Biswas et al, 2003). It was reported that C. jejuni invasion requires tyrosine phosphorylation 
of host proteins, and also the presence of lipid rafts in the host membrane (Hu et al, 2006b; 
Konkel et al, 2004; Wooldridge et al). There is also evidence that small guanosine 
triphosphate (GTP)-binding proteins, such as Rac1 and Cdc42, and membrane ruffling are 
required for C. jejuni host invasion (Krause-Gruszczynska et al, 2007a). It is possible that all 
of the mechanisms are important in vivo, while different strains and the presence and/or 
abundance of certain host receptors may have an impact on which invasion pathway 
predominates (Oldfield & Wooldridge, 2009).  
 
Host invasion seems to involve the mobilisation of bacterial effector proteins into host cells, 
which stimulates host cell signalling and triggers bacterial internalisation (Oldfield & 
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Wooldridge, 2009). It is reported that C. jejuni F3800 produces at least 14 proteins during co-
culture with epithelial cells, and a subset of these proteins are secreted in the presence of 
eukaryotic cells or cell culture-conditioned medium (Konkel & Cieplak, 1992; Konkel et al, 
1999). The functions of these proteins are unknown. However, confocal microscopy results 
indicates that one protein, CiaB, enters host cells during invasion (Konkel et al, 1999). 
Isogenic mutants lacking-ciaB are deficient in Cia protein secretion and impaired in their 
ability to invade host cells. Cia protein synthesis is stimulated by the bile component 
deoxycholate, serum and heat-stable eukaryotic host cell components, but the secretion is 
not (Rivera-Amill et al, 2001). It is suggested that Cia production might be stimulated at the 
early stage of colonisation, in the small intestine (Rivera-Amill et al, 2001). Then secretion 
happens only after adherence at the site of long-term colonisation (Rivera-Amill et al, 2001). 
The secretion of CiaB is further discussed in Section 1.9.2.  
 
Another flagella exporting protein, FlaC is also related to host cell invasion. Unlike the Cia 
proteins, synthesis of FlaC in the strain TGH9011 does not require contact with epithelial 
cells or culturing in conditioned medium (Song et al, 2004). After secretion, FlaC binds to the 
surface of human epithelial cells and plays a role in invasion, as mutants lacking flaC have 
invasion levels that were reduced to 14% compared with wild type cells (Song et al, 2004).  
 
1.7.4 Defensive Virulence Factors 
 
Cell surface carbohydrates and proteins that protect pathogens from host defence 
mechanisms belong to the class of defensive virulence factors, and include capsular 
polysaccharides, lipopolysaccharides and outer membrane proteins (discussed in Section 
1.8.2).  
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1.8 Virulence Determinants of C. jejuni 
 
Five classes of virulence factors have been widely discussed: adhesions, colonisation 
factors, invasion factors, toxins and defensive virulence factors. Apart from these, there are 
also other virulence traits that are indirectly involved in bacteria virulence, such as secretory 
machinery, sideophores, catalases and regulators, and these are also essential for 
pathogens to manifest infection (Brogden, 2000). Molecular mechanisms of C. jejuni 
virulence show C. jejuni is able to execute the N-linked glycosylation of more than 30 
colonisation, adherence and invasion related proteins (Dasti et al., 2009). Unlike other 
diarrhoea-causing bacteria, no other classical virulence factors have yet to be identified in C. 
jejuni except CDTs (Dasti et al., 2009). CDT holotoxin, which consists of three subunits CdtA, 
CdtB and CdtC, is the only virulence factors in C. jejuni shared with other enteric pathogens 
(Poly et al, 2007). 
 
1.8.1 Flagella 
 
The bipolar flagellum of C. jejuni is considered as one of its most important virulence factors 
(Guerry et al, 2000). The flagellum is not only depicted to facilitate motility but is also 
associated with processes such as chemotaxis, the secretion of virulence proteins (such as 
Campylobacter invasive antigens/Cia), auto-agglutination, micro-colony formation and 
avoidance of the innate immune response. All of these processes are found to be dependent 
on a fully functional flagellum (Dasti et al., 2009; Baker et al, 2006; Guerry, 2007; Wadhams 
& Armitage, 2004). Flagellar regulatory hierarchy that includes σ54 (encoded by rpoN) and σ28 
(encoded by fliA) as the flagellar σ-factors, and the phase variable two-component system 
FlgRS have been elucidated by various studies (Carrillo et al, 2004; Colegio et al, 2001; 
Hendrixson, 2006; Hendrixson & DiRita, 2003; Jagannathan et al, 2001; Wosten et al, 2004).  
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The flagellum allows the organism to move quickly (up to 75 µm/s) through a viscous 
environment and increases its ability to adhere and invade intestinal epithelial cells 
(Szymanski et al, 1995). Flagellin is the immunodominant antigen in both human and animal 
infections. The flagellum is essential for in vivo colonisation of C. jejuni in host organisms, 
and it is needed as the export apparatus for invasion antigen Cia and FlaC proteins secretion 
during the host invasion process (Guerry et al, 2000). Flagellin is modified by O-linked 
glycosylation, which is required for flagellar assembly and motility, virulence and epithelial 
cell adherence and invasion (Young et al, 2007). 
 
One of the most important proteins in the formation of flagella is FlaA. A mutation of the flaA 
gene results in a very short non-functional flagellum. This leads to a dramatic decline of C. 
jejuni colonisation ability in chickens (Nuijten et al, 2000). C. jejuni FlaB is involved in the 
flagella export apparatus. It is shown that in the absence of FlaB, C. jejuni is non-motile. 
Homologues of the flagellar master regulators FlhC and FlhD have not been identified in the 
C. jejuni genome (Parkhill et al, 2000). Another two flagella proteins, FlgP (encoded by 
cj1026c) and FlgQ (encoded by cj1025c), have been identified as required for the motility of 
C. jejuni, but not for flagellar biosynthesis (Sommerlad & Hendrixson, 2007). FlgP and FlgQ 
are not components of the transcriptional regulatory cascades to activate σ28 or σ54-
dependent expression of flagellar genes (Sommerlad & Hendrixson, 2007). Immunoblot 
analyses suggests that the majority of FlgP is associated with the C. jejuni OM, and the 
amount of it in the outer membrane is dependent on the presence of FlgQ, which suggests 
that FlgQ may be required for localization or stability of FlgP (Sommerlad & Hendrixson, 
2007).  
 
1.8.2 Lipopolysaccharide, Lipooligosaccharide and Capsule 
 
Lipopolysaccharides (LPSs) are also termed as endotoxins, which form a family of toxic 
phosphorylated glycolipids found in the outer membrane of Gram-negative organisms 
(Rietschel et al, 1990). LPSs are essential for the physical integrity and also functioning of 
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these Gram-negative bacteria outer membrane, including Campylobacter spp. (Rietschel et 
al, 1990). LPSs play an essential role for these bacteria, as they are involved in the 
interaction between the organisms with their environment and their hosts (Moran et al, 2000). 
LPS possesses potent immunomodulating and immunostimulating activity (due principally to 
their lipid component, lipid A), harbours binding sites for antibodies and non-immunoglobulin 
serum factors, and contributes to bacterial virulence (Rietschel et al, 1990).   
 
Interest in determining Campylobacter LPSs role in serotyping and pathogenesis has been 
raised for a number of reasons. First, a sero-typing typing system for C. jejuni and C. coli 
based on thermostable antigens, which is of the LPS class of molecules, was firstly 
described in the 1980s (Penner & Hennessy, 1980; Penner et al, 1983). Serotyping of clinical 
isolates has confirmed an association between antecedent infections with certain serotypes 
of C. jejuni and subsequent development of GBS and MFS (Kuroki et al, 1993; Moran et al, 
1996; Moran et al, 1991). Second, the application of serotyping of C. jejuni and C. coli based 
on thermostable antigens has led to the interest in its application to other species of 
Campylobacter (Aspinall et al, 1995; Kosunen, 1986; Perez-Perez et al, 1986). Third, the 
molecular basis for some LPS activities was unclear.  
 
The LOS is closed related to the LPS molecule. The LOS of C. jejuni is highly variable and 
their structure resembles human neuronal gangliosides, which is thought to lead to 
autoimmune disorders, which include GBS and MFS (Young et al, 2007). Mutations in LOS 
biosynthesis genes affect serum resistance, and the adherence and invasion of INT 407 cells 
(Fry et al, 2000a). The lack of N-acetylneuraminic acid from the LOS core decreases the 
bacterial immunogenicity in humans (Coker et al, 2002).  
 
The capsule structure of C. jejuni NCTC 11168 has been determined and it incudes 6-
methyl-D-glycero- α-L-glucoheptose, β-D-glucouronic acid modified with 2-amino-2-
deoxyglycerol, β-D-GalƒNAc and β-D-ribose (St Michael et al, 2002), with a novel 
modification on GalƒNAc (Szymanski et al, 2003). The structure variation of the C. jejuni 
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capsule can be attributed to multiple mechanisms, which include phase variation of structural 
genes and O-methyl phosphoramidate modification (Karlyshev et al, 2005a; Karlyshev et al, 
2000; St Michael et al, 2002; Szymanski et al, 2003). The capsule plays an important role in 
C. jejuni serum resistance, the adherence and invasion of epithelial cells, and chicken 
colonisation and virulence in a ferret model (Bachtiar et al, 2007; Bacon et al, 2001; Jones et 
al, 2004). It has been shown that the capsule polysaccharide is accessible to the immune 
system and structure variation is probably important in host immune response evasion 
(Young et al, 2007).  
 
1.8.3 Glycosylation 
 
Glycosylation is the most abundant polypeptide chain modification in nature. C. jejuni 
expresses two protein-glycosylation systems, the O-linked glycosylation system and the N-
linked glycosylation system (Young et al, 2007). The C. jejuni glycome and surface structures 
are shown in Figure 1.3. 
 
The O-linked glycosylation system in C. jejuni modifies flagellin, and the glycan is linked to 
the flagellin through a serine or threonine residue, which is required for flagella assembly 
(Young et al, 2007). Proteins of the O-linked-glycosylation systems together with their 
biochemical functions and a hypothetical biosynthetic pathway have been investigated by a 
range of sequence analysis studies, targeting mutation and chemical analysis (Chou et al, 
2005; Guerry et al, 2006; McNally et al, 2006; Thibault et al, 2001). A specific recognition 
sequence for O-linked glycosylation has not been identified yet, and the addition of the 
glycan is believed to require surface exposure and hydrophobicity (Thibault et al, 2001). It is 
suspected that the O-glycan might have a role in the interactions of flagellin subunits with 
one another or with other elements of the flagellar apparatus, as O-linked glycosylation of 
flagellin is required for the proper assembly of the flagellar filament (Goon et al, 2003). It was 
shown that O-link glycosylation defects caused a loss of motility, a decrease in the  
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Figure 1.3: The Campylobacter jejuni glycome and surface structures (reproduced 
from Young et al, 2007).  
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adherence to and invasion of host cells and decreased virulence in ferrets (Guerry et al, 
2006). As the flagellar apparatus of C. jejuni spans the inner and outer membranes, O-linked 
glycosylation of the flagellin monomer is believed to occur at the cytoplasm-inner membrane 
interface (Nothaft & Szymanski, 2010). Cytosine monophosphate-activated sugars are 
individually added to surface-exposed Ser or Thr residues in the flagellin subunit FlaA by a 
glycosyltransferase (Young et al, 2007).  
 
The N-linked-glycosylation of C. jejuni is a general glycosylation system, which modifies 
asparagine residues on many proteins (Young et al, 2007). It occurs at the cytoplasmic face 
of the inner membrane and the system is assembled by the Pgl system, which consists of a 
heptasaccharide, unlike the tetradecasaccharide that is transferred by the eukaryotic N-
linked-glycosylation machinery (Wacker et al, 2002; Young et al, 2002). The N-glycan 
heptasaccharide is flipped across the membrane and added as a block to target proteins in 
the periplasm (Young et al, 2007). Different from the O-linked glycosylation machinery, a 
consensus sequence element (sequon) is present in N-linked glycosylation, D/E-X1-N-X2-S/T 
(X1 and X2 can be any amino acids except proline) (Kowarik et al, 2006; Nita-Lazar et al, 
2005). The sequon is essential for glycosylation, but not sufficient, other sequences or 
factors, such as tertiary or quaternary structure may be also be required (Kowarik et al, 
2006). The N-linked glycan is conserved in all C. jejuni strains that have been examined 
(Young et al). After comparing the conserved N-linked glycosylation with the variability of the 
other surface carbohydrate traits, it has been suggested that N-linked glycosylation may play 
a more fundamental role in the biology of C. jejuni (Young et al, 2007). In C. jejuni, a 
heptasaccharide is built on the cytoplasmic side of the inner membrane on a lipid-linked 
precursor, undecaprenyl phosphate (Linton et al, 2005; Reid et al, 2008; Reid et al, 2009), 
and then the resulting lipid-linked oligosaccharide is translocated across the inner membrane 
into the periplasmic space by PglK, which is an ATP-dependent flippase (Alaimo et al, 2006; 
Kelly et al, 2006). Lipid-linked oligosaccharide is then transferred to Asn residues in target 
proteins by PlglB, which is a bacterial oligosaccharyltransferase.  
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The role of N-linked glycosylation in the biology of C. jejuni is not clear, even though the 
mechanisms of N-linked glycosylation are well understood. Conversely, although less is 
known about the O-linked glycosylation mechanisms, its role in C. jejuni biology, especially 
the part it plays in flagella assembly and host-cell interaction, is clear (Young et al, 2007). C. 
jejuni strains with pgl mutations show decreased adherence and invasion in the INT 407 cell 
line, as well as defects in natural competence (Larsen et al, 2004) and colonisation in the 
mouse and chicken models (Hendrixson & DiRita, 2004; Kakuda & DiRita, 2006; Karlyshev 
et al, 2004; Kelly et al, 2006; Szymanski et al, 2002). It is suggested that N-linked 
glycosylation might be involved in the evasion of the immune system, as N-linked 
glycosylation changes the immunoreactivity of at least some glycosylated proteins 
(Szymanski et al, 1999). However, most of the Pgl system modified proteins predicted are 
located in the periplasmic, rather than surface exposed (Young et al, 2002), therefore it is 
unclear how modifying these proteins would increase immune avoidance.  
 
1.8.4 Chemotaxis 
 
Chemotaxis can be characterised as flagellated bacteria that swim towards the preferred 
environment and away from a non-preferred environment and it plays an important role in 
both the commensal and pathogenic lifestyles of C. jejuni (Young et al, 2007). The general 
chemotaxis prerequisites are chemoreceptors, a chemosensory signal-transduction system 
and the flagellar apparatus (Li et al, 2014).  
 
A total of 10 methy-accepting chemotaxis receptors have been found in C. jejuni and these 
have been designated as ‘Tlps’ for transducer-like proteins (Li et al, 2014). The 
chemoreceptors from Campylobacter can be classified into three groups A, B, and C (Table 
1.5). Group A includes membrane-anchored chemoreceptors that have membrane-spanning 
regions through the inner and outer membrane. They sense periplasmic signals with a 
periplasmic sensory and a cytoplasmic signalling domain. The C. jejuni Group A receptors 
possesses a similar composition as the E. coli methy-accepting chemotaxis proteins and the 
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Halobacterium salinarium family A transducers (Zhang et al, 1996). In general, the structure 
can be described as two amino-terminal located transmembrane domains and a periplasmic 
ligand-binding domain, and then a highly conserved carboxy-terminal signalling domain 
(Morgan et al, 1993). Furthermore, a structurally conserved HAMP-domain (a linker domain 
present in Histidine-kinases, Adeny-cy-clases, Methyl-accepting-proteins and Phosphatases) 
connects the transmembrane helices (TMH) with the signalling domain (Zautner et al, 2012). 
The signal domains of Tlp2, 3 and 4 are identical (Parkhill et al, 2000). The receptor Tlp7 
only belongs to group A when it is encoded by one single gene (cjj81176-0975) as in the C. 
jejuni strains 81-176 and 81116. In the strains NCTC 11168 and B2, there are two genes 
involved in Tlp7 coding: the sections for periplasmic binding and transmembrane localisation 
are encoded on gene cj0952c; while the signalling domain is encoded by the adjacent gene 
cj0951c (Marchant et al, 2002; Tareen et al, 2010). Group B contains only one receptor, Tlp9 
(CetA), which is anchored in the inner membrane and interacts with CetB triggering pyruvate 
and fumarate signals (Hendrixson et al, 2001). CetA serves as an electron donor and CetB is 
known to be a respiratory electron acceptor (Hendrixson et al, 2001). CetA includes two 
TMH, a HAMP-domain and a highly conserved domain (HCD), and CetB has a PAS (Per, 
ARNT and Sim) domain. Both proteins together represent a bipartite energy taxis system 
(Zautner et al, 2012). Experiments reveal CetB is a signal sensing protein that conveys the 
signal to CetA, and then CetA transmits the energy taxis signals to core signal transduction 
proteins of the chemotactic system CheW/CheV, CheA(Y) and CheY (Elliott & Dirita, 2008; 
Hendrixson et al, 2001). Group C contains four chemoreceptors (Tlp5, 6, 7c and 8), which 
contain neither a periplasmic binding domain nor transmembrane regions, but only a single 
cytoplasmic signalling domain (Li et al, 2014). They are believed to reside only in the cytosol 
(Zautner et al, 2012).  
 
C. jejuni displays chemotactic motility towards amino acids that are found in high levels in the 
chicken gastrointestinal (GI) tract, and towards components of mucus (Hugdahl et al, 1988). 
Some Tlp corresponding genes knockout mutants, such as the ones that lack cj0019c  
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Table 1.5: Three different Campylobacter jejuni Tlp-chemoreceptor groups 
(reproduced from Zautner et al, 2012).  
Group types Tlp name Name Encoded gene 
Group A Tlp1  cj1506 
 Tlp2  cj0144 
 Tlp3  cj1564 
 Tlp4 docC cj0262 
 Tlp7mc *  cjj81176-0975 
 Tlp7m *  cj0952c 
 Tlp10 docB cj0019 
Group B Tlp9 CetA  cj1190 
Group C Tlp5  cj0019 
 Tlp6  cj0019 
 Tlp7c *  cj0951c 
 Tlp8  cj0019 
*Tlp7mc: Membrane-associated and cytoplasmic domains encoded by cjj81176-0975 in the C. 
jejuni strains 81-176 and 81116  
 Tlp7m: Membrane-associated partial receptor encoded by cj0952 in the C. jejuni strains 
NCTC 11168 and B2 
 Tlp7c: Cytoplasmic partial receptor encoded by cj0951c in the C. jejuni strains NCTC 11168 
and B2 
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(Tlp10) or cj0262c(Tlp4) or cj1506c(Tlp1), displayed decreased chicken colonisation ability 
(Hendrixson & DiRita, 2004; Zautner et al, 2012). However, a transposon insertion in gene 
Tlp10(cj0019) did not affect the in vitro motility of the bacteria. Strains that lack of CheY 
expression (encoded by cj1118c), which is the chemotaxis regulatory protein that controls 
flagellar rotation, exhibit decreased virulence in the ferret model (Yao et al, 1997). Tlp7 
(cj0952c/cj0951c, cjj81176-0975) could be linked to the sensing of electron donor formate, 
and Tlp1 was identified to represent the chemoreceptor for aspartate (Hartley-Tassell et al, 
2010; Tareen et al, 2010). 
 
The chemotaxis system also affects the bacterial motility of C. jejuni. Motility in turn is an 
essential factor for the pathogenicity of C. jejuni as the non-motile strains show a decreased 
capacity of infection (Morooka et al, 1985; Nachamkin et al, 1993; Pavlovskis et al, 1991). 
Therefore, the loss of chemoreceptor functions would reduce bacterial motility and, thus, 
reduce infectivity. It has been shown that a transposon insertion in Tlp3, Tlp4, Tlp7 and Tlp9 
is accompanied by reduced motility in C. jejuni (Golden & Acheson, 2002; Hendrixson et al, 
2001; Tareen et al, 2010; Vegge et al, 2009). Finally, since all chemotaxis sensed signals are 
transmitted to the flagellum via the chemotaxis core proteins, it is unsurprising that the loss of 
proteins, such as CheA and CheY, results in C. jejuni with reduced motility (Golden & 
Acheson, 2002). Despite the progress that has been achieved, the overall understanding of 
chemoreceptors roles and chemotaxis mechanisms is still incomplete and awaits further 
investigation.  
 
1.8.5 Toxins 
 
The most commonly known bacterial virulence factors are the bacterial toxins that poison the 
host cells and cause tissue damage (Garg & Gupta, 2008). They have been recognised as a 
major pathogenicity-associated factor.  
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C. jejuni Cytolethal distending toxin (CdtA,B,C) causes arrest at the G1/S or G2/M transition 
of the cell cycle, depending on the cell type (Hassane et al, 2001; Hassane et al, 2003; Lara-
Tejero & Galan, 2000; Lara-Tejero & Galan, 2001; Whitehouse et al, 1998). The active 
holotoxin is a complex that includes CdtA, CdtB and CdtC (Lara-Tejero & Galan, 2001) 
(Figure 1.4), and one study has even shown that the combined CdtB and CdtC still has some 
cytotoxicity in the absence of CdtA (Lee et al, 2003). 
 
CdtB is recognised as the toxic component, as microinjection or transfection of this subunit 
alone into host cells exhibits the effects that are obtained with the whole holotoxin complex 
(Lara-Tejero & Galan, 2000). CdtB is thought to act as a DNase as it is homologous with a 
family of DNase I-like proteins (Young et al, 2007). However, CdtB has weak DNase activity 
in vitro (Lara-Tejero & Galan, 2000), and studies that have attempted to determine if the DNA 
damage in vivo is caused by CdtB have produced conflicting results (Hassane et al, 2001; Li 
et al, 2002; Mao & DiRienzo, 2002; Sert et al, 1999; Whitehouse et al, 1998).  
 
CdtB is nuclear localised, and the CdtB sequences from several species reveal the presence 
of a putative bipartite nuclear-localisation signals located mostly in the carboxy half of the 
protein (McSweeney & Dreyfus, 2004). One of the putative nuclear-localisation signals from 
E. coli has been identified as essential for CdtB-II nuclear localisation and cytotoxicity 
(McSweeney & Dreyfus, 2004). Another CdtB from A. actinomycetemcomitans also contain a 
bipartite nuclear-localisation signal domain, which is also required for CdtB nuclear 
localisation (Nishikubo et al, 2003).  
 
The understanding of the exact roles of CdtA and CdtC in this family of toxins is still limited. 
CdtA and CdtC share some similarity with the B chain of the ricin toxin, which is responsible 
for receptor-mediated endocytosis of ricin (Lara-Tejero & Galan, 2001). CdtA and CdtC bind 
to HeLa cells with specificity, which is likely by the same receptor (Lee et al, 2003). CdtA and 
CdtC may mediate binding and subsequent internalisation through the same pathway as  
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Figure 1.4: Campylobacter jejuni cytolethal distending toxin CdtA, CdtB and CdtC 
(reproduced from Young et al, 2007).  
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H. ducreyi CDT, which is taken up into cells by clathrin-coated pits (Cortes-Bratti et al, 2000). 
CDT may be involved in C. jejuni asymptomatic, commensal infections by providing a way to 
either avoid host immune-response mechanisms, or redirect them towards tolerance (Young 
et al, 2007). CDT is responsible for some of the secretion of IL-8 and there is also a CDT-
independent IL-8 stimulation pathway (Hickey et al, 2000). In experiments, C. jejuni CDT 
induces apoptosis in monocytic cell lines in vitro (Hickey et al, 2005). Furthermore, the 
persistent C. jejuni colonisation of wild-type mice, but not NF-κB deficient mice, indicates that 
CDT might allow C. jejuni to escape immune surveillance by inducing NF-κB by CdtB (Fox et 
al, 2004). In chicks, CDT is expressed by bacteria in the caeca, although CDT-neutralising 
antibodies are not detected in the colonised chicks (Abuoun et al, 2005). In addition, C. jejuni 
mutants that lack CDT, colonise chickens with wild-type efficiency (Biswas et al, 2006). 
Therefore, it would seem that CDT is not an important factor in the colonisation of chickens. 
 
A number of putative haemolysins have also been identified from the C. jejuni NCTC 11168 
genome, including Cj0588 (TlyA) and Cj1351 (PldA) (Parkhill et al, 2000). PldA from E. coli is 
an OM-associated phospholipase A with haemolytic activity (Grant et al, 1997). A C. jejuni 
mutant lacking-pldA was observed to be impaired in its colonisation ability in the chicken 
caecum (Ziprin et al, 2001). The PldA protein does not appear to be secreted as C. jejuni can 
shed large numbers of OM-derived vesicles (Logan & Trust, 1982). Therefore, it is likely that 
haemolysin PldA and other OM-associated toxins may be shed from the cell by the process 
of vesicle shedding, which is similar to the pore-forming cytotoxin ClyA in E. coli (Wai et al, 
2003).  
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1.9 C. jejuni Protein Secretions 
 
To overcome the two lipidaceous barriers and allow some proteins to get to their extracellular 
target locations, Gram-negative bacteria have employed several secretion systems, which 
include types I-VI and the Chaperone/Usher pathway (Scott-Tucher & Henderson, 2009). 
Many of these systems are composed of a complex number of macromolecules (Scott-
Tucher & Henderson, 2009).  
 
The secretion mechanisms of Campylobacter are relative poorly understood compared to 
other bacterial pathogens. Both Sec-dependent secretion system and the Sec-independent 
twin-arginine translocation (Tat) export pathways have been identified from genome 
sequencing of Campylobacter (Fouts et al, 2005; Parkhill et al, 2000). In addition, genes for 
the signal recognition particle variant of the Sec pathway have also been revealed from the 
C. jejuni genome (Parkhill et al, 2000). The Sec system is generally required for periplasmic 
and outer membrane protein secretion in other Gram-negative organisms (Oldfield & 
Wooldridge, 2009). Four putative Tat components and 11 putative Tat substrates have been 
identified from Campylobacter genome analysis, which include an unusual alkaline 
phosphatase protein (PhoACj) and the nitrate reductase protein NapA (Oldfield & Wooldridge, 
2009). Inactivation of tatC results in the abolishment of protein PhoACj and NapA (van Mourik 
et al, 2008). No type I, III or type IV secretion systems encoding genes have been identified 
from the C. jejuni NCTC 11168 genome (Fouts et al, 2005). However, T4SS has been 
discovered from the C. jejuni strain 81-176 and pVir containing strains (Oldfield & 
Wooldridge, 2009). 
 
1.9.1 Autotransporter Proteins  
 
Autotransporter proteins are secreted proteins that direct their own secretion to the cell 
surface or extracellular location (Henderson et al, 2004). They belong to the type V secretion 
Chapter 1 
 50
system (T5SS) (Scott-Tucher & Henderson, 2009). Even sharing a common code of 
secretion, autotransporter proteins have highly diverse N-terminal functional domains that 
are often involved in a range of pathogenic processes (Henderson et al, 2004). The 
pathogenic mechanisms autotransporter protein are involved in include adhesion, toxigenicity 
and intracellular spread (Henderson et al, 2004). Two highly similar autotransporter protein 
related genes, capA and capB, have been identified from the C. jejuni NCTC 11168 genome 
(Ashgar et al, 2007).  
 
CapA (discussed in Section 1.7.1) and CapB possess characteristic molecular features of 
autotransporter proteins, which include an N-terminal signal peptide, relatively low cysteine 
content, a β-sheet rich C-terminal domain and a C-terminal autotransporter protein motif 
(Y/V/I/F/W)-X-(F/W) (Oldfield & Wooldridge, 2009). It has been confirmed to be an outer 
membrane protein found on the cell surface (Oldfield & Wooldridge, 2009). However, unlike 
other autotransporter proteins, CapA is not released into the extracellular environment 
(Oldfield & Wooldridge, 2009). CapA has been identified as a lipoprotein, due to the reduced 
amount of CapA in the outer membrane fraction of C. jejuni cells grown in the present of 
globomysin, a specific lipoprotein signal peptidase II inhibitor (Dev et al, 1985). It is also an 
adhesin (discussed in Section 1.7.1). There is no evidence of expression of CapB, or 
transcription of the capB locus in vitro, or it may only be expressed under certain unknown 
conditions (Oldfield & Wooldridge, 2009). 
 
1.9.2 Flagella Exporting Related Secretion 
 
The C. jejuni CiaB protein shares similarity with other invasion-related proteins, such as 
Salmonella SipB (Kaniga et al, 1995) and Yersinia YopB (Hakansson et al, 1996). CiaB also 
lacks an identifiable signal sequence (Konkel et al, 1999). Based on the evidence as above, 
this initially led to suggestions that Cia proteins are secreted via a type III secretion system 
(T3SS) (Oldfield & Wooldridge, 2009). However, analysis of the C. jejuni genome suggests 
that the only genes with significant similarity to those encoding T3SSs are those encoding 
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the flagellar export apparatus (Oldfield & Wooldridge, 2009). No known bacterial system has 
a dual role as a flagellum and as a portal for the secretion of proteins that are unrelated to 
the primary function of the flagellum (Oldfield & Wooldridge, 2009). This makes Cia secretion 
so unique as it has been shown to be dependent on the flagella apparatus in C. jejuni 
(Konkel et al, 2004; Song et al, 2004). Mutational experiments show that secretion of the Cia 
proteins need a functional flagellar basal body and hook and at least one of the filament 
proteins, FlaA or FlaB (Konkel et al, 2004).  
 
Another flagella exporting related protein is FlaC, which has sequence identity with the N- 
and C-terminal regions of proteins FlaA and FlaB (Song et al, 2004). It is not required for the 
flagellum formation or motility, but it is secreted via the flagellum, as mutations in the flagellar 
basal rod gene flgF and hook gene flgE abolishes the FlaC secretion (Song et al, 2004). The 
FlaC protein seems to be involved in host cell invasion (discussed in Section1.7.3). The 
small acidic protein FspA is also secreted via the flagella export system (Poly et al, 2007). 
Two variants of this protein are present, FspA1 and FspA2. FspA2 has been identified to 
rapidly induce apoptosis in INT407 cells, and thus likely to play a role in pathogenesis (Poly 
et al, 2007).  
 
Proteins such as CiaB and FspA are not secreted via typical secretion systems (secreted 
without any apparent signal peptide or other signal governing their secretion) are often 
termed non-classically secreted proteins (NCSPs) (Bendtsen & Wooldridge, 2009). Proteins 
secreted via those alternative routes are likely involved in pathogenesis (Bendtsen & 
Wooldridge, 2009). 
 
1.9.3 Type II-like Secretion System  
 
As mentioned in Section 1.5, natural transformation in C. jejuni requires homologues of 
proteins that are involved in type II protein secretion in other bacteria (Wiesner et al, 2003). 
T2SSs are involved in proteins secreted across the outer membrane and targeted delivery of 
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a variety of molecules including toxins, proteases, cellulases and lipases (Oldfield & 
Wooldridge, 2009). In silico analysis and transposon library screening identified genes that 
when mutated, caused transformation defects with 1000 times lower levels compared to the 
wide types (Wiesner et al, 2003). Five out of the 11 proteins identified in this study are similar 
to proteins that are also secreted by T2SSs of other bacteria (Wiesner et al, 2003). CtsD 
shares similarity to the outer membrane secretins of T2SS (a T2SS D homologue), CtsE to 
cytoplasmic ATPases (a T2SS E homologue), CtsF to inner membrane-spanning proteins (a 
T2SS F homologue), CtsG to major pseudopilins (a T2SS G homologue) and CtsT to minor 
pseudopilins (a T2SS H, I, J or K homologue) (Oldfield & Wooldridge, 2009). With the usage 
of the Protein Basic Local Alignment Search Tool (BLASTP) algorithm, a putative pre-pilin 
peptidase (a T2SS O homologue) was also identified (Wiesner et al, 2003). To be a fully 
functional type II secretion apparatus, it requires 12 core proteins (T2SS CDEFGHIJKLMO), 
with some species requiring additional proteins (Oldfield & Wooldridge, 2009). The 
incomplete nature of the T2SS-like system in C. jejuni reveals that these proteins may not 
constitute a functioning protein secretion system (Oldfield & Wooldridge, 2009).  
 
1.9.4 Type IV (pVir-encoded) Secretion System 
 
Plasmid pVir was first discovered in C. jejuni 81-176 in 2000 (Bacon et al, 2000). It is a 35-kb 
plasmid containing 54 predicted opening reading frames (ORFs) (Bacon et al, 2000), eight of 
which have similarity to a T4SS in the ruminant commensal Wolinella succinogenes (Baar et 
al, 2003). T4SSs are commonly involved in horizontal DNA transfer, in DNA uptake from or 
release into the extracellular milieu, in toxin secretion and in the injection of bacterial 
products into the target cell cytosol (Backert & Meyer, 2006). Seven type IV-like genes on 
pVir, gene cjp1, cjp2, cjp5, cjp6, cjp31, cjp53 and cjp54, have been proposed to encode 
proteins that form a secretion channel (Bacon et al, 2002). Protein Cjp1, Cjp2 and Cjp3 
homologues have been found in other bacterial systems as pore-forming proteins (Oldfield & 
Wooldridge, 2009). Homologues of Cjp5, Cjp6 and Cjp53 have been shown to be an ATPase 
(Backert & Meyer, 2006). Gene cjp54 encodes a 5-kDa protein that probably stabilises the 
Chapter 1 
 53
complex of type IV transmembrane channels (Bacon et al, 2002). Gene cjp31 encodes a 
putative protein with identity to TrbM of plasmid RP4, which is involved in the conjugal 
transfer of this plasmid (Oldfield & Wooldridge, 2009). Mutants lacking-Cjp2, Cjp3 or Cjp5 
showed reduced invasion abilities towards INT407 cell monolayers (Bacon et al, 2000; 
Bacon et al, 2002). However, mutants without Cjp1, Cjp6 or Cjp53 displayed wild-type levels 
of invasion (Bacon et al, 2002). Plasmid pVir contributes to the invasion ability of C. jejuni 
strain 81-176 towards INT 407 cells in vitro (Bacon et al, 2002). However, introduction of pVir 
to a pVir-absent strain NCTC 11168 did not increase its ability for invasion (Bacon et al, 
2002). Furthermore, only a limited number of C. jejuni clinical isolates contain pVir (Louwen 
et al, 2006; Schmidt-Ott et al, 2005; Tracz et al, 2005), which indicates that pVir may play a 
role in pathogenesis, including invasion, but only of a subset of C. jejuni strains (Oldfield & 
Wooldridge, 2009).   
 
Since some of the pVir T4SS proteins share similarity to Helicobacter pylori proteins that are 
involved in natural transformation, the transformation efficiencies of some of the Cjp mutants 
have also been investigated. Mutations in cjp1, cjp5 or cjp6 showed no difference in 
transformation levels compared to the wild-type strains (Oldfield & Wooldridge, 2009). 
However, mutants lacking cjp3 exhibited a modest defect in transformation efficiency (Bacon 
et al, 2000; Wiesner et al, 2003).  
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1.10 Control Strategies for Campylobacter 
 
Reducing the level of Campylobacter in poultry will limit the number of campylobacteriosis 
cases.  There are several strategies that have been studied. Firstly, high hygiene levels 
during poultry breeding and prevention of chicken carcass contamination has been 
considered as the most efficient method (Katarzyna et al, 2009). Nevertheless, it is difficult to 
introduce this strategy globally due to the relatively high cost related to the implementation of 
various interventions (Katarzyna et al, 2009). The method of upgrading biosecurity at the 
farm level and the hygiene practices in processing poultry may also vary between countries 
(Katarzyna et al, 2009).  
 
Alternatively, genus/species-specific bacteriophage treatment to chickens before butchering 
or directly onto the chicken carcasses is also under consideration (Atterbury et al, 2003; El-
Shibiny et al, 2005). However, there are many drawbacks to this method, such as the 
acquisition of resistance to bacteriophage control, and also campylobacter and 
bacteriophage genetic microbial diversity via recombination events (Scott et al, 2007).  
 
The most efficient strategy for decreasing campylobacteriosis is still immunoprophylactic 
methods (discussed in the next Section). Despite the high incidence of campylobacteriosis in 
industrialised countries, effective strategies to control Campylobacter contamination and to 
prevent campylobacteriosis are still hindered, as current knowledge about the pathogenic 
mechanisms, virulence and pathogen-host interaction mechanisms of Campylobacter is still 
limited.  
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1.11 Campylobacter Vaccines 
 
The most efficient strategy to prevent Campylobacter associated disease would be by 
implementing immunoprophylactic methods, which are protective vaccinations for humans 
and/or chickens (Jagusztyn-Krynicka et al, 2009). Many research groups have investigated 
an anti-Campylobacter human vaccine. For instance, the University of Maryland and the USA 
Naval Medical Research Centre showed that infection-induced immunity furnishes complete 
protection against the illness, but does not always prevent the colonisation (Tribble et al, 
2008a). In addition, the protection was only lasted for 1-2 months (Tribble et al, 2008a). In 
industrialised countries, the anti-Campylobacter vaccine for humans will be reserved for 
persons from high-risk groups, such as travellers to regions where the disease is endemic 
and immunosuppressed patients (Jagusztyn-Krynicka et al, 2009). The introduction of anti-
Campylobacter vaccines for children in developing countries is still under debate, as several 
important issues still need to be clarified, which include the necessity of immunisation during 
the first 6 months of life, the necessity of repeated booster vaccinations and the development 
of an efficient method of immunization (Tribble et al, 2008a).  
 
Anti-Campylobacter vaccine studies have mainly analysed the efficiency of vaccines 
containing killed bacteria and also subunit vaccines of different types (Jagusztyn-Krynicka et 
al, 2009). In recent years, significant progress has been made in anti-Salmonella or anti-
Shigella live-attenuated vaccines (Garmory et al, 2002; Levine et al, 2007; Phalipon et al, 
2008; Venkatesan & Ranallo, 2006). However, an attenuated Campylobacter strain that 
transiently colonises the hosts for long enough to induce a protective immune response has 
not been identified (Jagusztyn-Krynicka et al, 2009). In the development of human anti-
Campylobacter live-attenuated vaccines, eliminating the onset of GBS is still under 
investigation (Jagusztyn-Krynicka et al, 2009). In addition, the naturally transformable 
property of Campylobacter spp. makes vaccine design more complicated (Jagusztyn-
Krynicka et al, 2009). A Campylobacter recA mutant was constructed to prevent genetic 
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recombination, but it was never used for vaccination (Guerry et al, 1994). A selection of 
tested vaccines are listed in the Table 1.6, which includes different vaccine types and 
delivery methods. As noted there, several types of chicken anti-Campylobacter vaccines 
have also been created and investigated. As designing a successful vaccine depends on 
both the delivery mode and the antigen selected, further research is needed to work towards 
a commercial vaccine.  
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Table 1.6: List of tested anti-Campylobacter vaccines (reproduced from Jagusztyn-Krynicka, 2009).  
Type of vaccine Animal 
Route of 
vaccination/vaccination 
schedule 
Challenge Effect Ref. 
CWC vaccines 
C. jejuni 81-176 (formalin-
inactivated) 
Ferrets 
Orally, two or four does 
with/without LTR192G 
Orally, homologous or 
heterologous strain (109-
1010 CFU) 
40-89% of protection, 
depending on the 
vaccination regimen 
(Burr et 
al, 2005) 
Campyvax® (cells prepared 
according to the Nutriment 
Signal Technology)- 
Antex/NMRC 
Human 
volunteers 
Orally, two or four doses 
Phase II cinical trial 
(2002), Phase III clinical 
trial (results not 
available) 
Immunogenic 
(Tribble et 
al, 2008a) 
Recombinant protein purified from Escherichia coli cells 
Fused MBP-FlaA  (C. jejuni 
VC167) 
BALB/c 
mice 
Intranasally, two doses 50 µg 
MBP-FlaA with LTR192G 
Intranasally, C. jejuni 81-
176 (109 CFU) 
84% protection efficacy 
against colonisation 
(Lee et al, 
1999) 
   
Orally, C. jejuni 81-176 
(108-109 CFU) 
71-100% protective efficacy 
against colonisation, 
depending on the challenge 
does 
 
CFU: Colony-forming unit; CPS81-176 -CRM197 : Capsular polysaccharide of Campylobacter jejuni 81-176 strain conjugated to diphtheria toxin mutant CRM197 ; CRM: Cross-reacting 
molecule; CWC: Campylobacter whole-cell; MBP: Maltose-binding protein; MSP: Mouse-specific pathogen-free; NMRC: Naval Medical Research Center.  
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Table 1.6: List of tested anti-Campylobacter vaccines (reproduced from Jagusztyn-Krynicka, 2009) (cont.). 
Type of vaccine Animal 
Route of 
vaccination/vaccination 
schedule 
Challenge Effect Ref. 
Recombinant protein purified from Escherichia coli cells 
ACE961 – branched-chain 
amino acid ABC transport 
system periplasmic-binding 
protein (C. jejuni ML53) 
Mice 
Subcutaneously, three doses with 
alum 
Orally, C. jejuni 
ML1/ML53 (108 
CFU) 
Reduction of colonisation 
(Prokhorova 
et al, 2006) 
ACE1569 – putative 
periplasmic protein (C. jejuni 
ML53) 
Mice 
Subcutaneously, three doses with 
alum 
Orally, C. jejuni 
ML1/ML53 (108 
CFU) 
Reduction of colonisation 
(Prokhorova 
et al, 2006) 
Flagellum-secreted proteins 
FlaC (C. jejuni 81-176) 
BALB/c 
mice 
Intranasally with/without LTR192G; 
three doses delivered at 2-week 
intervals 
Intranasally, C. 
jejuni 81-176 or 
CG8486 (109 CFU) 
18% protection against 
disease from C. jejuni 81-176 
(Baqar et al, 
2008) 
FspA1 (C. jejuni 81-176) 
BALB/c 
mice 
Intranasally with/without LTR192G; 
three doses delivered at 2-week 
intervals 
Intranasally, C. 
jejuni 81-176 or 
CG8486 (109 CFU) 
Protection (with adjuvant) 
against disease: homologous 
challenge: 63.8%; 
heterologous challenge: 
44.8% 
(Baqar et al, 
2008) 
CFU: Colony-forming unit; CPS81-176 -CRM197 : Capsular polysaccharide of Campylobacter jejuni 81-176 strain conjugated to diphtheria toxin mutant CRM197 ; CRM: Cross-reacting 
molecule; CWC: Campylobacter whole-cell; MBP: Maltose-binding protein; MSP: Mouse-specific pathogen-free; NMRC: Naval Medical Research Center.  
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Table 1.6: List of tested anti-Campylobacter vaccines (reproduced from Jagusztyn-Krynicka, 2009) (cont.). 
Type of vaccine Animal 
Route of 
vaccination/vaccination 
schedule 
Challenge Effect Ref. 
Flagellum-secreted proteins 
FspA2 (C. jejuni 
CG8486) 
BALB/c mice 
Intranasally with/without 
LTR192G; three doses delivered 
at 2-week intervals 
Intranasally, C. 
jejuni 81-176 or 
CG8484 (109 CFU) 
47.2% protection (with adjuvant) 
against disease: homologous 
challenge 
(Baqar et 
al, 2008) 
Conjugated capsule polysaccharide vaccines 
CPS81-176 -CRM197  BALB/c mice 
Subcutaneously, 5 or 25 µg of 
CPS81-176 -CRM197  
Intranasally (3 X 
109 CFU) 
Immunogenic (IgM, IgA and IgG), 
significant dose-dependent 
reduction of illness – homologous 
strain challenge 
(Monteiro 
et al, 2009) 
CPS81-176 -
CRM197  adjuvant 
with alum 
Aotus 
nancymae 
(nonhuman 
primates) 
Subcutaneously, three doses (25 
µg) at 6-week intervals 
Intranasally (5 X 
1011 CFU) 
Dose-related serum IgG and IgM 
response, no increase in serum 
IgA response, protection against 
diarrhoea but not colonisation 
(Monteiro 
et al, 2009) 
CFU: Colony-forming unit; CPS81-176 -CRM197 : Capsular polysaccharide of Campylobacter jejuni 81-176 strain conjugated to diphtheria toxin mutant CRM197 ; CRM: Cross-reacting 
molecule; CWC: Campylobacter whole-cell; MBP: Maltose-binding protein; MSP: Mouse-specific pathogen-free; NMRC: Naval Medical Research Center. 
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Table 1.6: List of tested anti-Campylobacter vaccines (reproduced from Jagusztyn-Krynicka, 2009) (cont.). 
Type of vaccine Animal 
Route of 
vaccination/vaccination 
schedule 
Challenge Effect Ref. 
C. jejuni antigens delivered by attenuated Salmonella enterica sv. Typhimurium strains 
S. enterica sv.Typhimurium 
& Delta;phoP/Q peb1 
protein expressed from 
three plasmids (pYA3342, 
pMEG-1399 and pMEG-
1415) 
BALB/c 
mice, 
MSP 
Orally, two doses (108 
CFU) 
Orally, C. jejuni 81-176, 
C. jejuni MGN 4735  
Induction of specific serum 
IgG, measured by western 
blot; no protection 
(Sizemore et al, 
2006) 
S. enterica sv. Typhimurium 
&chi;3987 CjaA cloned into 
pYA3341 
Chicken 
Orally, two doses (108 
CFU) 
Orally, heterologous 
Campylobacter strains 
(108 CFU) 
[proportional to]6logs 
reduction of colonisation 
(Wyszynska et al, 
2004) 
S. enterica sv. Typhimurium 
&chi;3987 CjaD cloned into 
pYA3341 
Chicken 
Orally, two doses (108 
CFU) 
Orally, heterologous 
Campylobacter strains 
(108 CFU) 
Induction of specific 
intestinal sIgA and serum 
IgG; protection – not tested 
(Jagusztyn-Krynicka 
et al., Unpublished 
data) 
CFU: Colony-forming unit; CPS81-176 -CRM197 : Capsular polysaccharide of Campylobacter jejuni 81-176 strain conjugated to diphtheria toxin mutant CRM197 ; CRM: Cross-reacting 
molecule; CWC: Campylobacter whole-cell; MBP: Maltose-binding protein; MSP: Mouse-specific pathogen-free; NMRC: Naval Medical Research Center. 
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1.12 Aims of Project 
 
Despite the high incidence of C. jejuni and many years of research, the virulence factors of 
C. jejuni are still poorly understood compared with other enteric bacteria. Although the 
identification of the virulence factors needs various chemical and biological experiments, the 
approach of purely lab-based experiments is time-consuming, labour-intensive, and, requires 
used of expensive reagents. As the genome sequence of Campylobacter is known, 
bioinformatics methods can be used to narrow down the list of possible virulence factors, 
which may be exploited as vaccine candidates. In this work, it is proposed that proteins that 
aid Campylobacter to evade the chicken immune system are either secreted, or in the 
bacterial outer membrane, so as to directly interact with host components. In this study, we 
analysed 1623 predicted proteins based on their sequences through various bioinformatics 
analysis methods, in order to identify the number of C. jejuni proteins predicted to be located 
in the outer membrane or extracellularly. These may be involved in the virulence 
mechanisms of the pathogen. 
 
Most of the surface-exposed proteins are secreted with signal peptides, which localise them 
into the outer membrane or extracellular space. However, there is also a subset of proteins 
locates at these positions without a signal peptide. They are the proteins so called NCSPs. It 
is believed that these proteins secreted via alternative routes are involved in pathogenesis. 
The aims of this study are to select, express and purify some of the NCSPs encoded by the 
C. jejuni NCTC 11168 genome. The recombinant protein was assayed for its function. 
 
Results from this study will help to improve our understanding of pathogenic mechanisms, 
more specifically, the virulence factors involved in C. jejuni pathogenicity. A starting point for 
identifying potential virulence factors is to identify proteins that are secreted from 
campylobacter, and therefore can interact with host molecules/cells. However, many of these 
proteins are of unknown structure and function. This thesis describes the prediction and 
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modelling of a NCSP that we have demonstrated to cause chicken macrophage cell 
apoptosis. By modelling this and other NCSPs, the structures of potentially antigenic and/or 
functional regions may be examined, and lead to design of vaccines aimed at immunising 
poultry against Campylobacter colonisation. A vaccine would dramatically reduce the 
contamination of poultry. Consequentially it will help to reduce the incidence of 
campylobacteriosis in human populations and therefore ultimately reduce the cost of public 
health care service.  
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CHAPTER 2. BIOINFORMATICS 
ANALYSIS OF THE C. JEJUNI 
SECRETOME  
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2.1 Introduction 
 
The number of sequences entering into databanks has been rapidly increasing. For instance, 
the number of total protein sequences entries in Swiss-Prot was only 3,939 in 1986. A recent 
search on 9 July 2014 showed that the number has jumped to 546,000, meaning that the 
number of the entries now is more than 100 times the number in 1986. With the explosion of 
protein sequences entering into databanks, it is a fact that experimentally testing every single 
protein is both too time-consuming and costly. Therefore, bioinformatics tools would be 
helpful as a fast and effective way of identifying a newly found / hypothetical protein for its 
possible function / subcellular location.  
 
C. jejuni has the densest bacterial genome analysed to date, with 94.3% of the genome 
encoding proteins (Parkhill et al, 2000). In 2000, the complete genome sequence of C. jejuni 
subsp. jejuni NCTC 11168 was completed (in this study, where C. jejuni is mentioned we 
refer to C. jejuni subsp. jejuni). The entire genome contains 1,641,481 base pairs (bp) with a 
low G+C content (30.6%), and 1,654 CDS (Parkhill et al, 2000). In 2007, the genome 
sequence from C. jejuni NTCT 11168 was re-annotated and re-analysed (Gundogdu et al, 
2007). The number of predicted CDS was reduced to 1643, and 18.2% of CDS had their 
product functions updated (Gundogdu et al, 2007). As of February 2012, there were 1623 C. 
jejuni NCTC 11168 protein sequences accessible from NCBI (Accession: PRJNA57587, ID: 
57587). 
 
Elucidating Campylobacter proteins that have the potential to interact with the chicken 
immune system (i.e. secreted proteins) may lead to new approaches for eliminating 
Campylobacter from chickens and hence reduce the incidence of human infection. A range 
of bioinformatics techniques have been employed to identify secreted and surface-exposed 
proteins, which may have propensities for direct interactions with the chicken immune 
system. Of the approximately 1600 proteins encoded by the C. jejuni NCTC 11168 genome, 
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up to 400 are predicted to be secreted from the bacterium, or inserted into the outer 
membrane, as identified using a set of bioinformatics tools (Figure 2.1). This includes 
proteins predicted to contain a signal peptide, and a subset of proteins predicted to be non-
classically secreted. Secreted proteins are crucial for bacterial pathogenesis, particularly in 
the delivery of pathogenic and symbiotic bacteria into their hosts. Therefore, identification of 
bacterial secreted proteins plays an important role for the study of diseases, drug design and 
development of vaccines (Yu et al, 2010). These predicted proteins may perform a role that 
is critical to Campylobacter.  
 
These putative secreted proteins were first analysed using Gneg-PLoc and Gneg-mPLoc for 
their locations. Those proteins predicted as membrane proteins were further analysed for the 
presence of TMH and β-barrels (BB) using TMHMM and PRED-TMBB respectively. 
Enzyme/protease prediction has also been performed on these proteins for possible function 
prediction. Finally, VirulentPred was employed to screen the putative secreted proteins for 
virulence factors. The final result indicates there are 9 putative hypothetical virulent 
classically secreted proteins (CSPs) and 40 putative hypothetical virulent NCSPs. Among 
them, there were a few of proteins with less than 50 AAs or located intercellularly, which left 
a subset of 28 putative virulent extracellular NCSPs on the top of the list to be further 
analysed. A brief description of each web server used together with the website address is 
listed in Table 2.1. 
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Figure 2.1: Flow chart of Campylobacter jejuni NCTC 11168 secretome analysis 
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Table 2.1: List of the webservers used in this study 
No. Name Website address Target 
1 SignalP 3.0 http://www.cbs.dtu.dk/services/SignalP-3.0/ Protein signal peptide 
2 SignalP 4.0 http://www.cbs.dtu.dk/services/SignalP/ Protein signal peptide 
3 Signal-CF http://www.csbio.sjtu.edu.cn/bioinf/Signal-CF/ Protein signal peptide 
4 Signal-3L http://www.csbio.sjtu.edu.cn/bioinf/Signal-3L/ Protein signal peptide 
5 SecretomeP 2.0 http://www.cbs.dtu.dk/services/SecretomeP/ NCSPs 
6 Gneg-Ploc http://www.csbio.sjtu.edu.cn/bioinf/Gneg/ Protein subcellular localisation 
7 Gneg-mPloc http://www.csbio.sjtu.edu.cn/bioinf/Gneg-multi/ Protein subcellular localisations 
8 TMHMM 2.0 http://www.cbs.dtu.dk/services/TMHMM/ Protein TMH 
9 PRED-TMBB http://biophysics.biol.uoa.gr/PRED-TMBB/ OMP beta-strand 
10 MemType-2L http://www.csbio.sjtu.edu.cn/bioinf/MemType/ Membrane protein type 
11 EzyPred http://www.csbio.sjtu.edu.cn/bioinf/EzyPred/ Enzyme functional class 
12 ProtIdent http://www.csbio.sjtu.edu.cn/bioinf/Protease/ Protease type 
13 VirulentPred http://203.92.44.117/virulent/ Virulence protein 
NCSPs: non-classically secreted proteins; TMH: transmembrane helices; OMP: outer-membrane protein 
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2.2 Materials and Methods 
 
The C. jejuni NCTC 11168 protein sequences were retrieved from the Sanger website in the 
FASTA format.   
 
2.2.1 Classically Secreted Protein Prediction 
 
To accomplish virulence mechanisms, bacteria secrete proteins into their host environment, 
some of which may act to subvert or down-regulate the expanding immune response 
(Coombes et al, 2004). Extracellular secretion of proteins is classified as either classically 
secreted or non-classically secreted based on the secretion mechanism.  
 
In bacteria, the classical tripartite structured sec signal peptide governs most of the targeting 
of the secretion pathway. Besides Sec-dependent secretion, there is also a group of Sec-
independent secretion pathways, such as twin-arginine translocation (Tat) secretion, which 
with a twin-arginine consensus motif is located within the signal peptide itself (Bendtsen et al, 
2005). Both Sec- and Tat-dependent secretion only translocate protein across the inner 
membrane of the Gram-negative bacteria, while the N-terminal signal peptide plays an 
essential role in trans-outer membrane secretory systems as the tag signaling secretion.   
 
CSPs are synthesized at the ribosome and transported to their site of function as directed by 
the targeting signals. Although many different classes of targeting signals are present, one of 
the commonly occurring signals is formed by short, transient peptides known as signal 
peptides. Signal peptides are present in both prokaryotic and eukaryotic cells and are usually 
found at the amino terminus of proteins destined for secretion. Signal peptides are critical for 
classical protein secretion and are made up of 15-40 amino acids. They are characterised by 
three distinct domains, a positively charged amino terminal “n” region, a central hydrophobic 
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“h” region, and a cleavage site of a more polar carboxy terminal “c” region which is cleaved 
by signal peptidases during translocation across the membrane. 
 
In this study, five computational methods have been used to predict CSPs from C. jejuni 
NCTC 11168: SignalP 3.0 HMM, SignalP 3.0 NN (Bendtsen et al, 2004), SignalP 4.0 
(Petersen et al, 2011), Signal-CF (Chou & Shen, 2007b) and Signal-3L (Shen & Chou, 
2007b).  
 
SignalP is one of the most commonly used programs which utilises artificially trained neural 
networks (NN) to predict N-terminal peptides. Artificial NN is inspired by the sophisticated 
functionality of human brains where numerous of interconnected neurons process 
information in parallel (Wang, 2003). An artificial NN consists of an input layer of neurons (or 
nodes), couple of hidden layers of neurons, and a final layer of output neurons (Wang, 2003). 
The formula below shows a typical architecture, where the output, hi , of neuron i  in the 
hidden layer is, 
 hi  Vijx j Tihid
j1
N

   
where     is called activation (or transfer) function, N  the number of input neurons, Vij  
the weights, x j  inputs to the input neurons, and Ti
hid  the threshold terms of the hidden 
neurons (Wang, 2003). Artificial NN have been used for a great range of biological sequence 
analysis. In SignalP 1.0, a combined NN approach has been developed to recognise the 
signal peptides and their cleavage sites, which includes one network to recognize the 
cleavage site and another to differentiate the signal peptides and non-signal peptides 
(Nielsen et al. 1997). In version 2.0, a Hidden Markov Model (HMM) component was 
incorporated in its prediction strategy (Nielsen & Krogh, 1998). HMM is a popular statistical 
tool for modelling generative sequences (Blunsom, 2004). These sequences can be 
characterised by an underlying process that generating an observable sequence (Blunsom, 
2004). HMM in SignalP 2.0 contains submodels for the N-terminal part, the hydrophobic 
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region, and the cleavage site region (Nielsen & Krogh, 1998). In the version 3.0, both NN and 
HMM algorithms have been updated by the motivation of the idea that the cleavage site 
position and the amino acid composition of the signal peptide are correlated (Bendtsen et al, 
2004). However, SignalP 3.0 is limited in its ability to distinguish signal peptides from N-
terminal TMH. In 2011, SignalP 4.0 was introduced to overcome this problem. Signal-CF and 
Signal-3L are similarly based on the strategy used in SignalP 3.0 and SignalP 4.0. However, 
Signal-CF was reported to give a better performance on signal peptide cleavage site 
identification and non-secreted protein identification (Chou & Shen, 2007b). It is also 
recognised as one of the best servers to predict long signal peptides (Chou & Shen, 2007b). 
Signal-3L comes with one more layer compared to Signal-CF. This 3rd-layer is used to 
determine the unique cleavage site through a global sequence alignment operation (Chou & 
Shen, 2007b). 
 
2.2.2 Non-classically Secreted Protein Analysis 
 
NCSPs are proteins secreted from the cytoplasm but without a classic signal peptide, which 
are also called leaderless secretion or the non-conventional secretory pathway. The 
mechanism behind this type of secretion is still unknown. For a long time, it was believed that 
an N-terminal signal peptide was strictly required for exporting proteins to the extracellular 
space until non-classical secretion was identified in eukaryotes about 25 years ago. The first 
published bacterial NCSP was glutamine synthetase (GlnA) in Mycobacterium tuberculosis 
(M. tuberculosis) (Harth & Horwitz, 1997). Furthermore, it is found that NCSPs such as GlnA 
and superoxide dismutase are secreted in pathogenic M. tuberculosis, but only present in the 
cytoplasm of the non-pathogenic mycobacterium M. smegmatis (Harth & Horwitz, 1999a) 
(Harth & Horwitz, 1999b). Experiments of SecA2 gene deletion in M. tuberculosis, which is 
required for superoxide dismutase secretion, show the abolishment of M. tuberculosis 
virulence in mice. This suggests the new secretory pathway plays a role in the export of 
bacteria virulence factors (Braunstein et al, 2003). It is also believed that NCSPs often seem 
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to have a cytoplasmic function as well as an extracellular functional role (Bendtsen et al, 
2005), which makes them more intriguing to scientists. 
 
No signal or motif characteristic has been found in any of the majority of NCSPs. However, 
properties such as amino acid composition, secondary structure and disordered regions 
make NCSPs different from cellular proteins (Bendtsen et al, 2005). SecretomeP 2.0 
developed artificial neural networks based on these properties for identification of NCSPs. 
For Gram–negative bacteria proteins, the determining score is the 'SecP score', where a 
value above 0.5 indicates possible secretion. NCSPs should obtain a ‘SecP score’ exceeding 
the normal threshold, but at the same time be predicted without a signal peptide (Bendtsen et 
al, 2005). 
 
2.2.3 Protein Location Prediction 
 
Determining the subcellular localisation of a protein can provide insights into how it functions 
and the pathways that are involved, as well as how and in what kind of cellular environments 
they interact with each other or other molecules (Chou & Shen, 2008a). Knowledge of the 
protein subcellular location can also highlight whether the protein could either provide a 
therapeutic target or act as a biomarker. Proteins with multiple locations or dynamic features 
of this kind are particularly interesting, because they may have some special biological 
functions (Chou & Shen, 2008a). For instance, the E. coli aspartate receptor, which functions 
in bacterial chemotaxis, is also a maltose-binding protein (MBP) receptor (Jeffery, 1999).It 
has different but overlapping binding sites for aspartate and MBP (Mowbray & Koshland, 
1990; Wolff & Parkinson, 1988). Another example is bacterial Ftsh protein plays a role in 
assisting in the transport of proteins into and across membranes, and it is also an ATP-
dependent metalloprotease (Jeffery, 1999). In our study, we try to predict the proteins that 
are totally or at one stage exposed to the host immune system. 
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In this study, Gneg-PLoc and Gneg-mPLoc have been chosen to predict the locations of the 
putative secreted proteins obtained after classical and non-classical secretion analysis. Both 
predictors cover eight subcellular locations of Gram-negative bacteria proteins (Figure 2.2), 
which are cytoplasm, extracellular space, fimbrium, flagellum, inner membrane, nucleoid, 
outer membrane and periplasm (Chou & Shen, 2006a). Gneg-PLoc predicts the single 
location of each protein, while Gneg-mPLoc is able to predict the multiple possible locations 
of proteins.  
 
2.2.4 Membrane Protein Prediction 
 
It is believed that each cell is highly organized with many functional units or organelles, and 
most of these units are ‘enveloped’ by one or more cell membranes, which are the basis for 
many biological functions (Chou & Shen, 2007a). Although the main content of the cell 
membrane is the lipid bilayer, most of the specific functions of the membrane are actually 
performed by the membrane proteins (Chou & Shen, 2007a). The main functions of 
membrane proteins include (1) transporting molecules into and out of cells by such methods 
as ion pumps, channel proteins and carrier proteins; (2) passing various chemical messages 
such as nerve impulses and hormone activity between cells; (3) attachment to parts of the 
cytoskeleton in order to provide shape (Chou & Shen, 2007a) and so on. It is estimated that 
20-30% of all genes in most genomes encode membrane proteins (Krogh et al, 2001).  
 
Membrane proteins are of different types, and the function of each membrane protein is 
closely correlated with the type it belongs to (Chou & Shen, 2007a). For instance, a 
transmembrane protein can function on both sides of the membrane or transport molecules 
across it, while a protein that functions on only one side of the lipid bilayer is often associated 
with either the lipid monolayer or a protein domain on that side (Chou & Shen, 2007a).  
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Figure 2.2: Schematic illustration of the subcellular locations of Gram-negative 
bacterial proteins (reproduced from Chou & Shen, 2006a).  
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A trans-membrane protein can be an outer membrane auto-transporter, a pore-forming toxin 
(PFT), an immune receptor, etc. Therefore, information about membrane protein types would 
offer important clues toward identifying the function of an uncharacterised membrane protein 
(Chou & Shen, 2007a). The knowledge of the type a membrane protein belongs to can 
provide insight into its mode of motion, which is helpful for studying its biological process at 
the cellular level (Chou & Shen, 2007a).  
 
Integral membrane proteins can be divided into two distinct structural classes, the α-helical 
membrane proteins and the β-barrel membrane proteins (Bagos et al, 2004). The TMH and 
BBs of the putative secreted C. jejuni NCTC 11168 proteins have been analysed using 
TMHMM 2.0 (Krogh et al, 2001; Sonnhammer et al, 1998) and PRED-TMBB (Bagos et al, 
2004) respectively. TMHMM 2.0 uses HMM based algorithms (Bagos et al, 2004; Krogh et al, 
2001). One of the advantages of an HMM is that HMM is able to model helix length by setting 
upper and lower limits for the length of a membrane helix (Krogh et al, 2001). It is very well 
suited for TMH prediction as it can incorporate hydrophobicity, charge bias and helix length 
(Durbin et al. 1998). PRED-TMBB is capable of predicting transmembrane β-strands of the 
Gram-negative bacteria OMPs (Bagos et al, 2004).  
 
The membrane protein types were investigated by MemType-2L (Chou & Shen, 2007a). 
MemType-2L is a 2-layer predictor, featured by incorporating evolution information through 
Pseudo Position-Specific Score Matrix vectors and Optimized Evidence-Theoretic K-Nearest 
Neighbour classifiers (Chou & Shen, 2007a). The concept of Pseudo Position-Specific Score 
Matrix used in this method was adopted from (Chou, 2001; Chou, 2005), which as given by  
 pPsePSSM
  12  20G1G2 G20 
T
  
to represent the protein P , where 
 Gj
  1
L  Ei j  E(i ) j i1
L 2 ( j  1,2,,20;  L)   
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The Optimized Evidence-Theoretic K Nearest Neighbour classifier was employed in 
MemType-2L to identify the membrane proteins and their types (Chou & Shen, 2007a), which 
is a powerful classification engine that enhances the success rates of protein subcellular 
location prediction (Chou & Shen, 2006b).  
 
In MemType-2L, the 1st layer prediction engine is to identify a query protein as membrane or 
non-membrane protein. If the protein is predicted as membrane protein from the 1st layer 
prediction, the process is automatically continued with the 2nd-layer engine to further identify 
its membrane type. There are eight categories included in the 2nd-layer prediction (Figure 
2.3): (1) type I transmembrane, (2) type II transmembrane, (3) type III transmembrane, (4) 
type IV transmembrane, (5) multipass transmembrane, (6) lipid-chain-anchored membrane, 
(7) GPI-anchored membrane, and (8) peripheral membrane (Chou & Shen, 2007a). The 
classification is an extension of that by von Heijne and Gavel (1988). In the literature, type III 
proteins have also been defined as ‘type I without cleaved signal’ or type Ib. Examples of 
single spanning membrane proteins are the LDL receptor (type I), the transferrin receptor 
(type II), cytochrome p450 (type III) and synaptobrevin (type IV) (Spiess, 1995).  
 
2.2.5 Enzyme Prediction 
 
The main function of enzymes is catalysing chemical reactions, which plays a vital role in the 
metabolic process. In this section, there were two servers used to predict if a protein is an 
enzyme or more particular, a protease. Firstly, webserver EzyPred was employed to classify 
enzymes into six main function classes (1) Oxidoreductase, (2) Transferase, (3) Hydrolase, 
(4) Lyase, (5) Isomerase, and (6) Ligase, and further 49 subclasses (Shen & Chou, 2007a). 
EzyPred, which operates by fusing the FunD approach and Pseudo Position-Specific Score 
Matrix approach, is a 3-layer predictor, as the 1st layer engine identifies a query protein as 
enzyme or non-enzyme; the 2nd layer prediction engine is for the main functional class, and 
the 3rd layer predicts the sub-functional class of the query protein (Shen & Chou, 2007a).  
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Figure 2.3: Schematic illustration of the eight types membrane proteins: (1) type I 
transmembrane, (2) type II transmembrane, (3) type III transmembrane, (4) type IV 
transmembrane, (5) multipass transmembrane, (6) lipid-chain-anchored membrane, (7) 
GPI-anchored membrane, and (8) peripheral membrane. As shown in the figure, type I, 
II, III and IV are all single-pass transmembrane proteins (reproduced from Chou & 
Shen, 2007a).  
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Then, the putative proteases were predicted by ProtIdent to be one of six classes, which 
include (1) aspartic, (2) cysteine, (3) glutamic, (4) metallo, (5) serine, and (6) threonine (Chou 
& Shen, 2008b). Proteases are also termed proteinases or peptidases, are proteolytic 
enzymes, which are essential for the synthesis of all proteins, controlling their size, 
composition, shape, turnover, and ultimate destruction (Chou & Shen, 2008b). 
 
2.2.6 Virulent Protein Prediction 
 
Bacterial virulence factors play important roles in bacterial pathogenesis. Prediction of 
bacterial virulence proteins will be helpful for the identification and characterization of 
virulence-associated factors, finding drug/vaccine targets against proteins indispensable for 
pathogenicity and understanding the complex virulence mechanism in pathogens. Virulent 
protein prediction was performed using the server VirulentPred (Garg & Gupta, 2008). The 
prediction method used in VirulentPred is based on bi-layer cascade Support Vector Machine 
(Garg & Gupta, 2008).  Firstly, the top layer Support Vector Machine classifiers were trained 
and optimised with different individual protein sequence features such as amino acid 
composition, dipeptide composition, higher order dipeptide composition and Position Specific 
Iterated BLAST (PSI-BLAST) generated Position Specific Scoring Matrices (PSSM) (Garg & 
Gupta, 2008). Secondly, a similarity-search based module was developed using a dataset of 
virulent and non-virulent proteins as the BLAST database (Garg & Gupta, 2008).  
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2.3 Results 
 
2.3.1 Classically Secreted Protein Prediction 
 
All the C. jejuni NCTC 11168 CDS were analysed using the various webservers, and the 
results are shown in Table 2.2. The total CSPs numbers vary from 113 (by SignalP 4.0) 
(Appendix 1) up to 302 (by Signal-3L). The possible reason for the differences is that SignalP 
4.0 is claimed to be the only server which claims to be able to differentiate an N-terminal 
transmembrane helix from a signal peptide (Petersen et al, 2011). The limitation of all the 
servers mentioned except SignalP 4.0 is that they have only limited ability to distinguish 
between signal peptides and N-terminal TMH (Petersen et al, 2011). Both signal peptides 
and TMH are hydrophobic, but TMH normally have longer hydrophobic regions, and without 
cleavage sites (Petersen et al, 2011). However, the cleavage-site pattern itself is not 
sufficient to differentiate the two kinds of sequence (Petersen et al, 2011). This problem 
causes a lot of false positive prediction of TMH from signal peptides in any complete 
proteome, which is most likely what happened in this case.  
 
In training SignalP 4.0, the developers used two types of negative data. The first correspond 
to the negative data used in training earlier versions of SignalP, which contains cytoplasmic 
proteins and nuclear proteins (Petersen et al, 2011). The second data includes sequences 
that do not contain signal peptides but with transmembrane regions within the first 70 amino 
acids of the protein sequence (Petersen et al, 2011). There are two kinds of networks have 
been used in SignalP 4.0: transmembrane sequences as negative data to train SignalP-TM 
networks but trained SignalP-noTM networks without these data. These elements make 
SignalP 4.0 to be believed as the best signal-peptide predictor for all three Gram negative, 
Gram positive and Eukaryote organism types (Petersen et al, 2011). 
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Table 2.2: Total number of CSPs predicted by different servers. 
  SignalP 3.0 (HMM) SignalP 3.0 (NN) SignalP 4.0 Signal-CF Signal-3L 
Number of predicted CSPs 295 208 113 287 302 
Number of CSPs also 
predicted by   
SignalP 3.0 (HMM) 20 187 113 228 240 
SignalP 3.0 (NN) 187 6 109 159 168 
SignalP 4.0 113 109 0 95 98 
Signal-CF 228 159 95 3 279 
Signal-3L 240 168 98 279 5 
CSPs: classically secreted proteins. 
The numbers in red indicate the number of CSPs predicted only by that server. 
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It is worth mentioning that there is no SignalP 4.0 exclusive predicted sequence. All the 
putative CSPs picked up by SignalP 4.0 have been picked up by the SignalP 3.0 (HMM), and 
most of the other predictors.  
 
2.3.2 Non-classically Secreted Protein Analysis 
 
For the proteome of C. jejuni NCTC 11168, a total of 200 proteins obtained a ‘SecP score’ 
higher than 0.5, which is the threshold value to be a NCSP. However, many of these also 
have a predicted signal peptide, which would exclude them from the NCSP list. The final 
numbers of predicted NCSPs are listed in Table 2.3. As indicated in Section 2.3.1, the 
putative CSPs predicted results from SignalP 4.0 have been taken, which left us 140 putative 
NCSPs (Appendix 2) to be further analysed in the next section.  
 
2.3.3 Protein Location Prediction 
 
The locations indicated in red in Table 2.4 and Table 2.5 are of interest, as the proteins in 
these locations are the ones that have the potential to interact with chicken host 
molecules/cells. Sequences predicted to be less than 50 amino acids were labelled as ‘Too 
Short’, and excluded from the prediction as they might represent fragments rather than real 
proteins.  
 
For the putative CSPs, 23 of which were predicted located extracellularly or surface-exposed 
using Gneg-PLoc. Using Gneg-mPLoc, 40 putative CSPs were predicted to be located 
extracellularly or on the cell surface. Among them, 17 putative CSPs were predicted by both 
servers (Figure 2.4). The total number of putative CSPs that possibly to interact with the 
chicken immune system is 46 (about 41% of the total number). 
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Table 2.3 Number of NCSPs predicted by SecretomeP 2.0 after excluding the ones 
predicted to also contain a signal peptide. 
 SignalP 3.0 (HMM) 
SignalP 
3.0 (NN) 
SignalP 
4.0 
Signal-
CF 
Signal-
3L 
Number of proteins with > 0.5 
SecP score 200 200 200 200 200 
Number of proteins with > 0.5 
SecP score but also contain a 
signal peptide 
88 86 60 105 114 
Number of NCSPs 112 114 140 95 86 
NCSPs: non-classically secreted proteins 
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Table 2.4: Results of subcellular location prediction of CSPs and NCSPs using Gneg-
PLoc, SignalP 4.0 and SecretomeP 2.0.  
Servers SignalP 4.0 & SecretomeP 2.0 
Predicted protein locations CSPs NCSPs 
Extracelluar 10 27 
Flagellar 3 8 
Fimbrium 0 1 
Outer membrane 10 11 
Periplasm 9 7 
Inner membrane 7 2 
Cytoplasm 73 78 
Too short to be predicted 1 6 
Total Number 23/113 47/140 
Too short to be predicted: protein with less than 50 amino acids; CSPs: classically secreted 
proteins; NCSPs: non-classically secreted proteins. 
The locations shaded in red indicate proteins that can interact with chicken host cells. 
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Table 2.5: Results of multiple locations prediction of C. jejuni NCTC 11168 putative secreted proteins by using the server Gneg-mPLoc. 
CSPs and NCSPs prediction methods SignalP 4.0 & SecretomeP 2.0 
Locations CSPs NCSPs 
Extracellular. 12 25 
Fimbrium. 1 2 
Outer membrane. 13 9 
Extracellular. Fimbrium. 0 1 
Extracellular. Periplasm. 1 0 
Outer membrane. Extracellular. 1 1 
Inner membrane. Extracellular. 5 13 
Inner membrane. Outer membrane. 4 2 
Inner membrane. Extracellular. Fimbrium. 1 0 
Inner membrane. Cytoplasm. Extracellular. 1 1 
Inner membrane. Outer membrane. Extracellular. 0 1 
Inner membrane. Outer membrane. Cytoplasm. Extracellular. Periplasm. 1 0 
Cytoplasm. 3 8 
Periplasm. 23 7 
Inner membrane. 36 42 
Inner membrane. Cytoplasm. 4 19 
Inner membrane. Periplasm. 4 2 
Cytoplasm. Periplasm. 2 1 
Too short to be predicted. 1 6 
Total 40/113 55/140 
The locations shaded in red indicate proteins that can interact with chicken host cells; too short to be predicted: protein with less than 50 amino acids; 
CSPs: classically secreted proteins; NCSPs: non-classically secreted proteins.  
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Figure 2.4: Comparison of putative CSPs location prediction by Gneg-PLoc and Gneg-mPLoc. The 17 CSPs are the ones predicted to be 
extracellular or surface-exposed by both Gneg-PLoc and Gneg-mPLoc.  
CSPs: classically secreted proteins; OM: outer membrane; IM: inner membrane.  
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There are 47 putative NCSPs predicted to be located extracellularly or on the surface of the 
cells by Gneg-PLoc, and 55 putative NCSPs picked up by Gneg-mPLoc with at least one 
stage located extracellularly or exposed to the host environment. Thirty-two (32) of them 
were predicted extracellular or surface-exposed by both methods (Figure 2.5). The total 
number of putative NCSPs with the location of interest is 70 (50% of the total number).  
 
Generally, more putative NCSPs were predicted to be located extracellular and/or on the cell 
surface comparing to the CSPs, even NCSPs do not predicted to contain a signal peptide. It 
reveals the alternative pathways could exist within Gram-negative organisms as C. jejuni.  
 
2.3.4 Membrane Protein Prediction 
 
The numbers of proteins with TMH or TMBB are listed in Tables 2.6 to 2.9 and Figure 2.6. 
About 78% (88 proteins) of the 113 putative CSPs were predicted without TMH, and 17% (19 
proteins) were predicted contain one TMH. The 17% proteins all have their predicted TMH 
region located in the first 60 AAs, which indicates that the predicted TMH are most likely 
signal peptides (Krogh et al, 2001). Only about 5% putative CSPs (6 in total) were predicted 
containing TMH besides signal peptides. For these 6 putative CSPs, 5 of them were 
predicted also containing TMBBs, and the one that predicted containing 12 TMHs were 
predicted not an OMP by PRED-TMBB, which indicates that it is could be an inner-
membrane protein. The total number of putative membrane proteins predicted with TMH 
or/and with TMBB is 46, which means around 40% of the putative CSPs are putative 
membrane proteins. Five of them were predicted as TMBB-containing OMPs with the 
presence of TMH(s).  
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Figure 2.5: Comparison of putative NCSPs location prediction by Gneg-PLoc and Gneg-mPLoc. The 32 NCSPs are the ones predicted to be 
extracellular or surface-exposed by both Gneg-PLoc and Gneg-mPLoc.  
NCSPs: non-classically secreted proteins OM: outer membrane; IM: inner membrane. 
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Table 2.6: Putative CSPs trans-membrane helices and membrane type prediction. 
TMHMM 2.0 MemType-2L 
No. of 
TMH 
No. of 
CSPs 
Gpi 
Anchor  
Lipid 
Anchor  Multi-pass Peripheral 
Single-
pass Type 
I 
Single-
pass Type 
II 
Single-
pass Type 
IV 
Not a MP 
Too short 
to be 
predicted 
0 88 1 5 12 5 1 1 0 62 1 
1 19 0 2 2 0 0 0 1 14 0 
3 2 0 0 2 0 0 0 0 0 0 
4 1 0 0 1 0 0 0 0 0 0 
7 1 0 0 0 0 0 0 0 1 0 
12 1 0 0 1 0 0 0 0 0 0 
13 1 0 0 1 0 0 0 0 0 0 
Total 113 1 7 19 5 1 1 1 77 1 
TMH: transmembrane helices; MP: membrane protein; too short to be predicted: protein with less than 50 amino acids; CSPs: classically secreted 
proteins.  
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Table 2.7: Putative NCSP trans-membrane helices and membrane type prediction. 
TMHMM 2.0 MemType-2L 
No. of 
TMH 
No. of 
NCSPs Gpi Anchor 
Lipid 
Anchor Multi-pass Peripheral 
Single-
pass Type I
Single-
pass Type 
II 
Single-
pass Type 
IV 
Not a MP 
Too short 
to be 
predicted 
0 116 1 5 3 1 2 1 0 97 6 
1 22 1 1 3 1 0 3 0 13 0 
2 1 0 0 1 0 0 0 0 0 0 
12 1 0 0 0 0 0 0 0 1 0 
Total 140 2 6 7 2 2 4 0 111 6 
TMH: transmembrane helices; MP: membrane protein; too short to be predicted: protein with less than 50 amino acids; NCSPs: non-classically 
secreted proteins. 
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Table 2.8: Putative CSPs transmembrane beta-barrel and membrane type prediction. 
PRED-TMBB MemType-2L 
Types No. of CSPs Gpi Anchor
Lipid 
Anchor 
Multi-
pass 
Periphera
l 
Single-
pass 
Type I 
Single-
pass 
Type II 
Single-
pass 
Type IV 
Not a MP 
Too short 
to be 
predicted 
OMP with 
8 to 22 
BBs 
22 0 2 9 1 0 0 0 10 0 
OMP with 
< 8 or > 22 
BBs 
23 0 1 6 0 0 0 0 16 0 
Not an 
OMP 68 1 4 4 4 1 1 1 51 1 
Total 113 1 7 19 5 1 1 1 77 1 
OMP: outer-membrane protein; MP: membrane protein; too short to be predicted: protein with less than 50 amino acids; CSPs: classically secreted 
proteins; BB: beta-barrel.  
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Table 2.9: Putative NCSPs transmembrane beta-barrel and membrane type prediction. 
PRED-TMBB MemType-2L 
Types No. of NCSPs Gpi Anchor
Lipid 
Anchor 
Multi-
pass 
Periphera
l 
Single-
pass 
Type I 
Single-
pass 
Type II 
Single-
pass 
Type IV 
Not a MP 
Too short 
to be 
predicted 
OMP with 
8 to 22 
BBs 
19 1 2 0 0 1 1 0 14 0 
OMP with 
< 8 or > 22 
BBs 
25 0 2 3 1 0 0 0 18 1 
Not an 
OMP 96 1 2 4 1 1 3 0 79 5 
Total 140 2 6 7 2 2 4 0 111 6 
OMP: outer-membrane protein; MP: membrane protein; too short to be predicted: protein with less than 50 amino acids; NCSPs: non-classically 
secreted proteins; BB: beta-barrel.  
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 (A)  
(B)   
Figure 2.6: Number of putative CSPs (A) and putative NCSPs (B) predicted with TMH(s) 
and TMBB(s) using TMHMM 2.0 and PRED-TMBB. 
TMH: transmembrane helices; TMBBs: transmembrane beta-barrels; CSPs: classically 
secreted proteins; NCSPs: non-classically secreted proteins. 
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The membrane types of the putative CSPs were predicted using Memtype-2L. Fifteen (15) of 
the putative CPSs without TMH or TMBB were predicted as membrane proteins using 
Memtype-2L. However, 13 of them were also predicted as membrane proteins using Gneg-
mPLoc, which indicates these proteins might be the membrane proteins without TMH or 
TMBBs. For the putative 46 TMH and/or TMBB-containing CSPs, only 20 were predicted as 
membrane proteins by MemType-2L. As indicated in the Section 2.2.4, MemType-2L only 
predicts 8 types of membrane proteins. The rest putative 26 membrane proteins may belong 
to the other classes that are not included in MemType-2L.  
 
Of 140 putative NCSPs, 83% of them were predicted without TMH. For the 22 putative 
NCSPs predicted contain one TMH, 21 of them (15%) with the predicted TMH located in the 
first 60 AAs, which indicates that they might be indeed signal peptides (Krogh et al, 2001). 
Only 3 putative NCSPs predicted containing TMH(s) by TMHMM 2.0, which include one with 
1 TMH, one with 2 TMHs and another with 12 TMHs. The NCSP predicted contains 2 TMHs 
was also predicted as an OMP with 2 TMBBs, while the other two putative TMH-containing 
NCSPs are likely inner membrane proteins as they were predicted as non-OMP using PRED-
TMBB. The total number of putative TMH and/TMBB containing NCSPs is 46, which is 
exactly same as the number of putative TMH and/or TMBB containing CSPs. Among them, 
only 10 of them were predicted as membrane proteins by MemType-2L. As discussed above, 
the rest of putative TMH and/or TMBB containing proteins may belong to the other types 
rather than the eight types predicted by MemType-2L.  
 
2.3.5 Enzyme Prediction 
 
For a newly found protein sequence the most interested thing scientists wish to know is 
about its biological function. Enzyme prediction has been performed using EzyPred and the 
results are shown in Table 2.10. For C. jejuni NCTC 11168, 22 out of 38 annotated proteins 
have been correctly predicted using EzyPred. Another 2 hypothetical proteins  
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Table 2.10: The enzyme prediction obtained from the server EzyPred based on the (A) 113 putative CSPs and (B) 140 putative NCSPs 
(A) 
  Annotated enzymes Hypothetical proteins Annotated non-enzymes or unknown function Total  
Predicted by EzyPred as 
an enzyme 8 0 6 14 
Predicted by EzyPred as 
a non-enzyme 5 1 92 98 
Too short for EzyPred to 
predict 0 0 1 1 
Total  13 1 99 113 
(B) 
  Annotated enzymes Hypothetical proteins Annotated non-enzymes or unknown function Total  
Predicted by EzyPred as 
an enzyme 14 2 5 21 
Predicted by EzyPred as 
a non-enzyme 10 35 68 113 
Too short for EzyPred to 
predict 1 3 2 6 
Total  25 40 75 140 
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and 11 annotated proteins have also been predicted as enzymes by EzyPred. For the 11 
annotated proteins, some of them have been assigned with other functions and some have 
only been annotated with the location (such as periplasmic proteins). Therefore, they cannot 
be totally excluded from the enzyme class. The accuracy of EzyPred prediction for putative 
CSPs and NCSPs are roughly the same, around 60%. The remaining 40% have known the 
enzyme function, but have not been predicted.  
 
Proteases play important roles in regulating activation, synthesis and turnover of proteins, 
which is essential for the bacteria and any other organisms. Protease account for about 1-5% 
of genomes of infectious organisms (Chou & Shen, 2008b). Actually, according to the recent 
inference by Rawlings et al. (Rawlings et al, 2012), the number of protease/peptidase might 
be as least twice as much. For the protease prediction part (results as shown in Table 2.11), 
there are in total 4 annotated peptidases/proteases from the 253 putative secreted proteins, 
which were all successfully predicted by ProtIdent. There are in total 23 putative proteases 
predicted from the server, besides the 4 already been identified, 19 remain to be further 
identified. Among the 19 putative peptidases, 11 of them are hypothetical proteins. 
 
2.3.6 Virulent Protein Prediction 
 
Virulence of a bacterial pathogen is its relative ability to colonise the host, potentially/actually 
cause disease, normally described as the number of infecting bacteria, the route of its entry 
into the host and its intrinsic virulence factors (Garg & Gupta, 2008). Virulence factors 
commonly include proteins, carbohydrates and other molecules synthesised by the bacteria 
(Garg & Gupta, 2008). Virulence proteins are the most important virulence factors coded in 
the genes present in chromosomal DNA or mobile genetic elements such as bacteriophages 
or plasmids (Hastings et al, 2004; Weiss, 2002).  
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Table 2.11: The protease prediction obtained from the server ProtIdent based on the (A) 113 putative CSPs and (B) 140 putative NCSPs 
(A) 
 Annotated protease 
Annotated 
peptidase 
Annotated enzymes 
other than 
protease/peptidase 
Hypothetical 
proteins Others Total 
Predicted by ProtIdent 
as protease 0 1 0 0 4 5 
Predicted by ProtIdent 
as non-protease 0 0 12 1 94 107 
Too short for ProtIdent 
to predict 0 0 0 0 1 1 
Total 0 1 12 1 99 113 
(B) 
 Annotated protease 
Annotated 
peptidase 
Annotated enzymes 
other than 
protease/peptidase 
Hypothetical 
proteins Others Total 
Predicted by ProtIdent 
as protease 2 1 1 11 3 18 
Predicted by ProtIdent 
as non-protease 0 0 20 26 70 116 
Too short for ProtIdent 
to predict 0 0 1 3 2 6 
Total 2 1 22 40 75 140 
 
Chapter 2 
 96
Five classes of virulence factors have been widely discussed: adhesins, colonisation factors, 
invasion factors, toxins and defensive virulence factors. According to the server VirulentPred 
(Garg & Gupta, 2008), 195 putative secreted virulence proteins have been predicted from the 
group of C. jejuni NCTC 11168 putative secreted proteins, which include 154 known-
function/location proteins and 41 hypothetical proteins. The predicted attributes of the 41 
hypothetical virulent proteins (1 putative CSPs and 40 putative NCSPs) are listed in Table 
2.12 and Table 2.13. 
 
 
Chapter 2 
 97
Table 2.12: The prediction results of the 1 putative virulent hypothetical CSP from C. jejuni NCTC 11168 
CSPs ProtIdent EzyPred Gneg-PLoc Gneg-mPLoc MemType TMHMM PRED-TMBB 
Cj0371 Not a protease Not an enzyme Cytoplasm Cell inner membrane. Not a MP 1 1 
MP: membrane protein 
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Table 2.13: The prediction results of the 40 putative virulent hypothetical NCSPs from C. jejuni NCTC 11168 
NCSPs ProtIdent EzyPred Gneg-PLoc Gneg-mPLoc MemType TMHMM PRED-TMBB 
Cj0055c Not a protease 
Not an 
enzyme Cytoplasm Cell inner membrane. Extracellular. Not a MP 0 NOT an OMP 
Cj0056c Cysteine type Not an enzyme Cytoplasm Cell outer membrane. Not a MP 0 NOT an OMP 
Cj0152c Not a protease 
Not an 
enzyme Cytoplasm Cell inner membrane. Extracellular. Not a MP 1 NOT an OMP 
Cj0202c Not a protease 
Not an 
enzyme Cytoplasm Extracellular. Not a MP 0 4 
Cj0243c Not a protease 
Not an 
enzyme Cytoplasm Extracellular. Not a MP 0 NOT an OMP 
Cj0391c Serine type Not an enzyme Extracellular Extracellular. Not a MP 0 NOT an OMP 
Cj0418c Not a protease 
Not an 
enzyme Extracellular Cell outer membrane. Not a MP 0 NOT an OMP 
Cj0428 Not a protease 
Not an 
enzyme Extracellular Extracellular. Not a MP 0 NOT an OMP 
MP: membrane protein; OMP: outer membrane protein; too short to be predicted: protein with less than 50 amino acids. 
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Table 2.13: The prediction results of the 40 putative virulent hypothetical NCSPs from C. jejuni NCTC 11168 (cont.) 
NCSPs ProtIdent EzyPred Gneg-PLoc Gneg-mPLoc MemType TMHMM PRED-TMBB 
Cj0700 Not a protease 
Not an 
enzyme Cytoplasm Cell inner membrane. Extracellular. Not a MP 0 NOT an OMP 
Cj0736 Cysteine type Not an enzyme Cytoplasm Extracellular. 
Gpi anchor 
membrane 0 22 
Cj0738 Not a protease 
Not an 
enzyme OM Fimbrium.  
Multi-pass 
membrane 0 Not an OMP 
Cj0739 Serine type Not an enzyme Extracellular Cell outer membrane. Extracellular. 
Single-pass 
type I 0 NOT an OMP 
Cj0740 Aspartic type Not an enzyme Cytoplasm Extracellular. Not a MP 0 NOT an OMP 
Cj0741 Not a protease 
Not an 
enzyme Cytoplasm Extracellular. Not a MP 0 NOT an OMP 
Cj0748 Too short to be predicted 
Too short to 
be predicted
Too short to 
be predicted Too short to be predicted 
Too short to 
be predicted 0 NOT an OMP 
Cj0794 Cysteine type Not an enzyme Flagellar Extracellular. Not a MP 0 NOT an OMP 
MP: membrane protein; OMP: outer membrane protein; too short to be predicted: protein with less than 50 amino acids. 
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Table 2.13: The prediction results of the 40 putative virulent hypothetical NCSPs from C. jejuni NCTC 11168 (cont.) 
NCSPs ProtIdent EzyPred Gneg-PLoc Gneg-mPLoc MemType TMHMM PRED-TMBB 
Cj0814 Not a protease 
Not an 
enzyme Extracellular Extracellular. Not a MP 0 NOT an OMP 
Cj0815 Metallo type Not an enzyme Cytoplasm Cell inner membrane. Extracellular. Not a MP 0 NOT an OMP 
Cj0816 Not a protease 
Not an 
enzyme Cytoplasm Cell inner membrane. Not a MP 0 NOT an OMP 
Cj0839c Not a protease 
Not an 
enzyme OM Cell inner membrane. Extracellular. Not a MP 0 Not an OMP 
Cj0848c Not a protease 
Not an 
enzyme Cytoplasm Cell inner membrane. Not a MP 0 3 
Cj0849c Not a protease 
Not an 
enzyme Cytoplasm Cell inner membrane. Not a MP 0 NOT an OMP 
Cj0859c Metallo type Not an enzyme Extracellular Cell inner membrane. Not a MP 0 2 
Cj0873c Not a protease 
Hydrolases
Acting on 
ester bonds
Cytoplasm Cell inner membrane. Not a MP 0 NOT an OMP 
MP: membrane protein; OMP: outer membrane protein; too short to be predicted: protein with less than 50 amino acids. 
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Table 2.13: The prediction results of the 40 putative virulent hypothetical NCSPs from C. jejuni NCTC 11168 (cont.) 
NCSPs ProtIdent EzyPred Gneg-PLoc Gneg-mPLoc MemType TMHMM PRED-TMBB 
Cj0878 Too short to be predicted 
Too short to 
be predicted
Too short to 
be predicted Too short to be predicted 
Too short to 
be predicted 0 3 
Cj0916c Not a protease 
Not an 
enzyme Cytoplasm Cell inner membrane.  Not a MP 0 NOT an OMP 
Cj0970 Serine type Not an enzyme Extracellular Extracellular.  Not a MP 0 NOT an OMP 
Cj0971 Cysteine type Not an enzyme Extracellular Extracellular.  
Lipid anchor 
membrane 0 NOT an OMP 
Cj0972 Serine type Not an enzyme Extracellular Fimbrium.  Not a MP 0 2 
Cj0974 Too short to be predicted 
Too short to 
be predicted
Too short to 
be predicted Too short to be predicted 
Too short to 
be predicted 0 NOT an OMP 
Cj1036c Not a protease 
Not an 
enzyme Cytoplasm Cell inner membrane. Extracellular.  Not a MP 0 NOT an OMP 
Cj1164c Not a protease 
Hydrolases
Acting on 
ester bonds
Cytoplasm Cell inner membrane. Cytoplasm. Not a MP 0 NOT an OMP 
MP: membrane protein; OMP: outer membrane protein; too short to be predicted: protein with less than 50 amino acids. 
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Table 2.13: The prediction results of the 40 putative virulent hypothetical NCSPs from C. jejuni NCTC 11168 (cont.) 
NCSPs ProtIdent EzyPred Gneg-PLoc Gneg-mPLoc MemType TMHMM PRED-TMBB 
Cj1225 Not a protease 
Not an 
enzyme Cytoplasm Cell inner membrane.  Not a MP 0 NOT an OMP 
Cj1232 Not a protease 
Not an 
enzyme Cytoplasm Cell inner membrane.  Not a MP 0 NOT an OMP 
Cj1242 Not a protease 
Not an 
enzyme Extracellular
Cell inner membrane. Cell outer 
membrane. Extracellular.  Not a MP 0 NOT an OMP 
Cj1463 Not a protease 
Not an 
enzyme Cytoplasm Extracellular.  Not a MP 0 NOT an OMP 
Cj1464 Not a protease 
Not an 
enzyme Fimbrium Cell outer membrane.  Not a MP 0 1/2 
Cj1501 Not a protease 
Not an 
enzyme Cytoplasm Cytoplasm. Not a MP 0 NOT an OMP 
Cj1631c Not a protease 
Not an 
enzyme Flagellar Extracellular.  Not a MP 0 NOT an OMP 
Cj1656c Not a protease 
Not an 
enzyme Extracellular Extracellular. Fimbrium.  
Lipid anchor 
membrane 0 0 
MP: membrane protein; OMP: outer membrane protein; too short to be predicted: protein with less than 50 amino acids. 
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2.4 Discussion and Conclusion 
 
A number of identified C. jejuni virulence factors are known to be involved in chicken 
colonisation, which is still poorly understood. Individual experimental studies for all the 
encoded proteins are both too time-consuming and costly to carry out. Bioinformatics tools 
are useful for investigating these potential virulence proteins that may be involved in chicken 
colonisation and evasion of the host immune response. In this study, various servers were 
used to identify putative virulent non-classically secreted proteins from C. jejuni NCTC 11168 
that are fully or partially exposed extracellularly, which may be responsible for chicken 
immune down-regulation and/or the remarkable colonisation capability of C. jejuni in 
chickens.  
 
After assessing the 1623 protein sequences using a variety of bioinformatics tools, 28 
predicted virulent NCSPs have been identified which putatively interact with the extracelluar 
environment (Table 2.14). Among them, 11 of them have been predicted as a 
protease/peptidase. Genes cj0243c (σ54), cj0391c (σ28), cj0814 (σ54), cj0859c (σ28) and 
cj1656c (σ28) have been observed to be co-regulated with flagellar gene expression in 
Guerry-Kopecko et al.’s study (Guerry-Kopecko, 2012). σ54 promoters regulate the 
expression of genes required for basal body, hook and flagellar filament biosynthesis (Class 
II genes). σ28 promoters co-regulate the expression of genes required for extension and 
capping of the flagellum, and genes required for flagellin post-translational modification and 
secretion of virulence factors (Class III genes) (Carrillo et al, 2004). Furthermore, 
hypothetical protein Cj0391c and Cj1631c was overexpressed in biofilm-grown cells, along 
with other proteins involved in stress response, flagellar motility complex and adhesion 
(Kalmokoff et al, 2006). Protein Cj1656c have been predicted as a membrane protein using 
MemType. However, there is no TMH or TMBB has been bioinformatically detected.  
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Table 2.14 The 28 putative virulent NCS extracellular proteins 
NCSPs Size (AAs) NCSPs Size (AAs) 
Cj0055c 274 Cj0794 426 
Cj0056c 138 Cj0814 251 
Cj0152c 312 Cj0815 114 
Cj0202c 113 Cj0839c 65 
Cj0243c 388 Cj0859c 142 
Cj0391c 211 Cj0970 100 
Cj0418c 234 Cj0971 130 
Cj0428 127 Cj0972 107 
Cj0700 231 Cj1036c 83 
Cj0736 642 Cj1242 106 
Cj0738 54 Cj1463 113 
Cj0739 57 Cj1464 65 
Cj0740 54 Cj1631c 289 
Cj0741 308 Cj1656c 60 
These 28 predicted virulent NCSPs have been identified which putatively interact with the 
extracelluar environment 
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Protein Cj0152c, which has been predicted locates in the cytoplasm/cell inner membrane 
and extracellular, has been found in the C. jejuni outer membrane vesicles (OMVs) (Jang et 
al, 2014). In Gram-negative bacteria, OMVs are often released extracellularly attaching to 
host cells through adhesive molecules then transferring compounds into the host cells (Jang 
et al, 2014). As C. jejuni does not have the prototypical virulence-associated secretion 
systems, OMV plays an important role in the coordinated delivery of virulent proteins into 
host cells (Elmi et al, 2012). Protein Cj0391c and Cj0859c were also predicted as putative 
protease according to server ProtIdent. 
 
Among the listed gene candidates in Table 2.14, gene cj0391c has been selected for our 
experimental study (some others were expressed by other colleagues) and expressed as a 
recombinant protein in E. coli BL21(DE3) (Chapter 3). Protein Cj0391c was selected based 
on the following reasons: (1) gene cj0391c is σ28 co-regulated with flagellar gene expression 
(Guerry-Kopecko, 2012); (2) it was overexpressed in biofilm-grown cells, along with other 
proteins involved in stress response, flagellar motility complex and adhesion (Kalmokoff et al, 
2006); (3) it predicted mainly hydrophilic (Figure 2.7); (4) none of the prediction tool indicates 
it is a membrane protein or contains transmembrane region (it may dissolve well and 
fold/function correctly in the protein storage solution and tissue culture medium); (5) it is 
predicted as a stable protein based on its instability index using ProtParam server 
(Guruprasad et al, 1990) (Appendix 3). This recombinant protein was then tested against 
chicken macrophage cells for cell proliferation and the induction of apoptosis (Chapter 3).
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Figure 2.7: Cj0391c hydrophobicity/hydrophilicity plots prediction result using Kyte-
Doolittle Scale and Hopp-Woods Scale. (Kyte-Doolittle scale: positive values indicate 
hydropathic regions; Hopp-Woods scale: apolar residues with negative values, while 
the region of maximal hydrophilicity is likely to be an antigenic site) (Hopp & Woods, 
1981; Kyte & Doolittle, 1982).  
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CHAPTER 3. PROTEIN 
CJ0391C EXPRESSION AND 
ANALYSIS  
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3.1 Introduction 
 
The E. coli DH5α cells containing the pREST-A/Cj0391c construct were obtained from a 
previous study. Initially, plasmid DNA from the cells was extracted and sequenced to confirm 
that the plasmid contained the correct sequence and the resulting protein sequence is in 
frame with vector-encoded sequences. Next, the plasmid was introduced into the protein 
expression system E. coli BL21(DE3)pLySs. The final steps were to express, purify and 
analyse the recombinant protein Cj0391c from the pRSET-A construct contained in E. coli 
BL21(DE3) cells. A pilot protein expression study was performed to determine the time 
required to express the maximal amount of target protein after Isopropyl-β-D-
galactopyranoside (IPTG) induction. 
 
Once optimal induction conditions for the expression of recombinant protein Cj0391c were 
confirmed by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and 
Western Blot analysis, the protein expression study was ‘scaled-up’, and the entire IPTG-
induced culture prepared for protein purification using the sonication method. Recombinant 
protein from whole cell lysates (WCL) was purified using immobilised metal (nickel ion) 
affinity chromatography (IMAC) column, in which the nickel-bound polyHistidine tagged 
pRSET-A fusion protein attached to the recombinant protein was eluted with elution buffer 
(EB) containing increasing concentrations of imidazole.  
 
After confirmation of the optimal elution condition for recombinant protein Cj0391c by SDS-
PAGE and Western blot analysis, the pooled eluants were concentrated with Vivaspin (<5 
kDa cut-off) and buffer-exchanged with Phosphate buffered saline (PBS). The amount of the 
purified and concentrated protein was measured by Bradford assay. MTT (3-(4,5-
dimethylthiazolyl-2-yl)-2,5-diphenyltetrazolium bromide) cell proliferation assay was 
performed by adding filter sterilised recombinant protein Cj0391c at final concentrations of 5 
ug/mL, 20 ug/mL and 40 ug/mL to chicken macrophage cell HD11 culture. Cell viability was 
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measured at different time points using an iMark microplate absorbance reader for the 
presence of intracellular purple formazan, which indicates viable cells.  
 
An apoptosis assay was performed by using a Dead Cell Apoptosis Kit containing Annexin V 
Alexa Fluor® 488 and Propidium Iodide (PI) fluorescent dyes (Invitrogen Corporation, USA).  
The cells were incubated with 20 µg/mL of recombinant protein Cj0391c for 12 h before 
being subjected to CLSM. 
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3.2 Materials and Methods 
 
3.2.1 General Procedures 
 
Sterilisation of glassware, pipette tips, PCR tubes, centrifuge tubes, toothpicks, media and 
appropriate solutions was achieved by autoclaving at 121ºC for 20 min unless stated 
otherwise. All glassware was washed in pyroneg detergent and rinsed twice in distilled water. 
Finnpipettes® (ThermoFisher Scientific, USA) were used to dispense solutions ranging from 
0.5 µL to 10 mL. Volumes above 10 mL were measured with measuring cylinders. Weighting 
of solids less than 2 g was done using the Mettler Toledo XS105 Dual Range top loading 
analytical balance, while weighting of solids greater than 2 g was performed with the ISSCO 
Model 300 top loading balance. Volumes of 1.5 mL or less were separated by centrifugation 
with the Eppendorf microcentrifuge 5415D and volumes up to 50 mL were separated by 
centrifugation using either the Beckman Allegra™ 21R centrifuge or the Heraeus Multifuge 
1S-R centrifuge.  
 
All media were prepared using distilled water and aseptic techniques. Media containing 
supplements and/or antibiotics were autoclaved and cooled to approximately 50ºC before the 
addition of any supplement(s) or antibiotic(s). All media and ager plates were stored at 4ºC 
until required. 
 
Deionised distilled water was obtained by filtration through a Millipore Milli-Q™ water system  
(MQ water) (Millipore, USA) and was used to prepare all solutions unless otherwise stated. 
All solutions were prepared using analytical or molecular grade chemicals and stored at room 
temperature (RT) unless otherwise stated.  Solutions that were sterilised by filtration were 
passed through a sterile 0.2 µm syringe filter disc.   
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3.2.2 General Equipments and Suppliers 
  
96-well, colourless, flat bottom plates  Nunc, Denmark 
96-Well Microplate Polystyrene Black (350µl well 
volume)  
Chromacol, United Kingdom 
Acrodisc® (0.2 μm and 0.45 μm) Pall, USA 
Balances:  
 XS105 Dual Range analytical balance  Mettler Toledo, Australia 
 ISSCO Model 300 balance  ISSCO, Australia 
Biological safety cabinet class II, BH2000 series Clyde-Apac, Australia 
BioPhotometer  Eppendorf, Germany 
Centrifuge tubes:  
 1.5 mL microfuge tubes  Sarstedt, Germany 
 10 mL centrifuge tubes  Sarstedt, Germany 
 15 mL centrifuge tubes  Sarstedt, Germany 
 50 mL centrifuge tubes  Greiner Bio-One, Germany 
Centrifuges:  
 Eppendorf 5414D bench top centrifuge 
 (maximum speed 16,000 x g)  
Eppendorf, Germany 
 Heraeus Multifuge 1S-R centrifuge 
           (maximum speed 5000 x g)  
Thermo Electron Corporation, 
USA 
 Allegra™ 21R centrifuge 
           (maximum speed 5000 x g)  
Beckman Coulter, USA 
 
Cryovials (1.8 mL) Iwaki, Japan 
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Dry block heater Ratek, Australia 
Electrophoresis power supply:  
 EPS 3000xi BioRad Laboratories, USA 
 PowerPac 300 BioRad Laboratories, USA 
Electrophoresis units and components:  
DNA  
 Mini gel (Mini-sub cell GT cell)  BioRad Laboratories, USA 
 Midi gel (Wide mini-sub cell GT cell)  BioRad Laboratories, USA 
Electroporation cuvettes (0.2 cm) Molecular Bio Products, USA 
GelDoc imaging system BioRad Laboratories, USA 
FLUOstar Optima microplate reader BMG Labtech, Germany 
iBlot dry gel transfer device Invitrogen Corporation, USA 
iMark microplate absorbance reader BioRad Laboratories, USA 
Milli-Q® water filtration system Millipore, USA 
Petri dishes BioLab, Australia 
pH meter Metrohm AG, Switzerland 
Platform orbital shaker Ratek, Australia 
Polypropylene gravity flow column (1 mL) Qiagen, Germany 
Pulse controller & Gene pulser apparatus  BioRad Laboratories, USA 
Px2 Thermal Cycler Thermo Electron Corporation, 
USA 
Syringes  
 1, 3, 5, 10, 20, and 60 mL Terumo, Australia 
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 SGE 100 L glass syringe  SGE Analytical Science, Australia 
Transilluminator (Stern et al) Novex, Australia 
UVette® (10 mm) Eppendorf, Germany 
Vivaspin 20  
 5,000 Da MWCO  
 Diafiltration cup 
Sartorius-Stedim, Germany 
Water bath Ratek, Australia 
 
3.2.3 General Materials and Suppliers 
 
β-mercaptoethanol 
Electrophoresis purity (BioRad Laboratories, USA). 
 
Acetic Acid (glacial)  
(Merck, Germany). 
 
Acrylamide/bisacrylamide Solution 
40% acryl/bis (Amresco, USA), stored at 4ºC. 
 
Adenosine Triphosphate (ATP)  
20 mM ATP (Sigma-Aldrich, Germany), stored at -20ºC. 
 
Agarose 
1.5-2.5 % (w/v) agarose, DNA grade (Bioline, England). 
 
Ammonium Persulphate (APS) 
10% (w/v) ammonium persulphate (Sigma-Aldrich, Germany), stored at 4ºC. 
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Bacteriological Agar 
(Oxoid, England). 
 
Bovine Serum Albumin (BSA)  
1 – 10 mg/mL BSA (Promega, USA), aliquots stored at -20ºC. 
 
Bromophenol Blue 
(BDH, USA). 
 
Ethanol 
70% (v/v), 96% (v/v), 100% (v/v) (Merck, Germany).  
 
Ethylenediaminetetra-aetate (EDTA)  
0.5 M EDTA (Merck, Germany). 
 
Ficoll 400  
(BDH, USA) 
 
Glycerol 
10% (v/v) sterile glycerol (BDH, USA). 
 
Hydrochloric Acid (HCl) 
32% (Merck, Germany). 
 
Lambda (λ) DNA 
Stored at -20ºC (Promega, USA). 
 
Methanol 
100% (Merck, Germany). 
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Nickel Sulfate (NiSO4) 
0.2 M NiSO4 (BDH, USA), filtered through a 0.45 μm filter. 
 
Orange G 
Signal-Aldrich, Germany 
 
Phosphate Buffered Saline (PBS) 
Phosphate buffered saline (PBS) was prepared by dissolving 1 tablet of pre-made PBS, 
obtained from Oxoid, in 100 mL distilled water. It was autoclaved and stored at 4ºC.  
 
Phosphoric Acid 
85% (Chem-Supply, Australia). 
 
Sodium Acetate (NaOAc) 
3 M NaOAc (pH 5.2) (BDH, USA). 
 
Sodium Chloride (NaCl) 
0.15 M to 5 M NaCl (BDH, USA). 
 
Sodium Dodecyl Sulphate (SDS) 
10% (w/v) (Merck, Germany) 
 
Sodium Hydroxide (NaOH) 
0.1 M NaOH (Merck, Germany). 
 
Sulphuric Acid (H2SO4) 
1 M sulphuric acid (BDH, USA). 
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Tris-Acetate-EDTA (TAE) Buffer (1x) 
40 mM Tris-HCl (pH 8.0) (Merck, Germany), 20 mM acetic acid (Merck, Germany), 2 mM 
EDTA (Merck, Germany). 
 
Tris Buffered Saline (TBS) 
25 mM Tris-HCl (pH 7.4) (Merck, Germany), 0.18 M NaCl (BDH, USA). 
 
Tris-Base 
1.5 M Tris-base (Merck, Germany), adjusted to pH 8.8 with HCl. 
 
Tris-HCl 
1.0 M Tris-base (Merck, Germany), adjusted to pH 6.8 with HCl. 
 
Tryptone 
(Oxoid, England). 
 
Yeast Extract 
(Oxoid, England). 
 
3.2.4 Bacteriological Materials 
 
3.2.4.1 Antibiotic Stock Solutions 
 
Antibiotic solutions were prepared by dissolving the antibiotics in appropriate solvents to the 
desired concentration. These stock solutions were stored at -20ºC after being filter sterilised.  
Antibiotic stock concentrations were as follows: 
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Ampicillin 
Ampicillin (CSL, Australia) was prepared as a stock at 100 mg/mL in MQ water. It was 
sterilized by passing the solution through a 0.2 μm filter. Working concentration of  
100 μg/mL, aliquots stored at -20ºC. 
 
Chloramphenicol 
Chloramphenicol (Sigma-Aldrich, Germany) was prepared as a stock at 34 mg/mL in 96% 
ethanol (Merck, Germany), filtered through a 0.45 μm filter. Working concentration of 34 
μg/mL, aliquots stored at -20ºC. 
 
Skirrows Antibiotic Supplement 
Skirrows supplement was supplied by Oxoid and stored at 4ºC. Two millilitres of sterile MQ 
water was added into one 500 mg supplement vial and mixed with the media before 
dispensing. 
 
3.2.4.2 General Media  
 
All media were prepared according to manufacturer’s recommendations unless specified in 
the text. Sterilisation was performed at standard conditions, 121ºC for 20 min unless stated 
otherwise. Media was dispensed into sterile Petri dishes in a laminar flow cabinet. The media 
plates were dried at 37ºC for 1 h before use unless agar with a moist surface was required. 
 
Brucella Broth 
Brucella broth powder (2.8% w/v) was dissolved in distilled water and sterilised by 
autoclaving under standard conditions.   
 
Horse Blood Agar (HBA) with Skirrow’s Supplement (HBA-Sk) 
Columbia agar base (3.9% w/v) was dissolved in distilled water and sterilised by autoclaving 
under standard conditions. The sterile media was cooled to approximately 50ºC before the 
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addition of defibrillated horse blood (5% v/v) and one vial of Skirrow’s selective supplement 
(Oxoid, England). Each vial of Skirrow’s selective supplement contained 5 mg of 
vancomycin, 1250 i.u. of polymixin B and 2.5 mg of trimethoprim lactate. The media was 
mixed thoroughly and dispensed into Petri dishes. 
 
Luria Bertani (LB) Agar 
Tryptone (1% w/v) (Oxiod, England), yeast extract (0.5% w/v) (Oxiod, England), NaCl (0.5% 
w/v) (BHD, USA) and bacteriological agar (1.0% w/v) (Oxiod, England) were dissolved in 
distilled water and sterilised by autoclaving under standard conditions. The media was mixed 
thoroughly and dispensed into Petri dishes. 
 
Luria Bertani (LB) Agar with Antibiotic(s) 
Tryptone (1% w/v) (Oxiod, England), yeast extract (0.5% w/v) (Oxiod, England), NaCl (0.5% 
w/v) (BHD, USA) and bacteriological agar (1.0% w/v) (Oxiod, England) were dissolved in 
distilled water and sterilised by autoclaving under standard conditions. The sterile media was 
cooled to approximately 50ºC before adding antibiotic(s). The media was mixed thoroughly 
and dispensed into Petri dishes. 
 
Luria Bertani (LB) Broth 
Tryptone (1% w/v) (Oxiod, England), yeast extract (0.5% w/v) (Oxiod, England) and NaCl 
(0.5% w/v) (BHD, USA) were dissolved in distilled water and sterilised by autoclaving under 
standard conditions. 
 
Luria Bertani (LB) Broth with Antibiotic(s) 
Tryptone (1% w/v), yeast extract (0.5% w/v) and NaCl (0.5% w/v) were dissolved in distilled 
water and sterilised by autoclaving under standard conditions. The sterile media was cooled 
to approximately 50ºC before adding antibiotic(s). The media was mixed thoroughly and 
dispensed into Petri dishes. 
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Muller Hinton Agar 
Muller Hinton agar powder (3.8% w/v) was dissolved in distilled water and sterilised by 
autoclaving under standard conditions.  
 
Muller Hinton Broth 
Muller Hinton broth powder (2.1% w/v) was dissolved in distilled water and sterilised by 
autoclaving under standard conditions.  
 
SOC Media 
Tryptone (2% w/v), yeast extract (0.5% w/v), 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2 and 10 
mM MgSO4 were dissolved in distilled water and adjusted to pH 7.0 with NaOH. The media 
was then sterilised by autoclaving under standard conditions. Filter-sterilised 20 mM glucose 
is added prior to use. 
 
Tryptone/Skim Milk Storage Media 
Skim milk powder 10% (w/v), tryptone (1% w/v) and 10 mM Tris-base were dissolved in 
distilled water and adjusted to pH 7.5 with HCl. It was autoclaved at 109ºC for 10 min and 
stored at 4ºC. 
 
3.2.5 Bacteriological Methods 
 
3.2.5.1 Bacterial Strains, Plasmid and Culture Conditions 
 
The C. jejuni NCTC 11168 (Bolton & Coates, 1983) and C. jejuni 81116 (Smith & Muldoon, 
1974) are the strains used throughout this study. The C. jejuni strains were routinely grown 
on HBA or HBA/Skirrow plates, and incubated at 42ºC for 48-72 h under microaerophilic 
conditions. Microaerobic conditions were achieved by the use of an anaerobic jar and either 
a Campygen gas pack, or by the addition of a microaerobic gas mixture (CO2 10%, O2 5%, 
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N2 85%). Selected colonies were sub-cultured onto fresh plates to form pure lawn cultures 
and incubated under the same conditions.  
 
The E. coli strains used in throughout this study are E. coli BL21(DE3) (Invitrogen 
Corporation, USA) and E. coli DH5α (Hanahan, 1983). All E. coli strains were grown on LB 
Agar or in LB broth at 37ºC unless stated otherwise. The cells grown in LB broth were 
shaken on an orbital shaker at 200 revolutions per min (rpm). Appropriate antibiotics were 
added to the agar plates as per requirements of the various concentrations such as ampicillin 
at 100 μg /mL, and chloramphenicol at 34 μg/mL.  
 
The plasmid vector used in this project is pRSET-A (Invitrogen Corporation, USA) and the 
vector map is shown in Figure 3.1.  
 
3.2.5.2 Storage of Bacterial Strains 
 
All Campylobacter strains were stored at -80ºC in tryptone/skim milk freezing medium. One 
millilitre of sterilised tryptone/skim milk storage media was added to one lawn subculture of 
each strain within 48 h of incubation. The colonies were mixed with the storage media using 
a sterile L-shaped spreader and the bacterial culture was collected into a sterile cryogenic 
vial for long-term storage. 
 
All E. coli strains were stored at -80ºC in glycerol freezing medium. For short-term storage of 
these bacterial strains, strains were stored at 4ºC on appropriate media, supplemented with 
the appropriate antibiotics.  
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Figure 3.1: Map of vector pRSET-A (Reproduced from Invitrogen, USA). 
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3.2.5.3 Preparation of Electrocompetent Cells 
 
A single colony of E. coli was inoculated into 5 mL of LB broth and grown overnight at 37ºC 
on an orbital shaker. Two millilitres of an overnight E. coli culture was used to inoculate 200 
mL pre-warmed LB broth and the cells were grown at 37ºC with vigorous shaking until an 
absorbance of 0.3 – 0.5 at 600 nm (OD600nm) was achieved (early mid log phase). When the 
cells have reached this phase, the culture was divided into four 50 mL sterile Falcon tubes 
and chilled on ice for 30 min to slow down cell growth. Cells were harvested by centrifugation 
in a pre-chilled centrifuge for 15 min at 4,000 x g at 4ºC. The pellets were then resuspended 
in 50 mL ice-cold sterile MQ water and centrifuged at the same condition again. The cells 
were then resuspended in 25 mL ice-cold sterile MQ water and pelleted again. Finally, the E. 
coli cells were resuspended and combined in a total of 20 mL of ice-cold 10% sterile glycerol 
in MQ water and pelleted a final time. Ten per cent ice-cold sterile glycerol was added to a 
final volume of 50% of the cell pellet and divided into 50 μL aliquots and stored at -80°C for 
up to 6 months. Transformation efficiency was tested by adding 1 μg of undigested “empty” 
vector (miniprep sample) to a 50 μL vial of electrocompetent E. coli cells, and the cells were 
electro-transformed as described in the section below. 
 
3.2.5.4 Electrotransformation 
 
Briefly, 1-2 μL of purified plasmid DNA was added to 50 μL of pre-thawed electrocompetent 
E. coli cells prepared above. The cells and plasmid were transferred to an ice-cold sterile 
electroporation cuvette (Section 3.2.2). The cuvette was tapped lightly to settle the mixture to 
the bottom. Bubble present was removed before electrotansformation. The Gene Pulser 
setting used to deliver the DNA into the cell was set at 200 ohms, 25 μF capacitance, and 
2.0-2.5 kV, with a 4-5 ms pulse. The sample was pulsed once and 1 mL of SOC medium or 
LB broth was immediately added to the cuvette to resuspend the cells. After transferring the 
medium to a 1.5 mL microfuge tube, samples were incubated on at 37ºC for 1 h with 
shaking. One hundred microliters of sample was plated onto LB agar containing the 
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appropriate antibiotics and incubated at 37ºC overnight. The remaining culture was 
centrifuged and the pellet was resuspended in 100 μL of SOC medium or LB broth, then 
spread onto LB agar containing the appropriate antibiotics and incubated at 37ºC overnight. 
 
3.2.6 DNA Materials 
 
3.2.6.1 General Reagents 
 
11x DNA Loading Buffer 
10% (w/v) Ficoll 400 (BDH, USA), 50% (v/v) glycerol (BDH, USA), 0.5% (w/v) Orange G 
(Sigma-Aldrich, Germany), 1% SDS (Merck, Germany), 10 mM EDTA (BDH, USA), 50 mM 
Tris-base (Merck, Germany), adjusted to pH 8.0 with HCl; stored at 4°C.  
 
Ethanol 
70 % (v/v) ethanol prepared from absolute ethanol (96%) commercial grade (Merck, 
Germany). 
 
Ethidium Bromide 
6 mg ethidium bromide (Sigma-Aldrich, Germany) in 2 L MQ water. 
 
Glycerol 
10-80% (v/v) glycerol, autoclaved. 
 
Lambda(ߣ)-PstI DNA Ladder 
λ DNA (500 μg/mL) 100 μg, PstI (10 U/μl) 100 U, 10x restriction enzyme Buffer H (90 μL), 
and MQ water were added to a final volume of 900 μL. The mixture was incubated overnight 
at 37ºC before the addition of 10x gel loading dye (100 μL) and stored at 4ºC. A diagram of 
PstI digested λ-DNA is shown in Appendix 4.  
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MQ Water 
Sterile MQ water (Millipore) or deionised water was used to prepare reagents.  
 
Molecular Grade Water 
Distilled water, DNAse-free and RNAse-free for PCR reactions and plasmid DNA methods. 
 
Propan-2-ol (Isopropanol) 
100% (v/v) Isopropanol. 
 
Sodium Acetate (NaOAc) 
3 M NaOAc (BDH, USA), adjusted to pH 4.6 with HCl, autoclaved. 
 
Sodium Dodecyl Sulphate (SDS) 
1-10% (w/v) SDS (Merck, Germany). 
 
TAE Buffer 
40 mM Tris-base, 20 mM glacial acetic acid, 2 mM EDTA. 
 
TE Buffer, pH 8.0 
10 mM Tris-base, 1 mM EDTA, adjusted to pH to 8.0 with HCl. 
 
3.2.6.2 Commercial kits 
 
DNA Sequencing Kit (ABI version 3.1) 
Big Dye, 5x dilution buffer, stored at -20ºC (Monash University, Australia). 
 
QIAprep Spin Miniprep Kit 
(Qiagen, Germany). 
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Wizard® DNA Clean-up System Kit 
(Promega, USA). 
 
3.2.7 DNA Methods 
 
3.2.7.1 Plasmid DNA Extraction (Mini Prep) 
 
Plasmids were grown in E. coli DH5α and purified using the QIAprep Spin Miniprep kit 
(Qiagen, Germany) as per manufacturer’s protocol. Briefly, template DNA was loaded and 
bound to a QIAquick spin column. The DNA was washed in the supplied wash buffer, eluted 
in MG H2O and stored at −20ºC. 
 
3.2.7.2 DNA Purification from PCR 
 
Purification of DNA from PCR amplification was performed using the Wizard® DNA Clean-up 
System kit (Promega, USA) as per manufacturer’s protocol. Briefly, PCR product was mixed 
with direct purification buffer and resin. The mix was then passed through a mini-column, 
washed in isopropanol and eluted in MG H2O. 
 
3.2.7.3 Agarose Gel Electrophoresis 
 
Agarose gels (1.0%-2.0%) were used from DNA sample separation and visualisation. DNA 
sample (20 μL) was mixed with 2 μL of 11X DNA loading buffer before the gel 
electrophoresis. ߣ-PstI DNA ladder (10 μL) was loaded onto each gel. After electrophoresis, 
the gel was stained in a 3 mg/L ethidium bromide water bath for 5 min. The destaining 
process was followed as leaving under running water for 20-30 min. DNA products were 
visualized photographed using a BioRad GelDoc transilluminator.  
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3.2.7.4 Quantification of DNA Concentration 
 
Concentration of the extracted plasmid DNA was measured by appropriate methods. The 
amount of plasmid DNA was either by comparing the intensity of sample DNA against the 
lambda PstI digested molecular weight marker (50 μg/mL) (Appendix 4) on an agarose gel or 
by using the spectrophotometer. The purity of the sample was determined by ratio of ODs 
obtained at 260 nm and 280 nm (>1.8 for pure DNA) respectively. 
 
3.2.7.5 Sequencing PCR  
 
PCR was performed in a Px2 Thermal Cycler machine in sterile PCR tubes. Isolated plasmid 
DNA samples were used as templates for the PCR reaction. Sequence analysis of constructs 
was carried out with forward or reverse T7 promoter primers (Table 3.1). This analysis was 
performed to confirm the presence and orientation of inserts and to confirm all inserts were in 
frame with the start codon of the plasmid vector. PCR was performed using the protocol 
provided by Micromon DNA Sequencing Facility, Monash University, Melbourne, Australia. 
The details of the PCR setting and cycling conditions are stated in Table 3.2 and Table 3.3. 
The PCR products were sent to Monash University (Melbourne, Australia) for sequencing. 
 
3.2.8 Protein Materials 
 
3.2.8.1 General Materials 
 
Ammonium Persulfate (APS) 
10% (m/v) in MQ water 
 
Blocking Buffer 
5% (w/v) skim milk powder (Diploma, Australia) in TBS. 
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Table 3.1: Sequencing primers 
Name Sequence 5’-3’ Description 
T7 Forward TAATACGACTCACTATAGGG Sequencing primer for pRSET-A 
T7 Reverse GCTAGTTATTGCTCAGCGG Sequencing primer for pRSET-A 
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Table 3.2: Sequencing PCR setting 
Sequencing reaction components Volume 
5 x Dilution Buffer                                        3 µL 
T7 Forward Primer (50 ng/μL)                      1 µL 
T7 Reverse Primer (50 ng/μL) 1 µL 
Template DNA                                         ~ 300 ng 
Big Dye 2 µL 
MG H2O                                                To 20 µL 
Total Volume 20 µL 
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Table 3.3: Sequencing reaction cycling conditions 
Stage Details Temperature Time 
Stage 1 Initial denaturation 96ºC 1 min 
Stage 2 Denaturation 96ºC 10 sec 
Annealing 50ºC 5 sec 
Extension 60ºC 4 sec 
Number of cycles = 30 
Stage 3 Hold samples 4ºC Indefinitely 
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Bradford Reagent 
100 mg Coomassie Brilliant G-250 (Sigma-Aldrich, Germany) dye dissolved in 50 mL 95% 
(v/v) ethanol (Merck, Germany), then mixed with 100 mL 85% (v/v) phosphoric acid (Chem 
Supply, Australia), and brought up to 1 L with distilled water. Stored at 4°C and filtered 
through a 0.45 μm filter before use. 
 
Buffer 1 
0.1% sodium citrate (pH 4.5) (BDH, USA), 2.5% (w/v) Triton X-100 (Biorad Laboratories, 
USA). 
 
Buffer 2 
0.1% sodium citrate (pH 4.5) (BDH, USA). Dithiothreitol (DTT) (Molecular Biology Grade, 
Promega) was added to the concentration of 2mM just before use. 
 
Chelating Sepharose™ Fast Flow 
(GE healthcare, Sweden), charged with 0.2 M nickel sulphate (NiSO4) (BDH, USA). 
 
Coomassie Brilliant G-250  
(Sigma-Aldrich, Germany). 
 
Coomassie Blue Stain 
Coomassie brilliant blue (R) powder (0.1% w/v) was dissolved in methanol (40% v/v) (BDH, 
USA), and glacial acetic acid (10% v/v) (Merck, Germany). 
 
Destaining Solution 
Ethanol (10% v/v) (Merck, Germany) and glacial acetic acid (10% v/v) (Merck, Germany) was 
prepared in MQ water. 
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Dithiothreitol (DTT) 
1 M freshly made (Molecular Biology Grade, Promega) for every use. 
 
Ethylenediaminetetra-aetate (EDTA)  
0.5 M EDTA (Merck, Germany). 
 
Gelatin Gel  
125 mM Tris (pH 6.8) (Merck, Germany), 1% SDS (Merck, Germany), 12% bis/acrylamide 
(Amresco, USA), 0.1% (v/v) gelatin (Sigma-Aldrich, Germany) made up to volume with MQ 
water. APS 0.05% (w/v) (Sigma-Aldrich, Germany) and TEMED 0.1% (v/v) were added to 
polymerise.  
 
iBlot Transfer Stacks 
iBlot gel transfer stacks (nitrocellulose membrane), Regular (2 gels) or Mini (1 gel) 
(Invitrogen Corporation, USA). 
 
IMAC Stripping Solution 
0.5 M NaCl (BDH, USA), 50 mM EDTA (Merck, Germany). 
 
Imidazole 
5 M imidazole (Sigma-Aldrich, Germany), filtered through a 0.45 μm filter, stored at 4ºC in 
the dark. 
 
IPTG Solution 
Isopropylthio-β-D-galactosidase (IPTG; 24 mg/mL) was dissolved in water, filter sterilised 
and stored at -20ºC. 
 
Resolving Gel 
Tris-HCl pH 8.8 (375 mM) (Merck, Germany), SDS (0.1% w/v) (Merck, Germany), bis 
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acrylamide (12.5% v/v) (Amresco, USA) was prepared with MQ water. The setting agents 
ammonium persulfate (0.06% w/v) (Sigma-Aldrich, Germany) and TEMED (0.03% v/v) 
(BioRad Laboratories, USA) was added to the gel solution and mixed via inversion just prior 
to pouring. 
 
Non-reducing Loading Buffer (5X) 
60 mM Tris (pH 6.8), 25% (v/v) glycerol (BDH, USA), 2% (w/v) SDS (BDH, USA), 0.1% (w/v) 
bromophenol blue (Sigma-Aldrich, Germany). 
 
Precision Plus Protein™ Kaleidoscope™ Prestained Standard 
10 μL per well (BioRad Laboratories, USA), stored at -20ºC. 
 
Precision Plus ProteinTM Unstained Standards  
10 μL per well (BioRad Laboratories, USA), stored at -20ºC. 
 
Protein Binding Buffer 
50 mM Tris-HCl (pH 8.0) (Merck, Germany), 150 mM NaCl (BDH, USA), 10 mM imidazole 
(Sigma-Aldrich, Germany), prepared before use. 
 
Protein Elution Buffer 
50 mM Tris-HCl (pH 8.0) (Merck, Germany), 150 mM NaCl (BDH, USA), 100 mM – 200 mM 
Imidazole (Sigma Aldrich, Germany), prepared before use.  
 
Protein Loading Buffer (5 x) 
Protein samples were loaded on to polyacrylamide gels in 1x protein loading buffer. The 
buffer contained 60 mM Tris-HCl (Merck, Germany), 25% (v/v) glycerol (BDH, USA), 2% 
(w/v) SDS (Merck, Germany), 1.4 mM 2-mercaptoethanol (BioRad Laboratories, USA), 0.1% 
(w/v) bromophenol blue (Sigma-Aldrich, Germany) in MQ water and stored at -20ºC. 
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Protein Lysis Buffer 
50 mM Tris-HCl (pH 8.0) (Merck, Germany), 150 mM NaCl (BDH, USA), 20 mM imidazole 
(Sigma-Aldrich, Germany), 1 mg/mL lysozyme (Amresco, USA), prepared before use. 
 
Protein Post-Sample Wash Buffer 
50 mM Tris-HCl (pH 8.0) (Merck, Germany), 150 mM NaCl (BDH, USA), with 20 mM 
imidazole, prepared before use. 
 
Proteinase K (100X) 
300 U/mL dissolved in MQ water (Sigma-Aldrich, USA). 
 
SDS-PAGE Running Buffer (1 x)  
3% (w/v) Tris-HCl (Merck, Germany), 14.2% (w/v) glycine (Amresco, USA), 1% (w/v) SDS 
(Merck, Germany). 
 
Skim Milk Powder  
(Diploma, Australia). 
 
Sodium Citrate  
1% (w/v) (Merck, Germany) in distilled water and adjusted to pH 4.5. 
 
Sodium Dodecyl Sulphate (SDS) 
10% (w/v) (Merck, Germany) 
 
Sodium Hydroxide (NaOH) 
0.1 M NaOH (Merck, Germany). 
 
Stacking Gel 
The 4.5% stacking gel contained 125 mM Tris-HCl pH 6.8 (Merck, Germany), 0.1% (w/v) 
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SDS (Merck, Germany) and 4.5% bis-acrylamide (Amresco, USA) in MQ water. Just prior to 
pouring, 0.06% (w/v) ammonium persulfate (Sigma-Aldrich, Germany) and 0.03% (v/v) 
TEMED (BioRad Laboratories, USA) was added to the gel solution and mixed via inversion. 
The gel was then poured to overlay the set resolving gel. 
 
Sulphuric Acid (H2SO4) 
1 M sulphuric acid (BDH, USA). 
 
TEMED (N,N,N’,N’-tetramethylethylenediamine) 
Electrophoresis purity (BioRad Laboratories, USA). 
 
Whole Cell Lysis Buffer 
0.1 M Tris-HCl (pH 8.0) (Merck, Germany), 2% (w/v) SDS (Merck, Germany), 15% (v/v) 
glycerol (BDH, USA). 
 
3.2.8.2 Antibodies and Substrate 
 
Chloronapthol Substrate Solution 
Thirty micrograms of Chloronapthol (Sigma-Aldrich, Germany) and 10 mL methanol were 
mixed and made up to 50 mL with TBS. Thirty microliters of hydrogen peroxide (BDH, USA) 
was added just before developing. The solution was protected from light. 
 
Primary Antibody 
Monoclonal mouse anti-polyHistidine antibody IgG (GE Healthcare, Sweden) diluted 1:3000 
with 1% (w/v) skim milk in TBS; stored at -20ºC. 
 
Secondary Antibody 
Goat anti-mouse IgG conjugated to horseradish peroxidase (HRP) (Abcam, England) diluted 
1:5000 with 1% (w/v) skim milk in TBS; stored at -20ºC. 
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3.2.9 Protein Methods 
 
3.2.9.1 Pilot Expression Study 
 
After E. coli BL21(DE3) pRSET-A/cj0391c was grown overnight on LB agar containing 
ampicillin and chloramphenicol, a single colony was inoculated into 5 mL of LB broth 
containing the same antibiotics and incubated overnight at 37ºC with shaking at 200 rpm.  
Then, 0.5 mL of the overnight seed culture was inoculated into 50 mL of fresh LB broth and 
incubated at 37ºC with shaking until an OD of 0.4 – 0.7 at 600 nm was reached. Two millilitre 
volume of culture was taken before a final concentration of 1 mM IPTG was added to the 
remaining culture. Two millilitre aliquots were taken at 1–5 h and overnight after IPTG 
induction. Each cell pellet collected at the different time points were washed twice in 2 mL of 
10 mM Tris-HCl (pH 8.0), resuspended in 1 mL protein lysis buffer and stored on ice until all 
samples were collected and prepared for sonication. All E. coli samples were lysed by 
sonication (Branson Sonic Power Co., USA) on ice at 27% for 3 cycles of 15 sec pulses with 
30 sec rests between each pulse. 
 
3.2.9.2 Protein Expression and Cell Lysate Preparation 
 
For protein expression, fresh overnight-incubated seed culture was prepared each time for 
the IPTG induction on the following day. Two microlitres of seed culture was added into 200 
mL of fresh LB broth in a 1 L flask containing 100 µg/mL of ampicillin and 34 µg/mL of 
chloramphenicol. The cells grown at 37ºC with shaking at 200 rpm until an OD of 0.4 – 0.7 at 
600 nm was reached. A final concentration of 1 mM IPTG was added and protein expression 
was induced at 37ºC for the optimal time. 
 
Following induction of expression, cells were harvested by centrifugation at 4,700 x g for 15 
min at 4ºC in 50 mL Falcon tubes. The cell pellets were washed twice with 50 mL of 10 mM 
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Tris-HCl (pH 8.0). After washing, cells were resuspended in 5 mL of the protein lysis buffer 
and the sonicated (Branson Sonic Power Co., USA) on ice at 35% for 3 cycles of 15 s pulses 
with 30 s rest between each pulse.  
 
3.2.9.3 Immobilised Metal Affinity Chromatography (IMAC) 
 
(A) IMAC column preparation 
 
Ten millilitres of thoroughly mixed Chelating Sepharose Fast Flow resin slurry (containing 
20% ethanol) was added to a 5 mL gravity flow column. The resin was allowed to settle at 
the pre-marked 5 mL column level. The column was then washed with 10-column volume 
(CV) of MQ water to remove the ethanol. The gravity flow column was charged before use by 
passing 2.5 CV of 0.2 M nickel sulphate (NiSO4) (Ni2+) through the column, and then washed 
with at least 10 CV of MQ water to remove unbound metal ions and equilibrated with 5 CV of 
binding buffer just before usage.  
 
(B) IMAC purification 
 
The whole cell lysate was centrifuged in 1.5 mL microfuge tubes at 12,100 x g for 5 min at 
RT and the supernatant was filter sterilised before purification. Five millilitres of soluble cell 
lysate containing expressed recombinant protein was loaded to a pre-equilibrated IMAC 
column and incubated for 1 h with horizontal shaking at 4ºC to allow complete binding of the 
polyHistine-tagged protein to the nickel-bound resin.  
 
The column was then returned to the vertical position and allowed to settle for 15 min before 
5 mL of crude eluant was collected. The column was then washed with 5 CV of post-sample 
wash buffer and the flow-through eluant containing unbound protein was collected in 10 mL 
fractions and analysed for unbound protein via the Bradford Assay (Section 3.2.7.5). The 
nickel-bound polyHistidine-tagged protein was then eluted with 5 CV of EB containing 
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increasing concentrations of imidazole and the flow through was collected in 5 mL aliquots. 
Samples were analysed by SDS-PAGE (Section 3.2.7.6). 
 
(C) IMAC column cleaning and regeneration 
 
IMAC columns were re-used up to 4 times. Each time after usage, the column was stripped 
and cleaned. The column was stripped with 5 CV of IMAC stripping solution to elute the 
nickel. Residual EDTA from the stripping solution was then removed with 5 CV of 1 M NaOH, 
5 CV of MQ water and 5 CV of 2 M NaCl. The column was finally washed with 5 CV of MQ 
water and stored in 20% ethanol at 4ºC.  The column was recharged with nickel before 
usage. 
 
3.2.9.4 Protein Concentration and Buffer Exchange 
 
IMAC purified protein was concentrated using a centrifugal device, which concentrates the 
sample and removes the leftover small molecular weight un-specific proteins. Buffer 
exchange was performed afterwards to replace the EB with PBS. A Vivaspin 20 (5 kDa 
MWCO) centrifugal device was pre-conditioned twice with 10 mL MQ water. Then the EB 
contains protein was added into the top section of the Vivaspin 20. Centrifugation was 
performed at 5,000 x g for 10 min at 4ºC. The protein EB was allowed to filter through the 
device until less than 2 mL of solution remained on the top of the device. Then, 10 mL of 
PBS was added to the difiltration cup that has been inserted into the device. Centrifugation 
was repeated in 10 min intervals, until the volume of protein (in PBS) was reduced to less 
than 1 mL. Two times buffer exchanges were performed for each sample. The protein in PBS 
was then transferred from the device to a 1.5 mL microfuge tube and stored at -80ºC. 
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3.2.9.5 Bradford Assay 
 
The protein concentration was determined using the Bradford method (Bradford, 1976). 
BSA ranging from 0 to 20 µg per 100 μL of 0.15 M NaCl was used to prepare protein 
standards. Ten microlitres of sample was made up to 100 μL with 0.15 M NaCl. Nine-
hundreds microliters (900 µL) of Bradford reagent (Section 3.2.8.1) was added into sample 
and standards, which were mixed well and allowed to stand for 5 min at RT. Two hundred 
microlitres aliquots of each mixed sample was added to the wells of a 96-well microtitre plate 
in duplicate. Standards and samples absorbance were read at 600 nm with an iMark 
microplate absorbance reader. A standard curve, constructed by plotting the concentrations 
of the BSA standards (μg) versus absorbance, was used to determine the sample protein 
concentration. 
 
3.2.9.6 SDS-PAGE with Coomassie Blue Stain 
 
Proteins were separated by one-dimensional SDS-PAGE using a discontinuous buffer 
system. After the 12.5% resolving gel had set, the 4.5% stacking gel was then layered over 
the top of the resolving gel and a 12-comb cast inserted between the glass slides to form the 
wells. The protein gel system was assembled as per manufacturer’s protocol (BioRad 
Laboratories, USA), and then placed within the gel tank containing 1x SDS-PAGE running 
buffer. Protein samples were mixed with 5x SDS sample loading buffer, heated to 100ºC in a 
dry heating block for 5 min, and then loaded onto the gel together with a Precision Plus 
ProteinTM Standard (Appendix 5). The prestained KaleidoscopeTM protein standard (Appendix 
5) was used if the gel was then used to do immunoblotting. Unstained Precision Plus 
ProteinTM standard was used for gels stained by coomassie blue stain. Electrophoresis was 
performed at 60 V for 30 min, and then 180 V for 50 min.  
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On the completion of electrophoresis, the glass plates were separated and a scalpel blade 
was employed to cut off the stacking gel region. The gel was transferred to a square plastic 
container, then 25 mL of coomassie gel stain was added and the container was left overnight 
on a rotating shaker. After overnight staining, the coomassie was removed and replaced with 
25 mL of destain solution. The destaining process was performed for 3 h with shaking and 
stopped by replacing the solution with distilled water. 
 
3.2.9.7 Gelatin gel 
 
Gelatin gels were made using gelatin gel buffer. Protein samples were mixed with non-
reducing loading buffer and incubated at 37ºC for 15 min. Electrophoresis was performed at 
160 V for 2 h at 4ºC, with pre-chilled SDS-PAGE running buffer. Gelatin gels were then 
transferred into 100 mL of buffer 1 (Section 3.2.8.1). The gels were incubated in buffer 1 for 
20 min at RT with gentle shaking. The buffer was changed and incubation step repeated 
once. After incubated in buffer 1, the gels were then incubated in 100mL buffer 2 (Section 
3.2.8.1) for 5 min with shaking at RT. The buffer was changed and the incubation repeated 
twice. The final incubation was performed at 37ºC for 12-24 h with gentle shaking. These 
gels were stained using coomassie blue staining after incubation. Unstained area indicates 
the presence of proteolytic activity. 
 
3.2.9.8 Immunotransfer 
 
Western blotting was employed to transfer proteins from a SDS-PAGE gel onto a 
nitrocellulose membrane. After completion of electrophoresis, the gel was removed from the 
glass plates and the stacking gel was discarded. The iBlot dry blotting system was used 
according to the manufacturer’s instructions. The order of materials used to set up the iBlot 
system is shown below built from the anode stack at the bottom: (1) Anode stack (bottom); 
(2) Protein SDS-PAGE gel; (3) Filter paper (pre-soaked in distilled water); (4) Cathode stack 
(top); (5) Disposable sponge. The cassette was closed after air bubbles were removed from 
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the gel and filter paper. The transfer was performed in 7 min (Program 3). After 
immunotransfer was complete, the nitrocellulose membrane was maintained for 
immunoblotting.  
 
3.2.9.9 Immunoblotting 
 
The nitrocellulose membrane was firstly blocked in blocking buffer (Section 3.2.8.1) for 1 h 
after immunotransfered. A rotating shaker was used for all incubations and washes during 
immunoblotting. The membrane was then washed twice in 15 mL TBS for 2 min (each time), 
and then the primary antibody (Section 3.2.8.1) was added to the nitrocellulose membrane 
and left for 3 h at RT (or overnight at 4ºC). The membrane was then washed twice in 15 mL 
TBS for 5 min (each time), and the secondary antibody conjugated with HRP was added and 
incubated at RT for up to 2 h (or overnight at 4ºC). The membrane was washed three times 
in 15 mL TBS for 5 min (each time) before developing in 50 mL chloronapthol substrate 
solution for 30 min in dark, or until the desired resolution was achieved. The membrane was 
washed with distilled water to stop the reaction. 
 
3.2.10 Tissue Culture Materials 
 
3.2.10.1 Cell Lines 
 
Chicken macrophage cell line HD11 was used for in vitro analysis, obtained from RMIT 
central stock stored in liquid nitrogen. Cell lines were confirmed as mycoplasma free by 
performing dark field microscopy and samples were prepared by the instructions provided in 
the RMIT tissue culture manual. 
 
 
Chapter 3 
 141
3.2.10.2 Media and Solutions 
 
All solution and MQ water used for tissue culture have been autoclaved twice before usage 
unless stated otherwise. 
 
3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide (MTT) Solution 
To 100 mL of PBS, 0.5 g of MTT (Sigma-Aldrich, USA) was added and filter sterilised though 
a 0.2 µm filter and store in dark at 4ºC (for use up to 3 months). 
 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) 
1 M (Invitrogen Corporation, USA), stored at 4ºC. 
 
Annexin & Propidium Iodide (PI) Master Mix 
50 µL of Annexin (Invitrogen Corporation, USA) and 30 µL of PI (Invitrogen Corporation, 
USA) were mixed with 1.92 mL of annexin binding buffer. 
 
Annexin Binding Buffer 
400 µL of 5 X Annexin Binding Buffer (Invitrogen Corporation, USA) was mixed with 1.6 mL 
MQ water. 
 
Fetal Bovine Serum (FBS) 
Heat inactivated FBS was added to medium to a final concentration of 10% (v/v) 
(LifeTechnologies, USA). 
 
Gentamycin  
5 mg/mL filter sterilised and stored at -20ºC (Sigma-Aldrich, USA). 
 
Roswell Park Memorial Institute (RPMI) 1640 medium, GLUTAMAX®  
To 500 mL of RPMI (Invitrogen Corporation, USA), 5.81 mL of 1M HEPES buffer, 5.81 mL of 
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Pen/Step solution, 5.81 mL of 5 mg/mL gentamycin and 5.81 mL of 0.1 M sodium pyruvate 
were added by direct filter sterilisation. Aliquots were stored at 4ºC. Fresh aliquots of RPMI 
supplemented with 10% v/v FBS were used for cultures. 
 
MTT Solvent  
196 μL of HCl (purity 32%) was added to 50 mL DMSO. 
 
Pen/Strep  
100 U penicillin/mL and 100 μg streptomycin/mL (Sigma-Aldrich, USA). 
 
PI Working Stock 
10 µL of 1 mg/mL PI (Invitrogen Corporation, USA) was added into 90 µL of sterilised MQ 
water. 
 
Trypan Blue Solution 
1 % (w/v) trypan blue (Sigma-Aldrich, USA) dissolved in sterile PBS. 
 
Trypsin Solution 
Trypsin/EDTA is used to dissociate cells and stored at -20ºC (Sigma-Aldrich, USA).  
 
3.2.11 Tissue Culture Methods 
 
All the tissue culture steps have been carried out in a class II biohazard cabinet unless stated 
otherwise.  
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3.2.11.1 Tissue Culture Techniques 
 
Chicken macrophage cell line HD11 was stored in liquid nitrogen and maintained in RPMI 
containing 10% FBS, antibiotics (100 U/mL penicillin, 100 μg/mL streptomycin and 
0.05 mg/mL gentamycin), and 1 mM sodium pyruvate at 42ºC, 5% CO2, and 95% humidity. 
Cultures were grown to exponential phase (~ 80% confluent) before they were passaged 
either transferred to a larger flask or used experimentally. The cells were passaged no more 
than 15 - 20 times before a fresh stock of cells were resuscitated. Cultures were passaged 
by removing the media and washing the cells twice in PBS. An appropriate volume of trypsin 
solution was added and the flask was incubated at 42ºC for 5-10 min in 5% CO2. The 
dissociated cells were removed from the flask and the action of the trypsin was countered by 
the addition of RPMI containing 10% FBS. The cells were washed twice in media and an 
appropriate volume of cells were used to seed a new flask or flasks. Cells were stored in 
liquid nitrogen by dissociating them and washing them as described above, then 
resuspending them in media supplemented with 10% DMSO as a cryoprotectant. A 75 cm2
 
flask of ~80% confluent cells was used to bank down 2 cryovials each containing 1 mL of cell 
suspension. The cells were first incubated at -80ºC for 2 days before transferring to liquid 
nitrogen for long term storage. 
 
3.2.11.2 Cell Proliferation Assay 
 
Chicken macrophage cells were cultured in 75 cm2 tissue culture flask until 80% confluent 
was achieved. The cells were then seeded into a 96-well microtitre plate at the concentration 
of 105 cells/mL with the volume of 100 µL in each well. The plate was then incubated at 42ºC 
overnight to form a monolayer. After overnight incubation, 10 µL of filter sterilised samples in 
PBS were added into the wells (Figure 3.2). Controls include cells that were not exposed to 
any of the protein as well as positive controls (soluble fraction of C. jejuni 81116 cells) and  
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    Figure 3.2: Cell proliferation assay plate setup. 
    Control 1: PBS 10 µL 
    Control 2: PBS 10 µL 
    Control 3: PBS 10 µL 
    Sample 1: 1 µg of recombinant protein Cj0391c in 10 µL of PBS 
    Sample 2: 2 µg of recombinant protein Cj0391c in 10 µL of PBS 
    Sample 3: 4 µg of recombinant protein Cj0391c in 10 µL of PBS 
    Negative control 1: 1 µg of recombinant protein GFP in 10 µL of PBS 
    Negative control 2: 2 µg of recombinant protein GFP in 10 µL of PBS 
    Negative control 3: 4 µg of recombinant protein GFP in 10 µL of PBS 
    Positive control 1: 1 µg of soluble fraction of C. jejuni 81116 protein in 10 µL of PBS 
    Positive control 2: 2 µg of soluble fraction of C. jejuni 81116 protein in 10 µL of PBS 
    Positive control 3: 4 µg of soluble fraction of C. jejuni 81116 protein in 10 µL of PBS 
    Baseline: Chicken macrophage HD11 cells only 
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negative controls (GFP expressed using the same system). Each sample was tested in 
triplicates.  
 
After the cells were incubated with the samples for the time required, the plate was taken out 
and 20 µL of MTT solution was added into each well with light protection. The plate was 
wrapped with foil and shaken gently on a rotating shaker for 5 min. The plate was then 
returned to the CO2 incubator and processed for another 2 to 4 h. After the purple precipitate 
is visible, the overlaying medium was removed carefully and 100 µL of MTT solvent was 
added into each well to dissolve the formazan product. The plate was read by an iMark 
microplate absorbance reader, and OD600 recorded for each well. 
 
3.2.11.3 Apoptosis Assay 
 
Dead Cell Apoptosis Kit with Annexin V Alexa Fluor® 488 & Propidium Iodide (PI) Kit 
(Invitrogen Corporation, USA) has been employed for this study. Chicken macrophage cells 
were cultured in 75 cm2 tissue culture flask first until 80% confluent was reached. The cells 
were then seeded into a 24-well microtitre plate at a concentration of 105 cells/mL with the 
volume of 500 µL in each well. The plate was then incubated at 42ºC overnight to form a 
monolayer.  
 
Subsequently, 50 µL of filter sterilised samples in PBS together with negative control (green 
fluorescent protein/GFP expressed using the same system) were added into the wells 
(Figure 3.3). Every sample has been tested in triplicates. Fifty microliters of 96% ethanol was 
added to the positive control wells half hour before the start of the staining procedure.  
 
The cells were first washed in pre-chilled PBS before the addition of 200 µL Annexin and PI 
master mix into each test well in the dark The plate then was returned to the CO2 incubator 
and processed for another 15 min. The cells were washed 3 times with pre-chilled PBS with  
  
Chapter 3 
 146
 
 
 
 
Figure 3.3: Apoptosis assay sample plate setup 
B: Baseline (Chicken macrophage HD11 cells only) 
C: Control (50 µL of PBS only) 
N.C.: Negative Control (10 µg of recombinant GFP in 50 µL of PBS per well) 
P.C.: Positive Control (50 µL of 96% Ethanol) 
L: Low conc. of sample (2.5 µg of recombinant protein Cj0391c in 50 µL of PBS per well) 
M: Med. conc. of sample (5 µg of recombinant protein Cj0391c in 50 µL of PBS per well) 
H: High conc. of sample (10 µg of recombinant protein Cj0391c in 50 µL of PBS per well) 
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a final volume of 200 µL of PBS added to each well. Confocal imaging of cells was carried 
out with a Nikon Eclipse Ti-E A1 laser-scanning confocal system (Nikon Instrument Inc, 
USA), using the 100X and 200X objectives.  
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3.3 Results 
 
3.3.1 Protein Expression and Purification 
 
According to the protein pilot expression study, the optimal conditions for protein Cj0391c 
expression is incubation with 1mM IPTG at 37ºC for 5 h (Figure 3.4). The recombinant 
protein was then isolated by using nickel affinity chromatography (Section 3.2.7.3). The 
optimal imidazole concentration to elute the target protein Cj0391c is 140mM and the results 
are shown in Figure 3.5. 
 
GFP was employed as a negative control in both the chicken macrophage cell proliferation 
assay and apoptosis assay. The optimisation study has also been done for E. coli 
BL21(DE3) pREST-A/GFP. For GFP expression, the cells show the best expression profile in 
the presence of 0.01 mM IPTG when incubated overnight at 37ºC. The GFP was also 
purified using the IMAC columns (Section 3.2.7.3), and the imidazole concentration required 
in order to elute the bound GFP was 200 mM (Figure 3.6).  
 
For the expression of the recombinant protein Cj0391c, the target protein concentration did 
not increase significantly after 5 h and the yield has never reached the production level of 
GFP. One possible reason for this is that Cj0391c is a toxin, which may reduce the 
expression level in E. coli BL21(DE3).  
 
3.3.2 Protease Assay 
 
In section 2.3.5, protein Cj0391c has been predicted to be a protease by webserver EzyPred, 
and this was assayed by running a gelatin gel to detect gelatinase activity. Protease K was  
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(A)                                          (B) 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: SDS-PAGE and immunoblotting analysis of soluble fractions of E. coli 
BL21(DE3) cells protein expression system containing the pRSET-A/cj0391c insert at 
different time points with 1 mM IPTG induction at 37ºC 
(A) Lane 1. Precision Plus ProteinTM Unstained Standard  
     Lane 2. Soluble fraction of pre-IPTG induction 
     Lane 3. Soluble fraction of 5 h 1 mM IPTG induction  
     Lane 4. Soluble fraction of overnight 1 mM IPTG induction  
(B) Lane 1. Precision Plus ProteinTM KaleidoscopeTM Standard  
     Lane 2. Soluble fraction of pre-IPTG induction 
     Lane 3. Soluble fraction of 5 h 1 mM IPTG induction  
     Lane 4. Soluble fraction of overnight 1 mM IPTG induction  
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      (A)  
              (B)  
Figure 3.5: SDS-PAGE and immunoblotting analysis of recombinant protein Cj0391c 
post IMAC purification, concentration and buffer exchange 
Lane 1 (A) Precision Plus ProteinTM Unstained Standard  
            (B) Precision Plus ProteinTM KaleidoscopeTM Standard  
Lane 2 IMAC-purified bound-protein Cj0391c from the first 5 eluants  
Lane 3 IMAC-purified bound-protein Cj0391c from the 6st eluant  
Lane 4 Soluble fraction before IMAC-purification 
Lane 5 Flow-through from Vivaspin (5 kDa cut-off) 
Lane 6 Concentrated sample protein from Vivaspn  
Lane 7 Concentrated and buffer exchanged protein Cj0391c in PBS 
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(A)  
 
 
 
 
 
 
 
 
 
 
(B)  
 
 
 
 
 
 
 
 
 
Figure 3.6: SDS-PAGE and immunoblotting analysis of recombinant protein GFP after 
IMAC purification, concentration and buffer exchange 
Lane 1 (A) Precision Plus ProteinTM Unstained Standard  
            (B) Precision Plus ProteinTM KaleidoscopeTM Standard  
Lane 2 Concentrated and buffer exchanged protein GFP in PBS 
Lane 3 Total fraction of E. coli BL21(DE3) pREST-A/GFP overnight with 0.01 mM IPTG 
induction  
Lane 4 Flow-through from Vivaspin (5 kDa cut-off) 
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used as a positive control. The gelatin gel can be seen in Figure 3.7. No discernable 
protease activity has been observed and from the result, it can be conclude that recombinant 
protein Cj0391c is most likely not a protease.  
 
3.3.3 Cell Proliferation Assay 
 
This assay measures the cell proliferation rate and conversely, when metabolic events lead 
to apoptosis, the reduction in cell viability. Measurement of cell viability and proliferation 
forms the basis for numerous in vitro assays of a cell population’s response to external 
factors. The reduction of tetrazolium salts is now widely accepted as a reliable way to 
examine cell proliferation. The yellow tetrazolium MTT is reduced by metabolically active 
cells, in part by the action of dehydrogenase enzymes, to generate reducing equivalents 
such as nicotinamide adenine dinucleotide and nicotinamide adenine dinucleotide phosphate 
(Mosmann, 1983). The resulting intracellular purple formazan was solubilized and quantified 
by spectrophotometer. The chicken macrophage HD11 cells were used for the cell 
proliferation assay and results are shown in Figure 3.8. The HD11 cells viability was reduced 
after 72 h and 96 h incubation by approximately 75% and 90% respectively, which suggests 
the possible role of recombinant protein Cj0391c in reducing the chicken macrophage cells 
HD11 viability.  
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Figure 3.7: Gelatin gel of E. coli BL21(DE3) pRSET-A/Cj0391c expressed protein 
sample. Result indicates that no discernable protease activity of recombinant protein 
Cj0391c has been observed. Recombinant protein Cj0391c is most likely not a 
protease. 
Lane 1: Precision Plus ProteinTM Unstained Standard with molecular sizes listed. 
Lane 2: Total fraction of E. coli BL21(DE3) pRSET-A/Cj0391c protein expression before 
IPTG-induction. 
Lane 3: Total fraction of E. coli BL21(DE3) pRSETA/Cj0391c protein expression after 5 h 
IPTG-induction. 
Lane 4: Soluble fraction of E. coli BL21(DE3) pRSETA/Cj0391c protein expression after 5 h 
IPTG-induction. 
Lane 5: Filtered (0.2 µm) Soluble fraction of E. coli BL21(DE3) pRSETA/Cj0391c protein 
expression after 5 h IPTG-induction. 
Lane 6: Positive control Proteinase K 
 
Cj0391c 
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(A) 
   
(B) 
 
Figure 3.8: Chicken macrophage HD11 cells challenged with recombinant protein 
Cj0391c for 72 h (A) and 96 h (B). Each bar represents mean + standard errors of 3 
separate experiments in triplicate. The negative control used was GFP expressed by 
the same system. The positive control used was soluble fraction of C. jejuni 81116 
cells. The HD11 cells viability was reduced after 72 h and 96 h incubation by 
approximately 75% and 90% respectively, which suggests a possible role of 
recombinant protein Cj0391c in reducing viability of the chicken macrophage cells 
HD11.   
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3.3.4 Apoptosis Assay 
 
The apoptosis assay was performed using the Dead Cell Apoptosis Kit with Annexin V Alexa 
Fluor® 488 and Propidium Iodide (PI) Kit (Invitrogen Corporation, USA). It detects the 
externalization of phosphatidylserine in apoptotic cells using recombinant annexin V 
conjugated to green-fluorescent Alexa Fluor® 488 dye and dead cells using PI. PI stains 
necrotic cells with red fluorescence. After treatment with both fluorescent dyes, apoptotic 
cells show a green fluorescence, dead cells exhibit a combination of red and green 
fluorescence, and live cells show little or no fluorescence. After incubating the HD11 cells 
with the protein samples for 12 h, it is observed there is an apoptotic process in the chicken 
macrophage cells in the presence of recombinant protein Cj0391c (Figure 3.9 and 3.10). The 
images were taken under 100 times magnification and 200 times magnification using CLSM. 
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Figure 3.9: Confocal laser scanning microscopy (CLSM) micrographs for apoptosis assay with annexin V-Alexa Fluor 488 (green 
fluorescence) and propidium iodide (PI) (red fluorescence) in chicken macrophage cell line DH11 incubated for 12 h with 20 µg/mL of 
recombinant protein Cj0391c at 100x magnification. i. Negative control (GFP); ii. Recombinant protein Cj039c; iii: Positive control (Soluble 
fraction of C. jejuni 81116 cells). After incubating the HD11 cells with the protein samples for 12 h, it is observed there is an apoptotic 
process in the chicken macrophage cells in the presence of recombinant protein Cj0391c. 
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Figure 3.10: Confocal laser scanning microscopy (CLSM) micrographs for apoptosis assay with annexin V-Alexa Fluor 488 (green 
fluorescence) and propidium iodide (PI) (red fluorescence) in chicken macrophage cell line DH11 incubated for 12 h with 20 µg/mL of 
recombinant protein Cj0391c at 200x magnification. i. Negative control (GFP); ii. Recombinant protein Cj039c; iii: Positive control (Soluble 
fraction of C. jejuni 81116 cells). After incubating the HD11 cells with the protein samples for 12 h, it is observed there is an apoptotic 
process in the chicken macrophage cells in the presence of recombinant protein Cj0391c. 
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3.4 Discussion and Conclusion 
 
As a commensal, C. jejuni colonises heavily onto the chicken epithelial cell layer of 
particularly the ceca, however no intestinal inflammation is seen (Dhillon et al, 2006). 
However, induction of immune-associated gene and protein expression after Campylobacter 
colonisation has been observed through different studies. Analysis of isolated chicken tissue 
displayed an increased cytokine expression (Smith et al, 2008) and circulating 
monocytes/macrophages (Meade et al, 2009), and several different types of chicken cells 
produce or upregulate cytokines during in vitro infection (Larson et al, 2008; Li et al, 2008; 
Smith et al, 2005).  
 
Campylobacter activates human and chicken TLR2 and TLR4, but not TLR5. C. jejuni 
evades TLR-5 recognition through glycosylation of its flagella (Howard et al, 2009). 
Campylobacter initiates both MyD88 and TRIF-dependent immune responses in human 
through the activation of TLR2, TLR4 and TLR9 (Andersen-Nissen et al, 2005; Watson & 
Galan, 2005). Chickens lack TLR9, but have the unique DNA-sensing TLR21 (Brownlie et al, 
2009), which can be activated by Campylobacter chromosomal DNA (de Zoete et al, 2010). 
However, Campylobacter is unable to activate MyD88-independent IFN-ß transcription via 
chTLR4 signaling in the chicken (de Zoete et al, 2010). The activation of the human and 
chicken TLR2 complexes indicates that Campylobacter lipoproteins can act as a TLR2 
ligand.  
 
Macrophages belong to the mononuclear phagocytic system lineage. This cell type is unique 
in that as it is a crucial player in both the innate and adaptive immune responses (Qureshi, 
2003). The classic macrophage functions include chemotaxis, phagocytosis, the killing of 
bacteria and tumour cells, and cytokine production (Qureshi, 2003).  
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Chemotaxis is a function present in both monocytes and macrophages, which involves 
migration toward an inflammatory gradient (Qureshi, 2003). Chemotactic signals can be 
derived from bacterial products, certain synthetic peptides, products of the immune reaction, 
or certain factors released by the damaged cells and extracellular matrix (Qureshi, 2003). 
Macrophage cells perform phagocytic functions via several different mechanisms. Most of 
the phagocytic functions are mediated via target-specific receptors present on the 
macrophage cell surfaces. These receptors are capable of binding specific phagocytic 
targets (Chansiripornchai & Sasipreeyajan, 2009; Qureshi, 2003).  
 
A study of de Zoete et al. (2010) demonstrateds the poor activation of chTLRs by viable 
Campylobacter compared to lysed bacteria, which indicate bacterial integrity in the intestine 
as a potential determinant of inflammatory pathology. This suggests that bacterial lysis may 
be needed to expose full TLR-stimulative potential. In a hostile environment, Campylobacter 
will likely be disrupted after phagocytosis by macrophages and dendritic cells. However, the 
apoptotic effect observed from our study may contribute to a reduction in phagocytosis.  
 
Cellular assays indicate that chicken macrophage cells undergo apoptosis after 12 h 
incubation with recombinant protein Cj0391c. This phenomena may explain why C. jejuni can 
colonise the chicken intestine at a very high levels, as if the Cj0391c protein can kill 
macrophages they will be unable to (1) phagocytose and kill C. jejuni or (2) present 
processed antigen to T cells.  
 
Based on the above observations, we explore a number of hypotheses for the mechanisms 
by which Cj0391c induces chicken macrophage apoptosis as well as the possible structure of 
Cj0391c.  
 
(1) Protein Cj0391c may be a death receptor ligand with structure similar to protein tumour 
necrosis factor (TNF)-α or TNF-related apoptosis-inducing ligand (TRAIL). However, the 
protein sequence alignment results indicate that sequence alignment between protein 
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Cj0391c and these ligands is comparably poor (data not shown). Additionally, death receptor 
ligands are typically comprised of β-strands. None of the secondary structure and fold 
prediction methods employed on Cj0391c suggests that it contains any β-strand content.  
 
(2) It may be a toxin similar to Shiga-toxin. However, Shiga-toxin and Shiga-related toxins 
are composed of two subunits from two different genes, an effector subunit and a membrane 
binding subunit. Cj0391c is a most probably a single subunit in our experiment, as it was 
expressed as a single chain, but still causes chicken macrophage cell apoptosis. However, 
we cannot exclude the possibility that Cj0391c might be a Shiga-like toxin.  
 
(3) Cj0391c may be a toxin acting via formation of α-helical ion channel enabling the 
exchange of ions, causing DNA fragmentation and cell lysis (pore-forming toxin). In support 
of this hypothesis, a number of independent secondary structure and fold recognition 
methods predict that protein Cj0391c contains at least 8 helices. The lengths of the predicted 
helices range from 8 to 32 residues long, which is consistent with the length required to span 
a typical bilayer membrane.  
 
Pore-forming toxins (PFTs) are a class of proteins that convert from a soluble form to a 
membrane-integrated pore (Parker & Feil, 2005). They perform their toxicity either by 
destruction of the membrane permeability barrier or by delivery of toxic components through 
the pores (Mueller et al, 2009). They can be divided into two classes, α-PFTs and β-PFTs, 
depending on the suspected mode of membrane integration, either by α-helical or β-sheet 
elements (Gouaux, 1997). By 2013, there are only 3 α-PFTs with known 3D structure, 
cytolysin A (ClyA, aka HlyE) (PDB code 2WCD), fragaceatoxin C (FraC) (PDB code 3LIM) 
and dermcidin (PDB code 2YMK). The C-terminal sequence of protein Cj0391c aligns well 
with dermcidin (discussed in Chapter 4).  
 
Based on the bioinformatics analysis in Chapter 2 and the experimental results described in 
this chapter, a hypothesis has formed that Cj0391c may be an α-PFT. We further explore the 
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likelihood of this hypothesis by constructing a model, examining the theoretical structural 
stability and computationally analysed in a simple lipid bilayer under various conditions 
(Chapter 4).  
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4.1 Introduction 
 
In the previous chapters it was shown that Cj0391c induces apoptosis in chicken 
macrophages. This chapter describes attempts to model the structure of Cj0391c. Knowing 
the structure of the protein will lend insights into the mechanism by which Cj0391c exerts its 
activity against chicken macrophages.  
 
We employ a number of prediction techniques to obtain a structure. Several structure 
prediction methods including secondary structure prediction were used to propose secondary 
structure and possible folds of Cj0391c. The results from these approaches suggest that 
Cj0391c is an α-helical protein. Thus, one of its mechanisms of cytotoxicity may be similar to 
other helical toxins, including membrane disruption by penetration of peptides; and 
subsequent formation of ion channels. We also used sequence alignment to find an 
appropriate template, focusing on known α-helical PFTs (there were only three α-helical 
PFTs structures available in PDB prior to 2013). Fortuitously, the structure of an α-helical 
toxin, dermcidin, was solved recently. The C-terminus of protein Cj0391c has sequence 
similarity with this PFT. After the identification, a homology model of Cj0391c was built using 
dermcidin as a structural template, and molecular dynamics (MD) simulation was employed 
to simulate the dynamics of the structure within a simple lipid bilayer environment.  
 
There are two main reasons to perform the MD simulation. The first reason is to study the 
quality of the model built. We want to check if it is stable in a lipid bilayer environment at 
physiological temperature, thus indicating whether dermcidin is a plausible model for the C-
terminus of Cj0391c. Secondly, simulation enable us to generate experimentally testable 
hypotheses regarding the roles of temperature and zinc on several measurable properties 
including pore size and hexamer structure. The pore size is related to conductance, which 
can be tested with single channel recording, if the pore forms.  
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In particular, we simulated at a range of temperature from 300 K to 314 K, to examine the 
possible difference in Cj0391c functional properties within its two main hosts (human and 
chicken), as well as to determine the limits of the protein’s heat stability (to check if the 
structure is stable at high temperature). The effects of zinc have also been examined, as it is 
known to be crucial to the function of dermcidin. MD simulations were used to determine the 
role of zinc in the structure integrity and function of the proposed Cj0391c C-terminal 
hexametric transmembrane helix bundle.  
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4.2 Materials and Methods 
 
4.2.1 Protein Structure Prediction 
 
We have employed the fold prediction method, I-TASSER, to predict the 3D structure of 
Cj0391c as well as to predict its secondary structure. I-TASSER has been ranked as the best 
server for protein structure prediction according to the 2006-2012 CASP (Critical Assessment 
of Techniques for Protein Structure Prediction) experiment.  
 
I-TASSER is a hierarchical protein structure modelling approach based on the secondary-
structure enhanced Profile-Profile threading Alignment (Wu & Zhang, 2007) and the iterative 
implementation of the Threading ASSEmbly Refinement (TASSER) program (Zhang & 
Skolnick, 2004a). Initially, prediction of the protein Cj0391c structure had been attempted to 
using ab initio folding and threading methods, as there was no homology model available. I-
TASSER is the best server to predict protein structures with no homology model and it 
combines both ab initio folding and threading methods (Roy et al, 2010). After submitting the 
protein sequence, I-TASSER first generates three-dimensional atomic models from multiple 
threading alignments, and also iterative structural assembly simulations (Roy et al, 2010). 
Then the function of the same protein is inferred by structurally matching the 3D models with 
other proteins with known function (Roy et al, 2010). There are four stages involved in the 
prediction before the models are ready for estimation of prediction accuracy: (1) threading; 
(2) structural assembly; (3) model selection and refinement and (4) structural-based 
functional annotation (Roy et al, 2010). Threading refers to a bioinformatics procedure for 
identifying a structural unknown protein from solved structure protein databases, which may 
contain a similar structure or similar structural motif as the query protein (Roy et al, 2010). In 
the first stage, the query protein sequence is matched against a non-redundant sequence 
database by PSI-BLAST, to see the evolutionary relatives (Roy et al, 2010). In stage 2, 
continuous fragments in the threading alignments from the stage 1 results are excised and 
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used to assemble structural conformations for the sections that are well aligned, with the 
unaligned regions built by ab initio modelling as well (Wu et al, 2007; Zhang et al, 2003). In 
the third stage, the system performs the fragment assembly simulation again, which starts 
from the selected cluster centroids (Roy et al, 2010). In the final stage, the function of the 
query protein is inferred from the PDB, by structurally matching the predicted models against 
the proteins of known structure and function (Roy et al, 2010).  
 
The protein sequence of Cj0391c was submitted in I-TASSER for model building prediction. 
After the protein sequence submission, the following results have been obtained: (1) up to 5 
predicted models ranked based on the structure density of the SPICKER clustering; (2) C-
score of all the I-TASSER models; (3) estimated TM-score and RMSD (root-mean-square 
deviation) for the first model.  
 
SPICKER is a clustering algorithm to identify the near-native models by clustering protein 
structures generated during simulations (Zhang & Skolnick, 2004c). C-score is a confidence 
score for estimating the quality of the predicted models, which is typically in the ranger of [-5, 
2] (Roy et al, 2010). The C-score of the I-TASSER is defined as below, 
                                           
where M  is the multiplicity of structures in the SPICKER cluster; Mtot is the total number of 
the I-TASSER structure decoys used in the clustering (Zhang, 2008). The RMSD  in the 
formula is the average RMSD of the decoys to the cluster centroid, while Z i   represents 
the highest Z  score and Z0 i   is a program-specified Z -score cut-off for distinguishing 
between the good and bad models (Zhang, 2008). A higher C-score signifies a model with a 
higher confidence and vice-versa (Roy et al, 2010). Predicted TM-score and RMSD are also 
provided for model 1 from each job, which indicate how much the predicted models relative 
the native structures based on the C-score (Roy et al, 2010). TM-score is a scale for 
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measuring the structural similarity between two structures, while RMSD is an average 
distance of all residue pairs in two structures (Roy et al, 2010). The TM-score is defined to 
access the topological similarity of two protein structures and it is displayed as below  
                                                    
where di  is the distance of the i th pair of residues between two structures after an optimal 
superposition (Zhang & Skolnick, 2004b). In the same formula, d0  is equals to 
1.24 L 153 1.8 , and L  is the protein length (Zhang, 2008). TM-score is introduced to 
solve the problem of RMSD that RMSD is sensitive to the local error (Roy et al, 2010). In TM-
score, the small distance is weighted higher than the big distance, which makes the TM-
score insensitive to the local modelling error (Roy et al, 2010). A higher than 0.5 TM-score 
indicates that the predicted model is of correct topology, while a lower than 0.17 TM-score 
indicates a random similarity (Roy et al, 2010). It should be mentioned that the estimated 
quality is provided only for the first model, although the C-scores of all 5 models have been 
given (Roy et al, 2010). The correlation of C-score and modelling quality for the other lower-
ranked models are much weaker compared to the first model (Roy et al, 2010).  
 
4.2.2 Sequence Alignment 
 
We used Clustal-Omega (Sievers et al, 2011) to align the sequence of Cj0391c and human 
dermcidin (PDB code 2YMK). Sequence alignments are now one of the most widely used 
bioinformatics analyses (Larkin et al, 2007). Clustal is the oldest of the currently most widely 
used programs having been first distributed by post on floppy disks in the late 1980s (Larkin 
et al, 2007). The current Clustal programs all derive from Clustal W (Thompson et al, 1994). 
In benchmark tests, Clustal Omega shows distinctly more accurate results than most widely 
used, fast methods and comparable in accuracy to some of the intensive slow methods 
(Table 4.1) (Sievers et al, 2011). Clustal Omega employs seeded guide trees 
TM  score  1
L
1
1 di2 / d02'i1
L
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Table 4.1: HomFam benchmarking results (reproduced from Sievers et al, 2011).  
 93≤N≤2957 (41 families) 3127≤N≤9105 (33 families) 10099≤N≤50157 (18 families) 
Aligner TC/t (s) TC/t (s) TC/t (s) 
Clustal Omega 0.708/2114.0 0.639/11719.5 0.464/27328.9 
Kalign 0.569/324.9 0.563/6752.0 0.420/286711.0 
MAFFT default 0.550/238.9 0.462/3115.4 -/- 
MAFFT - parttree -/- -/- 0.253/6119.4 
MUSCLE default 0.533/104587.0 -/- -/- 
MUSCLE – maxiters 2 -/- 0.416/8239.2 0.216/110292.0 
The columns show total column score (TC) and total run time in seconds for groupings of small (<3000 sequences), medium (3000-10000 
sequences) and large (>10000 sequence) HomFam test cases respectively. TC gives the proportion of the total alignment columns that is recovered 
(Sievers et al, 2011).  
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and HMM profile-profile techniques to generate alignments (Sievers et al, 2011). The 
important feature of making the progressive alignment approach scale is the method used to 
make the guide tree (Sievers et al, 2011). Generally, it involves aligning all  sequences to 
each other giving time and memory requirements of  (Sievers et al, 2011). The 
methods which can routinely make alignments of more than about 10,000 sequences is very 
fast, but lead to a loss in accuracy. It has to be compensated for by iteration and other 
heuristics, while with Clustal Omega, a modified version of mBed (Blackshields et al, 2010) is 
used (Sievers et al, 2011). It has complexity of  and produces guide trees that 
are just as accurate as those from the other conventional means (Sievers et al, 2011). In 
Clustal Omega, the alignments are computed using a high accurate HHalign package 
(Soding, 2005), which aligns two profile HMM (Eddy, 1998).  
 
4.2.3 Comparative Protein Structure Modelling 
 
Comparative (or homology) modelling was employed to construct a 3D model of the C-
terminus of Cj0391c, using human dermcidin as a template. Comparative modelling can 
sometimes provide a useful 3D model for a protein that is related to at least one known 
protein structure (Eswar et al, 2006). Comparative modelling predicts the target protein 3D 
structure based primarily on its alignment to one or more known structure protein(s) (Eswar 
et al, 2006). In our study, the 3D structure of hexamer 391 model has been built based on 
protein dermcidin (PDB code 2YMK) using Modeller version 9.10 (Sali & Blundell, 1993). The 
steps in comparative protein structure modelling have been listed in Figure 4.1. The 
prediction process consists of fold assignment, target-template alignment, model building, 
and model evaluation (Dalton & Heffernan, 1989).  
 
Initially, the phosphatidylethanolamine-phosphatidylglycerol (POPE) bilayer was obtained 
from the website Lipidbook (http://lipidbook.bioch.ox.ac.uk), which contained 437 POPE  
 
N
 N 2 
 N logN 
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Figure 4.1: Steps in comparative protein structure modelling (adapted from Marti-
Renom et al, 2000). 
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lipids. Then, the hexamer 391 was inserted into POPE bilayer. Forty-seven (47) lipids next to 
the protein were then removed after positing protein 391 in the middle of the bilayer (with 
remaining 390 POPE lipids). A total number of 23335 and 32824 water molecules have been 
placed in the systems with zinc and without respectively. Twelve zinc ions have been added 
to the protein complex to generate another system (391-ZN). The positions of Zn were based 
on their corresponding positions in the dermcidin structure. 
 
4.2.4 Molecular Dynamics and Simulation 
 
Molecular dynamics is a technique for computer simulation of complex systems, modelled at 
the atomic level. The equations of motion are solved numerically to follow the time evolution 
of the system, allowing the derivation of kinetic and thermodynamic properties of interest by 
means of ‘computer experiments’. Biologically important macromolecules and their 
environments are routinely studied using molecular dynamics simulations. MD employs 
Newton’s Second Law of motion as below 
                                             F  m a  m  dv
dt
 m  d
2x
dt 2
 
where F  is the force exerted on the particle, m  is its mess, a  is its acceleration, v  is the 
velocity and x  is the particle position. The position of each atom is updated at each time 
step based on numerically solving Newton’s equations. Potential energy between atoms 
dictates motions of the atoms. This potential (force field) describes bonded (bond, angle, 
dihedral) and non-bonded (Lennard-Jones, electrostatic) interatomic interactions. Different 
force fields employ different parameters (e.g. spring constant for bonded interactions) based 
on experiments and high-level quantum chemistry calculations.  
 
MD is one of the most important and widely used molecular simulation techniques. This 
method was created subsequent to Monte Carlo in order to study the dynamical behaviour of 
many-particle systems. The technique used in this project is classical MD, as implemented in 
the program GROningen Machine for Chemical Simulations (GROMACS), which is a MD 
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package primarily designed for simulation of proteins, lipids and nucleic acids. The simulation 
system was built and calculations were performed using the GROMACS version 4.6.3 with 
the CHARMM36 force field. The starting structure coordinates of 391 was built and bilayer 
POPE was obtained from Lipidbook as described in Section 4.2.3 (Domanski et al, 2010).   
 
After the hexamer model 391 has been built by molecular modelling, it has been setup in lipid 
bilayer POPE (named 391-POPE in this study). Twelve zinc ions have been added in the 
complex (named 391-ZN-POPE in this study). Both complexes have been simulated under 3 
different temperatures (300 K, 310 K and 314 K) for 100 ns. Therefore, 6 sets of MD 
trajectories have been obtained using GROMACS. The six protein-ion-bilayer simulation 
complexes are named 391-300K, 391-310K, 391-314K, 391-ZN-300K, 391-ZN-310K and 
391-ZN-314K. 
 
After the topology file for the protein and bilayer was made, a simulation box was constructed 
with chosen proportions. The dimensions of each box was 100 x 100 x 100 Å and was filled 
with explicitly represented water molecules until water density reached ~ 1.0 g/cm3. As the 
solutes had a non-zero total charge, counterions (Cl-) were incorporated in the simulation box 
to neutralize the system. After the construction of the system was finalized, energy 
minimization was applied to correct for bad van der Waals contacts or steric clashes between 
the protein and water molecules. The first-order minimization method of steepest descent 
was performed to reach the lowest local energy point.  
 
The solvent equilibration stage consisted of constant pressure simulations at T = 300 K/310 
K/314 K, P = 1 bar with protein atoms restrained to allow the solvent and bilayer to relax 
around the solute. Equilibration of the entire system was performed afterwards when the 
protein was allowed to move. At the end of the simulations, RMSD, helix bending and pore 
size were analysed using different tools. Visualisation and structural representation of each 
system were performed using Visual Molecular Dynamics (VMD) (Humphrey et al, 1996). 
Time steps of 2 ps were used to integrate the equations of motion. The neighbor list of the 
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simulations was updated every 10 steps. The pressure coupling used was the Parrinello-
Rahman barostats (reference here). The thermostat used was Bussi’s thermostat (Bussi et 
al, 2007). Particle Mesh Ewald summation was used to treat electrostatics (Essmann et al, 
1995).  
 
4.2.5 Helix Dynamics Analysis 
 
Helix flexibility plays a key role in the mechanisms of channel gating, receptor activation and 
molecule transport for membrane proteins (Dahl et al, 2012). The flexibility of α-helices is 
important for pore-forming protein function and calls for better visualisation and analysis 
(Dahl et al, 2012). The dynamics of transmembrane α-helices can be explored by MD 
simulations, which is becoming an increasingly important tool to complement the protein 
function study and structure stability evaluation.  
 
In this study, a plugin for VMD called Bendix was employed for helix dynamics investigation. 
Bendix features custom helix representation and geometry indicative graphics that assist 
analysis of both static structures and complex molecular dynamics simulation trajectories 
(Dahl et al, 2012). The Heatmap display of helix curvature aiding analysis of the relationship 
between different structures, dynamic conformational changed and structure stability.  
 
4.2.6 Pore Size Analysis 
 
We used PoreWalker (Pellegrini-Calace et al, 2009), a web-available method for the 
detection and characterisation of channels in our models from their 3D structure before and 
after MD analysis. The algorithm of PoreWalker is both heuristic and iterative, which includes 
the steps in Figure 4.2. In term of outputs, in addition to diameter profiles, PoreWalker 
describes several specific pore features, in particular the shape and the regularity of the 
channel cavity, and the position of pore centres along the channel. These features can be 
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very helpful to gain further insights into the functional and structural properties of pore-
forming protein channels by triggering specific in silico or experimental analyses. The protein 
structures in PDB format were submitted on the server for analysis and the results outputs 
are in the following 4 sections (1) Pore shape, which shows the prediction of the shape of the 
pore; (2) Pore visualisation: eight pictures (four for the whole structure and four to the pore 
only) are provided to visualise the pore and estimated way through it; (3) Slideshows of cross 
sections of the pore, which contain snapshots corresponding to pore slices of X Å and taken 
from the lowest to the highest x-coordinates; (4) Features of the cavity, which show the 
centres of the pore at 1 Å slices and the smallest diameter per slice (Pellegrini-Calace et al, 
2009).  
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Figure 4.2: Flowchart of PoreWalker stepwise algorithm (reproduced from Pellegrini-
Calace et al, 2009).   
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4.3 Results 
 
4.3.1 Protein Structure Prediction 
 
The first time protein Cj0391c sequence submission to the I-TASSER server was done on 
Aug 3rd, 2010 and the latest submission was on Jun 27th, 2014. The secondary structure 
prediction based on the protein sequence only is shown in Figure 4.3. The 3D structure 
prediction results are shown in Figure 4.4 and 4.5. 
 
The secondary structure predictions are represented as H for helix and C for Coil, together 
with the confidence scores, which range from 9 (most confident) to 0 (least confident). The 
results obtained from two submissions are very similar, with only a few amino acids 
difference in some of the helix lengths.  
 
There were also five 3D structures generated by the webserver each time, which are ranked 
by the C-score indicating the confidence of prediction (Roy et al, 2010). 
 
The C-score of the best-predicted Cj0391c model has been improved from –3.66 to -2.12 
through 4 years time, likely due to more protein structures being available from PDB for the 
server to use to build Cj0391c structures. The RMSD of the best model has also been 
improved from 14.2±3.8Å to 10.2±4.6Å. It is clear that the best predicted model obtained in 
the year 2014 is completely different from the model obtained from the year 2010. However, 
all of the predicted models indicate that Cj0391c is most likely an α -helical protein. The TM-
score changed from 0.3±0.10 to 0.46±0.15, which is also a big improvement. However, it is 
still lower than 0.5, which is the threshold for a reasonably correct topology. Therefore, the 
3D models predicted from I-TASSER were not used for the simulation. Nevertheless, the 
strong evidence for α-helicity of a substantial portion of the protein led us to seek α-helical 
structural templates.  
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(A)  
        
(B)  
      
Figure 4.3: Secondary structure prediction of Cj0391c from I-TASSER on (A) Aug 3rd, 2010 and (B) Jun 27th, 2014. (Prediction: H: helix C: 
Coil; Confidence score range from 9-most confident to 0-least confident) 
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                                      (A)             
                                                    Model 1   C-score=-3.66   
               Estimated TM-score = 0.3±0.10   Estimated RMSD = 14.2±3.8Å            
   (B)   (C)    
               Model 2   C-score=-4.28                                Model 3   C-score=-4.99            
   (D)   (E)         
                   Model 4   C-score=-5                                 Model 5   C-score=-4.50 
Figure 4.4: Protein Cj0391c structure prediction results from I-TASSER on Aug 3rd, 
2010 
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                                    (A)            
                                                 Model 1   C-score=-2.12   
                    Estimated TM-score = 0.46±0.15   Estimated RMSD = 10.2±4.6Å              
   (B)   (C)  
                    Model 2   C-score=-4.08                             Model 3   C-score=-3.12            
   (D)   (E)       
                 Model 4   C-score=-3.78                                Model 5   C-score=-4.18 
Figure 4.5: Protein Cj0391c structure prediction results from I-TASSER on Jun 27th, 
2014 
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4.3.2 Sequence Alignment 
 
As discussed in Chapter 3, protein Cj0391c may be a toxin acting via formation of α-helical 
ion channel. Additionally, as indicated by I-TASSER results, Cj0391c is most likely an α-
helical protein. Prior to 2013, there was no α-helical toxin with sequence similarity with 
Cj0391c was identified on PDB. However, in late 2013, an α-helical toxin called dermcidin 
(PDB code 2YMK) was identified. This protein has some sequence similarity with Cj0391c.  
 
The sequence alignment between dermcidin (PDB code 2YMK) and protein Cj0391c was 
performed using Clustal Omega, and the result is shown in Figure 4.6. The alignment score 
is 16.67 and the result indicates that the C-terminal of protein Cj0391c aligns well with 2YMK. 
The sequence alignment was used for homology modelling in section 4.3.3. Note that only 
the C-terminus of Cj0391c aligns well with 2YMK. This suggests that the C-terminal region 
may act as the membrane-permeating domain, while the N-terminal part may serve other 
functions, such as initial binding/anchoring to membrane, in a similar fashion to, for instance, 
equinatoxin-II. The binding of equinatoxin-II to lipid membranes is a two-step process, an 
exposed aromatic cluster mediates the initial attachment, and the N-terminal amphiphilic 
helix translocates into the lipid phase (Hong et al, 2002).  
 
4.3.3 Model Construction 
 
The protein model was constructed by modeller 9.10, and posited in the POPE bilayer. The 
systems are shown in Figure 4.7 (without zinc) and Figure 4.8 (with zinc). 
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Figure 4.6: Sequence alignment of protein Cj0391c and dermcidin 2YMK using Clustal 
Omega. 
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Figure 4.7: The hexamer protein model 391 inserted in bilayer POPE without the present of zinc.  
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Figure 4.8: The hexamer protein model 391 inserted in bilayer POPE with the present of 12 Zn2+ (Green balls: Zn2+). 
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4.3.4 RMSD Analysis 
 
The root-mean-square deviation (RMSD) of a protein during MD simulation is a frequently 
used measure of the structural difference between confirmations of a protein. It can be used 
to examine the change of confirmation during the course of a MD simulation. To investigate 
the stability of protein 391 under various conditions, RMSD calculations have been 
performed. The plots show a moving average of 100 ps to enable effective comparison of the 
overall trends between the systems.  
 
The RMSD plots of the trajectories of 391 from different systems are shown in Figure 4.9. 
RMSD was performed on the backbone atoms of the whole hexamer helix bundle. It can be 
observed that in the presence of Zn, RMSD levels out at ~4 Å at temperatures of 300 K,  
310 K and 314 K, Indicating relative stability of the bundle at these temperatures. Without the 
presence of Zn, at 300 K, a similar RMSD value was obtained, indicating that at this 
temperature even without Zn the bundle structure is maintained. However, when the 
simulation temperature reached 310 K and 314 K, without Zn, RMSD is substantially higher 
and does not level out even after 100 ns of MD simulation. Results suggesting that the 
bundle structure is quite different from that of dermcidin. Thus, Zn appears to maintain 
hexamer structure at temperature > 310 K, but at low temperature 300 K, Zn is not essential 
for this role. 
 
The individual helix RMSD of each model are shown in Figure 4.10 to Figure 4.15. RMSD of 
the 391-300K model indicates that three helices (helix 1, 5 and 6) exhibited similar RMSD at 
the end of the simulation. The other three helices show much higher RMSD. Therefore, 
without Zn, at 300 K, half of the helices maintained their structures, while the others did not. 
The specific details of each helix structure are discussed in the Section 4.3.3. At 310 K, the 
same model without Zn, substantial divergence in RMSD values are observed for all of the 
helices. Two helices (helix 1 and helix 6) maintained similar structures to dermcidin, while all 
the other helices range from 4 to 8 Å. The one with the highest RMSD value is the helix 3, 
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which lost helicity completely. This indicates breaking of symmetry in helix structure, which 
means the 6 helixes do not have the same structure anymore. For the same hexamer without 
Zn at 314 K (391-314K model), all of the helices except helix 4, showed very high RMSD, 
which indicates that all but one helix has completely diverged from the initial structure. The 
bundle lost helical symmetry totally.  
 
The RMSD of 391-ZN-300K, two helices (helix 3 and 4) with slightly lower RMSD comparing 
to the other four. Generally, all of the helices have similar RMSD at the end of the 100ns 
simulation. The 391-ZN-310K model also had comparably low RMSD (all below 4 Å). Helix 6 
is the one with the lowest RMSD (<2.5 Å) through the whole simulation, while helix 3 is the 
one with the highest. For the model 391-ZN-314K, most helices have fairly low and similar 
RMSD, except helix 2, which indicates the helix structure for 5 out of 6 helices was 
maintained.   
 
In conclusion, after 30 ns, the RMSD from systems 391-310K and 391-314K are almost 
double the value of the other 4 systems, which indicates at higher temperature (>=300 K), 
zinc helps to keep the structure stable. For the simulation temperature at 300 K, the RMSD 
values are quite similar for both models (with and without zinc).  
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           Figure 4.9: RMSD plots of the trajectories of the protein 391 from systems 391-300K, 391-310K, 391-314K, 391-ZN-300K, 391-ZN-310K 
and 391-ZN-314K.  
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                   Figure 4.10: RMSD plots of the trajectories of each helix from system 391-300K. 
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                  Figure 4.11: RMSD plots of the trajectories of each helix from system 391-310K. 
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               Figure 4.12: RMSD plots of the trajectories of each helix from system 391-314K.  
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                Figure 4.13: RMSD plots of the trajectories of each helix from system 391-ZN-300K. 
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               Figure 4.14: RMSD plots of the trajectories of each helix from system 391-ZN-310K. 
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               Figure 4.15: RMSD plots of the trajectories of each helix from system 391-ZN-314K. 
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4.3.5 Helix Dynamics Analysis 
 
The helices with the highest RMSD value from each model was chosen for bending analysis 
by using the tool Bendix, providing the most extreme example of helical distortion that 
resulted in each simulation. The results are shown in Figure 4.16 to Figure 4.21. The angle-
indicative heatmapping of each model and helix with the highest RMSD have been 
displayed. The colour scheme is Red-Green-Blue: red indicates the areas of highest helix 
axis angle; green for intermediate angle magnitudes; blue for angles closed to, or at 0 
degrees (Dahl et al, 2012). The heatmap display of helix curvature aiding analysis of the 
relationship between different structures and dynamic conformational changed (Dahl et al, 
2012). Angle data has also been displayed using a 3D landscape, where it takes into account 
the maximum angle computed during each trajectory and uses it as the colour threshold to 
scale the heatmap accordingly (Dahl et al, 2012). 
 
For the low temperature model 391-300K, which is without Zn, it can be observed that the 
helix bundle retains its tight-packed structure, similar to the initial homology model. All 
helices are quite straight, which is in agreement with the RMSD results (as in Figure 4.9). It is 
obvious that distortive bending occurred in the mid-section, which consist of residues 185 to 
190, Pro-Gln-Ile-Ser-Gln-Asn (PQISQN). Proline is a common helix-breaking residue, located 
at the hinge region in bent helices of many transmembrane proteins. Proline residues cause 
kinks in helices, and sterically prevent the (i-3)-carbonyl-(i + 1)-amino backbone hydrogen 
bond form forming (von Heijne, 1991). It is believed most transmembrane helix deformations 
(~60%) happen at proline residues (Yohannan et al, 2004). In the middle of a helix, proline 
distorts ideal α-helix geometry, due to the steric conflicts with the preceding residue and the 
loss of a backbone H bond (Reiersen & Rees, 2001). These distortions caused by proline 
might be functionally important in a helix. For instance, the distortion locations can be a weak 
point to facilitate movements required for the function of some transmembrane channels 
(Bright et al, 2002; Jin et al, 2002; Tieleman et al, 2001). For hexamer 391, helix kinking may 
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therefore also be important for its ion permeability. This may be tested experimentally by 
mutagenesis studies (eg. P185A mutants).  
 
For the model 391-310K, most helices are distorted, in agreement with the obtained RMSD. 
The highest extent of distortion again occurs around residues 185 to 190. The whole bundle 
itself formed a ‘hourglass’ shape, with helices bent at the middle part of the complex. For the 
391-314K model, all helices are highly distorted, and the bending region is still in the middle 
section. The model lost helical bundle symmetry and the ‘hourglass is more evident. In the 
model 391-ZN-300K, all the helices are all aligned straight in a tight-packed array, which is 
similar to dermcidin. Only one helix (helix 5) substantial disordered at the top section from 
residues 194 to 198, which are Lys-Val-Ser-Asp-Arg (KVSDR). For the model 391-ZN-310K 
and 391-ZN-314K, despite of the high temperatures, both model helices are still straight but 
exhibit more extreme bending at the end and limited bending at the middle.  
 
In conclusion, simulation results indicate that the most bended area of the no zinc models is 
in the middle section of the bundles. However, for the models with the present of zinc, the 
most flexible areas are at the end of the helices. For the overall structures, zinc helps to keep 
the bundle together and stop the helix bending at the middle when the simulation 
temperature is 310 K or 314 K.  
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           (A)              (B)  
(C)  
Figure 4.16: Bendix analysis of model 391-300K. (A) Angle-indicative heatmapping of 
model 391-300K from MD simulation. (B) Angle-indicative heatmapping of helix 2 of 
model 391-300K from MD simulation. (C) Heatmap surface of the helix 2 trajectory 
from model 391-300K MD simulation.  
  
Time (ns) 
20 
100 
80 
Residues (aa) 
60 
40 
157 
162 166 170 
174 
178 
182 
186 
190 
194 
198 
203 
Chapter 4 
 196
     
          (A)        (B)     
(C)  
Figure 4.17: Bendix analysis of model 391-310K. (A) Angle-indicative heatmapping of 
model 391-310K from MD simulation. (B) Angle-indicative heatmapping of helix 2 of 
model 391-310K from MD simulation. (C) Heatmap surface of the helix 2 trajectory 
from model 391-310K MD simulation.  
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        (A)      (B)  
(C)  
Figure 4.18: Bendix analysis of model 391-314K. (A) Angle-indicative heatmapping of 
model 391-314K from MD simulation. (B) Angle-indicative heatmapping of helix 1 of 
model 391-314K from MD simulation. (C) Heatmap surface of the helix 1 trajectory 
from model 391-314K MD simulation.  
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               (A)            (B)  
(C)  
Figure 4.19: Bendix analysis of model 391-ZN-300K. (A) Angle-indicative heatmapping 
of model 391-ZN-300K from MD simulation. (B) Angle-indicative heatmapping of helix 5 
of model 391-ZN-300K from MD simulation. (C) Heatmap surface of the helix 5 
trajectory from model 391-ZN-300K MD simulation.  
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                          (A)                      (B)  
(C)  
Figure 4.20: Bendix analysis of model 391-ZN-310K. (A) Angle-indicative heatmapping 
of model 391-ZN-310K from MD simulation. (B) Angle-indicative heatmapping of helix 3 
of model 391-ZN-310K from MD simulation. (C) Heatmap surface of the helix 3 
trajectory from model 391-ZN-310K MD simulation.  
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                           (A)             (B)      
(C)  
Figure 4.21: Bendix analysis of model 391-ZN-314K. (A) Angle-indicative heatmapping 
of model 391-ZN-314K from MD simulation. (B) Angle-indicative heatmapping of helix 2 
of model 391-ZN-314K from MD simulation. (C) Heatmap surface of the helix 2 
trajectory from model 391-ZN-314K MD simulation.  
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4.3.6 Pore Size Analysis 
 
The initial Cj0391c homology model, as well as PDB structures obtained from the final frame 
of each of the MD simulation trajectories have been uploaded to PoreWalker website for pore 
size and features analysis. The results from PoreWalker are shown in Figure 4.22 to Figure 
4.29.  
 
Figure 4.22 shows the results from PoreWalker, which present the pore diameter profile for 
homology model of Cj0391c based on dermcidin. The structure submitted was the 391 
hexamer model before simulation. For the model without Zn at 300 K, the pore diameter is 
relatively high at the two ends (5~7 Å), while low at the centre (~ 2 Å). When the temperature 
is at 310 K, the profile shows a more distinct shape, wide at both ends and narrow in the 
middle, which is consistent with the ‘hourglass’ shape appearance of the helix bundle. The 
pore size and shape is quite similar from the simulation temperature at 314 K compared with 
310 K, just with even more apparent shape. The starting 391 model with the presence of Zn 
is similar to the starting model of 391 without Zn. For the 391-ZN-300K model, the pore is 
narrow at one end and wide at the other. The shape of the bundle resembles slight ‘peeling 
off’ at one end, which can be observed from Figure 4.26 (A). When the simulation 
temperature is increased to 310 K with Zn present, the pore structure is very similar to the 
model at 300 K. This trend was the same when the temperature reached 314 K. The lowest 
size is about 3 Å.  
 
Results show that the pores are filled with both positively and negatively charged residues, 
and further work will be required to ascertain whether the pore is ion selective. Generally, for 
the models without zinc, the middle of the pore is narrower compare to the models with zinc, 
which is consistent with the results obtained from the helix dynamics analysis indicating 
higher degree of bending at the middle for the zinc-free structures. However, all of the model  
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Figure 4.22: Pore size analysis of model 391 without zinc before MD simulation  
(A) visualisation of a pore section showing pore-lining residues and pore centres at 3Å steps: 
the section of the structure was obtained by cutting the protein structure along the xy-plane, 
where the x-axis corresponds to the pore-axis, and y-coordinate>0 only are displayed. Pore-
lining atoms and residues are coloured in orange and blue, respectively. The remaining part 
of the protein is shown in green. Red spheres represent pore centres at given pore heights 
and their diameters correspond to 1/10 of the pore diameter calculated at that point; (B) 
representation of the shape of the pore and shape characterization string: the pore is 
simplified as a stack of building blocks going from the most negative to the most positive 
coordinate along the pore axis (x-axis). D, U and S indicate conical frustums of decreasing 
diameter, conical frustums of increasing diameter and cylinders, respectively; (C) pore 
diameter profile at 3Å steps corresponding the pore shape in (B). Pore axis (X-Coord): the 
position along the pore axis is shown as x-coordinate in Å. Dia (Ang): pore diameter value in 
Å; (D) visualization of a pore section showing the position of the biggest spheres (pore 
centres) that can be built along the channel at 1Å steps: the section of the structure was 
obtained by cutting the protein structure along the xy-plane. The protein structure is coloured 
in green; (E) diagram of the regularity of the pore cavity as number of lines that can 
approximate the positions of the pore centres at 1Å steps (PRINCIP). The pore is 
represented as a series of consecutive straight and wiggly lines representing channel areas 
where pore centres can (straight) or cannot (wiggly) be fitted to a line, going form the most 
negative to the most positive coordinate along the pore axis (x-axis). Vertical lines describe 
either the only low-RMSD areas throughout a pore or low-RMSD areas that are co-linear. 
Diagonal lines represent low-RMSD areas, which are different from the low-RMSD areas 
other identified along the channel. Curve lines indicate areas where pore centres are highly 
spread; (F) pore diameter profile at 1Å steps. Pore axis (X-Coord): the position along the 
pore axis is shown as x-coordinate in Å. Dia (Ang): pore diameter value in Å (Figure legend 
reproduced from Pellegrini-Calace. et al, 2009). 
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Figure 4.23: Pore size analysis of model 391 without zinc after simulating for 100 ns at 
300 K (See Figure 4.21 caption for details explanation). 
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Figure 4.24: Pore size analysis of model 391 without zinc after simulating for 100 ns at 
310 K (See Figure 4.21 caption for details explanation). 
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Figure 4.25: Pore size analysis of model 391 without zinc after simulating for 100 ns at 
314 K (See Figure 4.21 caption for details explanation). 
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Figure 4.26: Pore size analysis of model 391 with zinc before MD simulation (See 
Figure 4.21 caption for details explanation).  
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Figure 4.27: Pore size analysis of model 391 with zinc after simulating for 100 ns at 
300 K (See Figure 4.21 caption for details explanation). 
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Figure 4.28: Pore size analysis of model 391 with zinc after simulating for 100 ns at 
310 K (See Figure 4.21 caption for details explanation). 
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Figure 4.29: Pore size analysis of model 391 with zinc after simulating for 100 ns at 
314 K (See Figure 4.21 caption for details explanation). 
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channels are big enough to fit at least one water molecule. The overall pore sizes are wider 
with the low temperature simulations, indicating that conductance might be higher at low 
temperature. 
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4.3.7 Bilayer and Water Environment Around Zinc 
 
The Zn2+ were initially placed in the same positions of the dermcidin model, on the outside of 
the bundle in between the helices. These positions are not normally considered a favourable 
environment for divalent cations. However, after 100 ns simulation, the lipid bilayer adapts so 
that the Zn2+ is complexed to polar groups of lipid headgroups; and also water partially 
permeates the bilayer near the Zn2+ to form a solvent ‘shell’. Figure 4.30 (A) shows the 
structure of the 391-ZN-300K 100 ns simulation model, while similar results are obtained in 
the other simulation models. Illustration of one Zn2+ in the 391-ZN-300K simulation after 100 
ns complexed to water molecules and phosphate groups of surrounding POPE is shown in 
Figure 4.30 (B). Thus Zn2+ does not remain in an energetically unfavourable environment of 
the lipid tails. Instead, the bilayer structurally adapts to form a polar environment around the 
Zn2+. Similar phenomena have been examined by previous MD simulations. For example, in 
the study of Wang and Larson (2014), the function of charged ions involved in facilitating 
water channel formation has also been discussed, involving similar distortion of bilayer 
structure to accommodate passage of charged ions through the membrane core region.  
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(A)  
(B)                         
Figure 4.30: (A) The structure of model 391-ZN-300K after 100 ns simulation.  
(B) Illustration of one Zn2+ in the 391-ZN-300K simulation after 100 ns complexed to 
water molecules and phosphate groups of surrounding POPE (green: Zn2+; red: 
oxygen; yellow: phosphorus; white: hydrogen). 
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4.4 Discussion and Conclusion 
 
Using dermcidin as a structural template, we employed homology modelling to build the 
hexamer structure of Cj0391c (the hexamer is named 391 in this study), and simulated its 
atomic-level motions in a lipid bilayer using fully-solvated molecular dynamics. Their 
dynamics have been investigated by atomistic MD methods, in which the motions of the 
individual atoms of the proteins together with their solvent/cellular environments are explicitly 
computed based on Newtonian mechanics. Molecular simulation software packages 
GROMACS was used to obtain MD trajectories.  
 
We examined the effects of zinc on the structure of protein 391, and propose that while zinc 
has comparatively little effect on hexamer symmetry at low temperature, it is crucial to 
maintaining symmetry and helix linearity at elevated temperatures. Simulations also 
elucidated the influences of zinc and temperature on pore size and shape, forming a basis 
for experiments to study the functional properties of this protein under various conditions.  
 
Based on the experimental observations from Chapter 3, we explore a number of hypotheses 
for the mechanisms by which Cj0391c induces chicken macrophage apoptosis as well as the 
possible structure of Cj0391c.  
 
The first hypothesis raised was protein Cj0391c might be a death receptor ligand with 
structure similar to TNF-α or TRAIL. However, the protein sequence alignment results 
indicate that sequence alignment between protein Cj0391c and these ligands is comparably 
poor (as death receptor ligands are typically comprised of β-strands). None of the secondary 
structure and fold prediction methods employed on Cj0391c suggests that it contains any β-
strand content.  
 
The second hypothesis was protein Cj0391c may be a toxin similar to Shiga-toxin. However, 
Shiga-toxin and Shiga-related toxins are composed of two subunits from two different genes, 
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an effector subunit and a membrane binding subunit. Cj0391c is a most probably a single 
subunit in our experiment (Chapter 3), as it was expressed as a single chain, but still causes 
chicken macrophage cell apoptosis. However, we cannot exclude the possibility that Cj0391c 
might be a Shiga-like toxin.  
 
Finally, protein Cj0391c may be a toxin acting via formation of α-helical ion channel enabling 
the exchange of ions (pore-forming toxin), causing DNA fragmentation and cell lysis. Pore-
forming toxins (PFTs) are a class of proteins that convert from a soluble form to a 
membrane-integrated pore (Parker & Feil, 2005). They can be divided to two main groups 
based on the suspected mode of membrane integration, α-PFTs and β-PFTs. Since all the 
secondary structure prediction utilised all indicated  similar results, Cj0391c is proposed to be 
α-helical, and the C-terminal is also α-helical. However, it does not align well with any known 
helical toxin, except dermcidin (PDB code 2YMK). The sequence alignments with the only 
three 3D assembled structures available α-PFTs in PDB, which are cytolysinA (ClyA, aka 
HlyE) (PDB code 2WCD), fragaceatoxin C (FraC) (PDB code 3LIM) and dermcidin (PDB 
code 2YMK), are displayed in Figure 4.30. They are the only α-PFTs with assembled 3D 
structure available in PDB by 2013.  
 
ClyA is a cytotoxic toxin towards cultured mammalian cells, which induces apoptosis of 
macrophages and promotes tissue pervasion (Fuentes et al, 2008; Lai et al, 2000; 
Oscarsson et al, 1999). FraC is an actinoporin isolated from the sea anemone Actinia 
fragacea, which consists of a crown-shaped nonamer with an external diameter of about 11.0 
nm and an internal diameter of ~5.0 nm (Mechaly et al, 2009). Dermcidin is an antimicrobial 
peptide that has a broad spectrum of activity (Schittek et al, 2001). It is expressed in the 
sweat glands and secreted into the sweat and transported to the epidermal surface (Schittek 
et al, 2001). The structure of assembled dermcidin solved at 2.5-Å resolution shows a 
channel architecture comprising a hexameric bundle formed elongated α-helices, with overall 
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Figure 4.31: Protein sequences alignments between Cj0391c and 2YMK, Cj0391c and 
3LIM, & Cj0391c and 2WCD using Clustal Omega.  
 
  
 
CLUSTAL O(1.1.0) multiple sequence alignment 
 
 
Cj0391c                          MQVNTFSNIASMARTQVSNKKADDAKENTKDKNVQSANSSKDVDKNTLEKLNALGGKGIT 
2YMK:A|PDBID|CHAIN|SEQUENCE      ------------------------------------------------------------ 
                                                                                              
 
Cj0391c                          QIYLVQFQQQTMNAVIGSSNAQTGLDSLLNGANLDTAKSILTNIDFASLGYSSKNPLDMN 
2YMK:A|PDBID|CHAIN|SEQUENCE      ------------------------------------------------------------ 
                                                                                              
 
Cj0391c                          TDELQQLVSEDGFFGVENTANRIADFVIKGGGDDVEKLKKGLEGMKKGFEQAEKMWGGEL 
2YMK:A|PDBID|CHAIN|SEQUENCE      ----------------------------------SSLLEKGLDGAKKAVGGLGKLGKDAV 
                                                                    . *:***:* **..    *:    : 
 
Cj0391c                          PQISQNTIDAALKKVSDRIDELGGKTLDLQA 
2YMK:A|PDBID|CHAIN|SEQUENCE      EDLES-VGKGAVHDVKDVLDSVL-------- 
                                  ::.. . ..*::.*.* :*.:          
 
 
 
 
CLUSTAL O(1.1.0) multiple sequence alignment 
 
 
Cj0391c                          MQVNTFSNIASMARTQVSNKKADDAKENTKDKNVQSANSSKDVDKNTLEKLNALG----- 
3LIM:A|PDBID|CHAIN|SEQUENCE      ---------------------AD-----VAGAVIDGAGLGFDVLKTVLEALGNVKRKIAV 
                                                      **     .    ::.*  . ** *..** *  :       
 
Cj0391c                          ------GKGITQIYLVQFQQQTMNAVIGSSNAQTGLDSLLNGANLDT--AKSILTNIDFA 
3LIM:A|PDBID|CHAIN|SEQUENCE      GIDNESGKTWTAM-NTYFRSGTSDIVL-PHKVAHGKALLYNGQKNRGPVATGVVGVIAY- 
                                       **  * :  . *:. * : *:   :.  *   * ** :     *..::  * :  
 
Cj0391c                          SLGYSSKNPLDMNTDELQQLVSEDGFFGVENTANRIAD----FVIKGGGDDVEKLKKGLE 
3LIM:A|PDBID|CHAIN|SEQUENCE      --SMSDGNTLA-------V------LFSVPYDYNWYSNWWNVRVYKGQKRADQRMYEELY 
                                   . *. * *               :*.*    *  ::     * **     ::: : *  
 
Cj0391c                          GMKKGFEQAEKMWGGELPQISQNTIDAALKKVSDRIDELGGKTLDLQA--- 
3LIM:A|PDBID|CHAIN|SEQUENCE      YHRSPFR-GDNGWHSRGL-------GYGLK-SRGFMNSSGHAILEIHVTKA 
                                   :. *. .:: * ..           .**     ::. *   *:::.    
!
 
 
CLUSTAL O(1.1.0) multiple sequence alignment 
 
 
Cj0391c                          MQVNTFSNIASMARTQVSNKKADDAKENTKDKNVQ-------SANSSKDVDKNTLEKL-- 
2WCD:A|PDBID|CHAIN|SEQUENCE      -----------MHHHH-------HHTEIVADKTVEVVKNAIETADGALDLYNKYLDQVIP 
                                            * : :       . .* . **.*:       :*:.: *: :: *:::   
 
Cj0391c                          -----------------------------------------------NALGG--KGITQI 
2WCD:A|PDBID|CHAIN|SEQUENCE      WQTFDETIKELSRFKQEYSQAASVLVGDIKTLLMDSQDKYFEATQTVYEWCGVATQLLAA 
                                                                                    *  . :    
 
Cj0391c                          YLVQFQQQTMNAVIGSSNAQTGLDSLLNGAN-LD-TAKSILTNIDFASLGYSSKNPLDMN 
2WCD:A|PDBID|CHAIN|SEQUENCE      YILLFDEYNEKKA--SAQKDILIKVLDDGITKLNEAQKSLLVS--SQSFNNASGKLLALD 
                                 *:: *:: . : .  *:: :  :. * :* . *: : **:*..    *:  :* : * :: 
 
Cj0391c                          TDELQQLVSEDGFFGVENTANRIADFVIKGGGDDVEKLKKGLEGMKKGFEQAEKMWGGE- 
2WCD:A|PDBID|CHAIN|SEQUENCE      SQLTNDFSEKSSYFQSQVDKIRKEAY--AGAAA---GVVAGPFGLIISYSIAAGVVEGKL 
                                 ::  ::: .:..:*  :    *   :   *..     :  *  *:  .:. *  :  *:  
 
Cj0391c                          LPQIS--------------------QNTIDAALKKVSDRIDELGGKTLDLQA-------- 
2WCD:A|PDBID|CHAIN|SEQUENCE      IPELKNKLKSVQNFFTTLSNTVKQANKDIDAAKLKLTTEIAAIGEIKTETETTRFYVDYD 
                                 :*::.                    :: ****  *:: .*  :*  . : ::         
 
Cj0391c                          ------------------------------------ 
2WCD:A|PDBID|CHAIN|SEQUENCE      DLMLSLLKEAAKKMINTCNEYQKRHGKKTLFEVPEV 
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dimensions of ~8 X 4 nm (Song et al, 2013). Channel formation involves trimerization of 
antiparallel peptide dimers, which results in a firmly enclosed channel structure (Song et al, 
2013).  
 
The C-terminal sequence of protein Cj0391c aligns well with dermcidin. Thus, we further 
explore the likelihood of the hypothesis that Cj0391c is an α-PFT with the similar structure as 
dermcidin by examining the theoretical structural stability of Cj0391c in a helical pore bundle 
within a simple lipid bilayer under various conditions.  
 
Generally, the 391 hexamer model is more stable with the present of zinc at temperature of 
310 K and 314 K. At 300 K, there is not much total RMSD difference between the models 
391-300K and 391-ZN-300K. However, the most flexible helices are different, which are helix 
2 and helix 5 respectively. For the helices bending areas, there is a trend that with the 
present of zinc, the models bend more at the ends; while for the models without zinc, most of 
the bending occurs near the middle of the protein. The hexamer 391 pore channel size is 
also linked with the presence of the zinc, as with the presence of the zinc, the pore channel 
is wider in the middle. For the models without zinc, the channel is wider at the two ends. The 
overall pore size is bigger when simulated at lower temperature. In a dermcidin crystal 
structure study (Song et al, 2013), results show that zinc plays a crucial role to keep the 
dermcidin hexameric structure at the temperature of 310 K, which is consistent with the 391 
MD simulation. Furthermore, simulations suggest that the bilayer can undergo deformation 
such that Zn2+ ions may reside in the membrane core region without being exposed to a 
hydrophobic lipid tail environment.  
 
There are two more α-PFTs with crystal structure solved in 2014, which are Tc Toxin TcdA1 
(PDB code 4O9Y/1VW1) and listeriolysin (PDB code 4CDB). The sequence alignments 
between Cj0391c and these two are attached in Appendix 6 and 7. After including the two 
new α-PFTs, dermcidin still has the best sequence alignment with Cj0391c.  
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CHAPTER 5. CONCLUSIONS 
AND FUTURE DIRECTIONS 
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In this study, various servers were used to identify putative virulent NCSPs from C. jejuni 
NCTC 11168 that are fully or partially exposed extracellularly. The final list of 28 putative 
NCSPs on the list may include proteins that are responsible for chicken immune system 
down-regulation and/or the remarkable colonisation capability of C. jejuni in chickens. 
Indeed, these two activities may be linked.  
 
During the course of this study, a similar study was reported by Nielsen and co-workers, also 
aimed at identifying immunogenic and virulence-associated proteins from C. jejuni NCTC 
11168 (Nielsen et al, 2012). They identified 25 genes that may encode potential antigens 
from C. jejuni NCTC 11168. These antigens do not overlap with the final protein list in our 
study, as they did not consider hypothetical proteins. Hence the current work is aimed at 
identifying a different cohort of potential virulence proteins. 
 
Among them, Cj0243c (σ54), Cj0391c (σ28), Cj0814 (σ54), Cj0859c (σ28) and Cj1656c (σ28) 
have been observed to be co-regulated with flagellar gene expression (Guerry-Kopecko, 
2012). σ54 promoters regulate the expression of genes required for basal body, hook and 
flagellar filament biosynthesis, while σ28 promoters co-regulate the expression of genes 
required for extension and capping of the flagellum, and genes required for flagellin post-
translational modification and secretion of virulence factors (Carrillo et al, 2004). This 
indicates that these proteins may be involved in related functions. They can be similar to the 
flagella related secretion protein CiaB, which shares similarity with other invasion-related 
proteins, such as Salmonella SipB (Kaniga et al, 1995) and Yersinia YopB (Hakansson et al, 
1996). CiaB also lacks an identifiable signal sequence, and is therefore non-classically 
secreted (Konkel et al, 1999). Another flagella exporting-related protein is FlaC, which has 
sequence identity with the N- and C-terminal regions of proteins FlaA and FlaB (Song et al, 
2004). FlaC is not required for the flagellum formation or motility, but it is secreted via the 
flagellum, and the FlaC protein seems to be involved in host cell invasion (discussed in 
Section1.7.3 and Section 1.9.2). The small acidic protein FspA is also secreted via the 
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flagella export system (Poly et al, 2007). Two variants of this protein are present, FspA1 and 
FspA2. FspA2 has been identified to rapidly induce apoptosis in INT407 cells, and thus likely 
to play a role in pathogenesis (Poly et al, 2007).  
 
Hypothetical proteins Cj0391c and Cj1631c were overexpressed in C. jejuni NCTC 11168 
biofilm-grown cells (pH 4-7), along with other proteins involved in stress responses, flagellar 
motility and adhesion (Kalmokoff et al, 2006). These two proteins are the only two 
hypothetical proteins overexpressed in Kalmokoff et al.’s study. Both of them are included in 
the 28 protein candidates identified in this study.  
 
Protein Cj0152c, which has been predicted to be located in the cytoplasm/cell inner 
membrane and also extracellularly, has been found in C. jejuni outer membrane vesicles 
(OMVs) (Jang et al, 2014). In Gram-negative bacteria, OMVs are often released 
extracellularly attaching to host cells through adhesive molecules and then transferring 
compounds into the host cells (Jang et al, 2014). As C. jejuni does not have the prototypical 
virulence-associated secretion systems, OMVs play an important role in the coordinated 
delivery of virulence proteins into human intestinal epithelial cells (Elmi et al, 2012).  
 
Based on the information as above, other protein candidates could be further analysed. One 
of the protein candidates Cj0428 has been expressed in the same E. coli BL21(DE3) pRSET-
A system, but the production was very low in this system. There was not enough protein 
could be collected at the end of expression. Another expression system could be tested for 
Cj0428c expression. However, the instability index obtained for this protein from ProtParam 
indicates it is an unstable protein, which may be the reason that it was not successfully 
expressed. Finally, some of the other protein candidates have also been expressed and 
analysed by other colleagues (data not shown).  
 
Protein candidate Cj0391c from C. jejuni NCTC 11168 has shown apoptotic effects in a 
chicken macrophage cell line HD11 in our study. Other cell lines have also been tried, which 
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include Chinese hamster ovary (CHO) cell line and human intestinal (INT 407) cell line. 
Interestingly, Cj0391c shows no noticeable effect on either of these (data not shown). One of 
the possible reasons could be that the specific surface structure of chicken macrophage cells 
may be required for Cj0391c to fully fold or function.  
 
Based on experimental results and secondary structure prediction results, it is suggested that 
Cj0391c is an α-PFT which forms pores in chicken macrophage cells. A Cj0391c hexamer 
model was built based on a recently solved α-PFT structure, dermcidin.  
 
For molecular models, there was no homology model we could use to build Cj0391c 
structure as no template with sufficient similarity was detected in the protein data bank. In the 
future, more protein sequences with/without annotated function and 3D models will be 
available from the database, which might lead us to find a structural homologue of Cj0391c.  
 
Experimentally, the mechanisms of action of Cj0391c on chicken macrophage membrane 
could be further analysed by: (1) single channel conductance measurement (patch clamp) to 
test the channel conductance/pore size differences between each model (if the pore forms); 
(2) electron microscopy can be employed to view the pore structure in chicken macrophage 
membranes; (3) circular dichroism can be employed to conform the protein secondary 
structure; (4) the hexamer structure, such as helix bending and flexibility, could be further 
analysed by probing with a number of experimental techniques, including X-ray diffraction, 
electron microscopy, nuclear magnetic resonance, and fluorescence probe techniques 
(Bhunia et al, 2010; Dzuba & Raap, 2013; Groulx et al, 2010).  
 
As mentioned in Section 3.4, there are several mechanisms that Cj0391c may induce 
apoptosis in chicken macrophages. This study explored one possibility. Future work would 
involve exploring other oligomers, arrangements, etc. Simulations of spontaneous 
oligomerisation within a membrane will also be performed in the future.  
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As indicated from the Section 1.11, a vaccine would help to reduce the colonisation of C. 
jejuni in chickens, thus reducing levels of transmission to people. Protein Cj0391c could be 
tested as a vaccine candidate in chicken, as inactivating this protein may allow chicken 
macrophages to phagocytose and kill the colonising bacteria.  
 
In summary, this work has used bioinformatics techniques to mine the Campylobacter 
genome for potential virulence factors. As genome sequence analysis becomes routine, 
these kinds of analyses may yield potential vaccine and/or targets for a wide range of 
pathogens.  
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Appendices  
Appendix 1: Predicted C. jejuni NCTC 11168 Classically Secreted Proteins using 
SignalP 4.0 
periplasmic protein  
Accession: YP_002345089.1 GI: 218563309  
outer membrane protein  
Accession: YP_002345087.1 GI: 218563307  
periplasmic protein  
Accession: YP_002345047.1 GI: 218563267  
periplasmic protein  
Accession: YP_002345038.1 GI: 218563258  
DNA ligase  
Accession: YP_002345037.1 GI: 218563257  
periplasmic protein  
Accession: YP_002345036.1 GI: 218563256  
periplasmic thiredoxin  
Accession: YP_002345032.1 GI: 218563252  
periplasmic protein p19  
Accession: YP_002345027.1 GI: 218563247 
iron permease  
Accession: YP_002345026.1 GI: 218563246  
periplasmic protein  
Accession: YP_002345001.1 GI: 218563221  
periplasmic protein  
Accession: YP_002344995.1 GI: 218563215  
haemin uptake system outer membrane receptor  
Accession: YP_002344983.1 GI: 218563203 
periplasmic protein  
Accession: YP_002344912.1 GI: 218563133  
periplasmic oxidoreductase  
Accession: YP_002344894.1 GI: 218563115  
periplasmic protein  
Accession: YP_002344891.1 GI: 218563112  
flagellar basal body P-ring protein  
Accession: YP_002344844.1 GI: 218563065  
capsule polysaccharide export system periplasmic protein  
Accession: YP_002344827.1 GI: 218563048  
lipoprotein  
Accession: YP_002344769.1 GI:218562990 
periplasmic protein  
Accession: YP_002344768.1 GI:218562989 
periplasmic protein  
Accession: YP_002344764.1 GI:218562985 
periplasmic protein  
Accession: YP_002344760.1 GI:218562981 
periplasmic protein  
Accession: YP_002344759.1 GI:218562980 
enterochelin uptake periplasmic binding protein  
Accession: YP_002344743.1 GI: 218562964  
periplasmic protein  
Accession: YP_002344679.1 GI:218562900 
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fibronectin domain-containing lipoprotein  
Accession: YP_002344670.1 GI:218562891 
major outer membrane protein  
Accession: YP_002344650.1 GI: 218562871  
MFS transport protein  
Accession: YP_002344632.1 GI:218562853 
periplasmic protein  
Accession: YP_002344631.1 GI:218562852 
peptidase M23 family protein  
Accession: YP_002344606.1 GI:218562827 
exporting protein  
Accession: YP_002344605.1 GI:218562826 
lipoprotein thiredoxin  
Accession: YP_002344598.1 GI: 218562819  
NLPA family lipoprotein  
Accession: YP_002344591.1 GI: 218562812  
50 kda outer membrane protein precursor  
Accession: YP_002344561.1 GI: 218562782  
periplasmic protein  
Accession: YP_002344560.1 GI: 218562781  
periplasmic cytochrome C  
Accession: YP_002344544.1 GI: 218562765  
periplasmic thioredoxin  
Accession: YP_002344499.1 GI: 218562720  
liproprotein  
Accession: YP_002344424.1 GI: 218562645  
lipoprotein  
Accession: YP_002344421.1 GI: 218562642  
periplasmic protein  
Accession: YP_002344416.1 GI: 218562637  
branched-chain amino-acid ABC transporter periplasmic binding protein  
Accession: YP_002344414.1 GI: 218562635  
branched-chain amino-acid ABC transporter periplasmic binding protein  
Accession: YP_002344413.1 GI: 218562634  
periplasmic protein  
Accession: YP_002344393.1 GI: 218562614  
amino-acid transporter periplasmic solute-binding protein  
Accession: YP_002344377.1 GI: 218562598  
periplasmic protein  
Accession: YP_002344364.1 GI: 218562585  
lipoprotein  
Accession: YP_002344348.1 GI: 218562569  
F0F1 ATP synthase subunit C  
Accession: YP_002344334.1 GI: 218562555  
bifunctional adhesin/ABC transporter aspartate/glutamate-binding protein  
Accession: YP_002344319.1 GI: 218562540  
periplasmic protein  
Accession: YP_002344307.1 GI: 218562528  
periplasmic protein  
Accession: YP_002344305.1 GI: 218562526  
periplasmic protein  
Accession: YP_002344276.1 GI: 218562497  
protein disulphide isomerase  
Accession: YP_002344273.1 GI: 218562494  
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periplasmic protein  
Accession: YP_002344271.1 GI: 218562492  
ankyrin repeat-containing periplasmic protein  
Accession: YP_002344241.1 GI: 218562462  
Na+/H+ antiporter family protein  
Accession: YP_002344239.1 GI: 218562460  
flagellar biosynthesis protein FliP  
Accession: YP_002344227.1 GI: 218562448  
lipoprotein  
Accession: YP_002344225.1 GI: 218562446  
periplasmic protein  
Accession: YP_002344191.1 GI: 218562412  
periplasmic nitrate reductase small subunit  
Accession: YP_002344190.1 GI: 218562411  
NLPA family lipoprotein  
Accession: YP_002344179.1 GI: 218562400  
NLPA family lipoprotein  
Accession: YP_002344178.1 GI: 218562399  
NLPA family lipoprotein  
Accession: YP_002344177.1 GI: 218562398  
ferric enterobactin uptake receptor  
Accession: YP_002344163.1 GI: 218562384  
hemagglutination activity domain-containing protein  
Accession: YP_002344155.1 GI: 218562376  
periplasmic protein  
Accession: YP_002344153.1 GI: 218562374  
histidine-binding protein precursor  
Accession: YP_002344152.1 GI: 218562373  
periplasmic solute-binding protein  
Accession: YP_002344145.1 GI: 218562366  
transthyretin-like periplasmic protein  
Accession: YP_002344133.1 GI: 218562354  
lipoprotein  
Accession: YP_002344075.1 GI: 218562296  
secreted transglycosylase  
Accession: YP_002344074.1 GI: 218562295  
periplasmic phosphate binding protein  
Accession: YP_002344043.1 GI: 218562264  
periplasmic protein  
Accession: YP_002344039.1 GI: 218562260  
major antigenic peptide PEB-cell binding factor  
Accession: YP_002344026.1 GI: 218562247  
DNA/RNA non-specific endonuclease  
Accession: YP_002344024.1 GI: 218562245  
periplasmic protein  
Accession: YP_002344022.1 GI: 218562243  
lipoprotein  
Accession: YP_002344021.1 GI: 218562242  
periplasmic protein  
Accession: YP_002343992.1 GI: 218562213  
exporting protein  
Accession: YP_002343971.1 GI: 218562192  
lipoprotein  
Accession: YP_002343931.1 GI: 218562152  
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succinate dehydrogenase flavoprotein subunit  
Accession: YP_002343874.1 GI: 218562095  
periplasmic protein  
Accession: YP_002343862.1 GI: 218562083  
acidic periplasmic protein  
Accession: YP_002343861.1 GI: 218562082  
periplasmic protein  
Accession: YP_002343857.1 GI: 218562078  
lipoprotein  
Accession: YP_002343843.1 GI: 218562064  
sulfite oxidase subunit YedY  
Accession: YP_002343816.1 GI: 218562037  
lipoprotein  
Accession: YP_002343812.1 GI: 218562033  
hypothetical protein Cj0371  
Accession: YP_002343808.1 GI: 218562029  
outer membrane channel protein CmeC  
Accession: YP_002343802.1 GI: 218562023  
cytochrome C551 peroxidase  
Accession: YP_002343796.1 GI: 218562017  
molybdate-binding lipoprotein  
Accession: YP_002343741.1 GI: 218561962  
major antigenic peptide PEB3  
Accession: YP_002343730.1 GI: 218561951  
periplasmic protein  
Accession: YP_002343658.1 GI: 218561879  
biopolymer transport protein  
Accession: YP_002343637.1 GI: 218561858  
TonB-denpendent outer membrane receptor  
Accession: YP_002343636.1 GI: 218561857  
iron transport protein  
Accession: YP_002343635.1 GI: 218561856  
 lipoprotein  
Accession: YP_002343634.1 GI: 218561855  
periplasmic protein  
Accession: YP_002343627.1 GI: 218561848  
heme-binding lipoprotein  
Accession: YP_002343618.1 GI: 218561839  
TAT (Twin-Arginine Translocation) pathway signal sequence domain protein  
Accession: YP_002343605.1 GI: 218561826  
periplasmic solute binding protein  
Accession: YP_002343603.1 GI: 218561824  
periplasmic protein  
Accession: YP_002343574.1 GI: 218561795  
translocation protein TolB  
Accession: YP_002343572.1 GI: 218561793  
periplasmic protein  
Accession: YP_002343553.1 GI: 218561774  
periplasmic protein  
Accession: YP_002343552.1 GI: 218561773  
lipoprotein  
Accession: YP_002343551.1 GI: 218561772  
lipoprotein  
Accession: YP_002343550.1 GI: 218561771  
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lipoprotein  
Accession: YP_002343549.1 GI: 218561770  
cytolethal distending toxin B  
Accession: YP_002343540.1 GI: 218561761  
cytolethal distending toxin C  
Accession: YP_002343539.1 GI: 218561760  
periplasmic protein  
Accession: YP_002343521.1 GI: 218561742  
cytochrome C  
Accession: YP_002343508.1 GI: 218561729  
cytochrome C551 peroxidase  
Accession: YP_002343492.1 GI: 218561713  
non-specific DNA binding protein  
Accession: YP_002343483.1 GI: 218561704  
monohaem cytochrome C  
Accession: YP_002343476.1 GI: 218561697  
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Appendix 2: Predicted C. jejuni NCTC 11168 Non-classically Secreted Proteins using 
SecretomeP 2.0 and SignalP 4.0 
flagellar hook protein FlgE  
Accession: YP_002345095.1 GI:218563315 
50S ribosomal protein L3  
Accession: YP_002345073.1 GI: 218563293  
50S ribosomal protein L4  
Accession: YP_002345072.1 GI: 218563292  
50S ribosomal protein L23  
Accession: YP_002345071.1 GI: 218563291  
50S ribosomal protein L2  
Accession: YP_002345070.1 GI: 218563290  
30S ribosomal protein S19  
Accession: YP_002345069.1 GI: 218563289  
50S ribosomal protein L22  
Accession: YP_002345068.1 GI: 218563288  
50S ribosomal protein L24  
Accession: YP_002345062.1 GI: 218563282  
50S ribosomal protein L6  
Accession: YP_002345058.1 GI: 218563278  
50S ribosomal protein L15  
Accession: YP_002345055.1 GI: 218563275  
lipoprotein  
Accession: YP_002345045.1 GI: 218563265  
hypothetical protein Cj1656c  
Accession: YP_002345025.1 GI: 218563245  
lipoprotein  
Accession: YP_002345022.1 GI: 218563242  
hypothetical protein Cj1631c  
Accession: YP_002345000.1 GI: 218563220  
TonB transport protein  
Accession: YP_002344999.1 GI: 218563219  
periplasmic protein  
Accession: YP_002344990.1 GI: 218563210  
30S ribosomal protein S20  
Accession: YP_002344980.1 GI: 218563200  
30S ribosomal protein S11  
Accession: YP_002344962.1 GI: 218563182  
hypothetical protein Cj1501  
Accession: YP_002344880.1 GI: 218563101  
cbb3-type cytochrome c oxidase subunit II  
Accession: YP_002344869.1 GI: 218563090  
30S ribosomal protein S9  
Accession: YP_002344859.1 GI: 218563080  
flagellar hook-associated protein FlgK  
Accession: YP_002344848.1 GI: 218563069  
hypothetical protein Cj1464  
Accession: YP_002344846.1 GI: 218563067  
hypothetical protein Cj1463  
Accession: YP_002344845.1 GI: 218563066  
periplasmic protein  
Accession: YP_002344838.1 GI: 218563059 
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ATP/GTP-binding protein  
Accession: YP_002344832.1 GI: 218563053  
cystathionine beta-lyase, N-terminus  
Accession:YP_002344777.1 GI:218562998 
catalase  
Accession: YP_002344773.1 GI: 218562994  
flavodoxin FldA  
Accession: YP_002344770.1 GI: 218562991  
secreted serine protease  
Accession: YP_002344753.1 GI: 218562974  
periplasmic cytochrome C  
Accession:YP_002344746.1 GI:218562967 
periplasmic cytochrome C  
Accession:YP_002344745.1 GI:218562966 
coiled-coil protein  
Accession:YP_002344736.1 GI:218562957 
flagellin  
Accession: YP_002344727.1 GI: 218562948  
flagellin  
Accession: YP_002344726.1 GI: 218562947  
N-acetylmuramoyl-L-alanine amidase  
Accession: YP_002344660.1 GI: 218562881  
chaperone protein DnaJ  
Accession: YP_002344651.1 GI: 218562872  
phosphotyrosine protein phosphatase  
Accession:YP_002344649.1 GI:218562870 
isomerase  
Accession:YP_002344646.1 GI:218562867 
periplasmic protein  
Accession:YP_002344643.1 GI:218562864  
hypothetical protein Cj1242  
Accession: YP_002344633.1 GI: 218562854  
peptidase M23 family protein  
Accession:YP_002344626.1 GI:218562847 
hypothetical protein Cj1232  
Accession: YP_002344623.1 GI: 218562844  
serine protease  
Accession: YP_002344619.1 GI: 218562840  
hypothetical protein Cj1225  
Accession: YP_002344616.1 GI: 218562837  
periplasmic protein  
Accession:YP_002344610.1 GI:218562831 
periplasmic protein  
Accession: YP_002344584.1 GI: 218562805  
bipartate energy taxis response protein CetB  
Accession: YP_002344580.1 GI: 218562801  
ubiquinol-cytochrome C reductase iron-sulfur subunit  
Accession: YP_002344577.1 GI: 218562798  
Sec-independent protein translocase  
Accession: YP_002344567.1 GI: 218562788  
hypothetical protein Cj1164c  
Accession: YP_002344555.1 GI: 218562776  
S-adenosylmethionine synthetase  
Accession: YP_002344489.1 GI: 218562710  
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single-stranded DNA-binding protein  
Accession: YP_002344464.1 GI: 218562685 
aspartyl/glutamyl-tRNA amidotransferase subunit A  
Accession: YP_002344454.1 GI: 218562675  
hypothetical protein Cj1036c  
Accession: YP_002344431.1 GI: 218562652  
lipoprotein  
Accession: YP_002344378.1 GI: 218562599  
outer-membrane protein  
Accession: YP_002344370.1 GI: 218562591  
hypothetical protein Cj0974  
Accession: YP_002344369.1 GI: 218562590  
hypothetical protein Cj0972  
Accession: YP_002344367.1 GI: 218562588  
hypothetical protein Cj0971  
Accession: YP_002344366.1 GI: 218562587  
hypothetical protein Cj0970  
Accession: YP_002344365.1 GI: 218562586  
50S ribosomal protein L34  
Accession: YP_002344359.1 GI: 218562580  
periplasmic protein  
Accession: YP_002344342.1 GI: 218562563  
hypothetical protein Cj0916c  
Accession: YP_002344314.1 GI: 218562535  
DNA-binding protein HU  
Accession: YP_002344311.1 GI: 218562532  
lagellar hook-associated protein FlgL  
Accession: YP_002344286.1 GI: 218562507  
hypothetical protein Cj0878  
Accession: YP_002344278.1 GI: 218562499  
cytochrome C  
Accession: YP_002344275.1 GI: 218562496  
hypothetical protein Cj0873c  
Accession: YP_002344274.1 GI: 218562495  
hypothetical protein Cj0859c  
Accession: YP_002344266.1 GI: 218562487  
hypothetical protein Cj0849c  
Accession: YP_002344256.1 GI: 218562477  
hypothetical protein Cj0848c  
Accession: YP_002344255.1 GI: 218562476  
secreted transglycosylase  
Accession: YP_002344250.1 GI: 218562471  
hypothetical protein Cj0839c  
Accession: YP_002344246.1 GI: 218562467  
hypothetical protein Cj0816  
Accession: YP_002344223.1 GI: 218562444  
hypothetical protein Cj0815  
Accession: YP_002344222.1 GI: 218562443  
hypothetical protein Cj0814  
Accession: YP_002344221.1 GI: 218562442  
hypothetical protein Cj0794  
Accession: YP_002344201.1 GI: 218562422  
nitrate reductase catalytic subunit  
Accession: YP_002344187.1 GI: 218562408  
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periplasmic protein  
Accession: YP_002344183.1 GI: 218562404  
TonB transport protein  
Accession: YP_002344162.1 GI: 218562383  
hypothetical protein Cj0748  
Accession: YP_002344161.1 GI: 218562382  
hypothetical protein Cj0741  
Accession: YP_002344159.1 GI: 218562380  
hypothetical protein Cj0740  
Accession: YP_002344158.1 GI: 218562379  
hypothetical protein Cj0739  
Accession: YP_002344157.1 GI: 218562378  
hypothetical protein Cj0738  
Accession: YP_002344156.1 GI: 218562377  
hypothetical protein Cj0736  
Accession: YP_002344154.1 GI: 218562375  
periplasmic protein  
Accession: YP_002344146.1 GI: 218562367  
flagellin  
Accession: YP_002344138.1 GI: 218562359  
hypothetical protein Cj0700  
Accession: YP_002344118.1 GI: 218562339  
flagellar basal body rod protein FlgG  
Accession: YP_002344116.1 GI: 218562337  
flagellar basal-body rod protein  
Accession: YP_002344115.1 GI: 218562336  
periplasmic protein  
Accession: YP_002344112.1 GI: 218562333  
flagellar basal body L-ring protein  
Accession: YP_002344105.1 GI: 218562326  
lipoprotein  
Accession: YP_002344058.1 GI: 218562279  
secretion protein HlyD  
Accession: YP_002344036.1 GI: 218562257  
pyridine nucleotide-disulphide oxidoreductase  
Accession: YP_002343990.1 GI: 218562211  
flagellar capping protein  
Accession: YP_002343979.1 GI: 218562200  
flagellar basal body rod protein FlgB  
Accession: YP_002343959.1 GI: 218562180  
flagellar basal body rod protein FlgC  
Accession: YP_002343958.1 GI: 218562179  
flagellar hook-basal body protein FliE  
Accession: YP_002343957.1 GI: 218562178  
30S ribosomal protein S12  
Accession: YP_002343925.1 GI: 218562146  
50S ribosomal protein L1  
Accession: YP_002343909.1 GI: 218562130  
50S ribosomal protein L11  
Accession: YP_002343908.1 GI: 218562129  
50S ribosomal protein L33  
Accession: YP_002343905.1 GI: 218562126  
50S ribosomal protein L28  
Accession: YP_002343884.1 GI: 218562105  
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succinate dehydrogenase subunit C  
Accession: YP_002343876.1 GI: 218562097  
3-ketoacyl-(acyl-carrier-protein) reductase  
Accession: YP_002343872.1 GI: 218562093  
hypothetical protein Cj0428  
Accession: YP_002343865.1 GI: 218562086  
hypothetical protein Cj0418c  
Accession: YP_002343855.1 GI: 218562076  
GMC oxidoreductase subunit  
Accession: YP_002343852.1 GI: 218562073  
oxidoreductase subunit  
Accession: YP_002343851.1 GI: 218562072  
transmembrane protein  
Accession: YP_002343841.1 GI: 218562062  
hypothetical protein Cj0391c  
Accession: YP_002343828.1 GI: 218562049  
periplasmic fusion protein CmeA  
Accession: YP_002343804.1 GI: 218562025  
flagellar motor protein MotB  
Accession: YP_002343774.1 GI: 218561995  
ferredoxin  
Accession: YP_002343771.1 GI: 218561992  
50S ribosomal protein L32  
Accession: YP_002343768.1 GI: 218561989  
transmembrane protein  
Accession: YP_002343710.1 GI: 218561931  
molybdopterin containing oxidoreductase  
Accession: YP_002343706.1 GI: 218561927  
highly acidic protein  
Accession: YP_002343693.1 GI: 218561914  
50S ribosomal protein L35  
Accession: YP_002343686.1 GI: 218561907  
hypothetical protein Cj0243c  
Accession: YP_002343685.1 GI: 218561906  
preprotein translocase subunit SecG  
Accession: YP_002343678.1 GI: 218561899  
ribosome recycling factor  
Accession: YP_002343677.1 GI: 218561898  
hypothetical protein Cj0202c  
Accession: YP_002343660.1 GI: 218561881  
TonB transport protein  
Accession: YP_002343639.1 GI: 218561860  
superoxide dismutase  
Accession: YP_002343628.1 GI: 218561849  
50S ribosomal protein L31  
Accession: YP_002343615.1 GI: 218561836  
hypothetical protein Cj0152c  
Accession: YP_002343612.1 GI: 218561833  
peptidoglycan associated lipoprotein  
Accession: YP_002343573.1 GI: 218561794  
periplasmic protein  
Accession: YP_002343571.1 GI: 218561792  
cytolethal distending toxin A  
Accession: YP_002343541.1 GI: 218561762  
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hypothetical protein Cj0056c  
Accession: YP_002343520.1 GI: 218561741  
hypothetical protein Cj0055c  
Accession: YP_002343519.1 GI: 218561740  
flagellar hook protein  
Accession: YP_002343514.1 GI: 218561735  
flagellar basal body rod modification protein  
Accession: YP_002343513.1 GI: 218561734  
 flagellar hook-length control protein  
Accession: YP_002343512.1 GI: 218561733  
cytoplasmic L-asparaginase  
Accession: YP_002343501.1 GI: 218561722  
molydopterin containing oxidoreductase  
Accession: YP_002343477.1 GI: 218561698  
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Appendix 3: Estimated half-life and Instability index of Cj0391c using ProtParam 
(Gasteiger et al, 2005).  
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Appendix 4: PstI digested DNA 
 
 
 
                                 
Appendices 
 276
Appendix 5: Protein Standards 
 
 
 
                                                             
 
  
A. Precision Plus ProteinTM 
Unstained Standard 
B. Precision Plus ProteinTM 
KaleidoscopeTM Standard 
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Appendix 6: Sequence alignment of Cj0391c and TcdA1 (PDB code 4O9Y/1VW1) by 
Clustal Omega 
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Appendix 6: Sequence alignment of Cj0391c and TcdA1 (PDB code 4O9Y/1VW1) by 
Clustal Omega (cont.)  
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Appendix 6: Sequence alignment of Cj0391c and TcdA1 (PDB code 4O9Y/1VW1) by 
Clustal Omega (cont.)  
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Appendix 7: Sequence alignment of Cj0391c and listeriolysin (PDB code 4CDB) by 
Clustal Omega 
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Appendix 8: Protein 391 molecular dynamics simulation files (please see DVD 
attached) 
 
